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Summary 
Salmonella enterica, Campylobacter jejuni and Campylobacter coli are the most common causes of 
foodborne bacterial infections worldwide. Both bacterial species have many modes for transmission 
in the food chain through which humans can be infected. The widespread use of antimicrobial drugs 
for food animals and the consequent dissemination of antimicrobial drug resistance have been well 
described in literature. Much less investigated is the association between human antimicrobial drug 
use and the adverse consequences it may have on human infections. 
This thesis addresses the relation between antimicrobial drug use in humans, and the acquisition of 
infection with antimicrobial resistant non-typhoidal Salmonella, Campylobacter coli (C. coli), and 
Campylobacter jejuni (C. jejuni). The main objectives were: 
1) To assess if the history of human use of antimicrobial drugs is a risk factor for acquiring infection with 
an antimicrobial Salmonella or Campylobacter strain.  
2) To compare clinical outcome of disease for patients infected with Salmonella Typhimurium having 
different antimicrobial susceptibility profiles (i.e. pansusceptible, resistant or multidrug-resistant). 
3) To examine how clinical outcome of an infection is affected by previous antimicrobial exposure.  
A general overview of the discovery of antimicrobials, and the development and mechanisms of 
antimicrobial drug resistance in Salmonella, C. jejuni¸ and C. coli  are described in chapter 2. Several 
features of the epidemiology, sources of infection, antimicrobial resistance, and surveillance of 
Salmonella and Campylobacter are described in chapter 3 and 4, respectively. 
The history of human use of antimicrobial drugs in relation to acquiring an infection with Salmonella or 
Campylobacter, and the subsequent risk of the causative pathogen being resistant to the drug taken 
previously and unrelated to the infection in question was assessed in Manuscript I and Manuscript II. 
Both studies had the same study design: registry based case-control study, for which several of the 
Danish registries were merged using the unique Civil Registration Number (CPR), and approximately ten 
controls were matched to each patient on sex, age, and county of residence. Data on history of 
antimicrobial use was derived from the National Prescription database; cases enrolled in the study were 
retrieved from the National Registry for Enteric Patients (NREP); the Integrated Database on Labour 
Market Research provided data on socio-demographics of cases and controls; and the Civil Registry 
System was used to derive the CPR numbers, date of birth, and residential area of cases and controls. 
A total of 22,609 Salmonella cases that were laboratory confirmed between 1997 - 2005, were enrolled in 
the study. The analyses were performed separately for Salmonella Typhimurium (S. Typhimurium, 4,534 
cases), Salmonella Enteritidis (S. Enteritidis, 4,195 cases), and all other Salmonella serotypes combined 
(5,776 cases). We found that treatment with trimethoprim, sulphonamides, broad-spectrum penicillins, 
tetracyclines and fluoroquinolones, during one year before diagnosis, was associated with an increased 
risk of non-typhoid Salmonella infection. Overall, the highest risk was associated with the prior use of 
fluoroquinolones. The risk increased as the time-window of exposure approached the infection date. The 
Odds Ratios (OR) for previous use of fluoroquinolones were OR 4.6 (95% confidence interval (CI): 3.8 – 
5.5) for other Salmonella serotypes, an OR 2.2 (95%CI: 1.7 – 2.9) for S. Typhimurium, and an OR 2.1 
(95%CI: 1.8 – 2.4) for S. Enteritidis. Additionally for fluoroquinolones, we found an interaction term for 
the pathogen being resistant to fluoroquinolones and a history of fluoroquinolone use; OR 3.6 (95%CI: 1.2 
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– 10.3) for S. Typhimurium and OR 2.7 (95%CI: 1.2 – 5.9). Meaning that the risk for being diagnosed with a 
fluoroquinolone resistant S. Typhimurium after treatment with this drug in up to a year before diagnosis 
was 7.2 (2.0*3.6) times higher for patients than for controls. For S. Enteritidis the corresponding risk was 
4.5 (1.7*2.7) times higher for cases than for controls. These findings are ascribed to the competitive and 
the selective effect of acquiring antimicrobial resistance, respectively. The competitive effect occurs 
when a course of antimicrobials taken disrupts the natural barrier effect of the gut flora. The selective 
effect is an additional effect, occurring when a person is exposed to a pathogen resistant to the 
antimicrobial taken.  This increases the risk of infection further due to the selective pressure put on other 
bacteria susceptible to the drug taken. 
Between 1999 – 2005, a total of 31,699 cases of Campylobacter were laboratory confirmed in Denmark, 
and thus enrolled in the study. We found that being diagnosed with Campylobacter was associated with 
an increased odds of exposure to a course of fluoroquinolones, macrolides, broad spectrum penicillins, 
tetracyclines, and sulphonamides and trimethoprim, up to one year before onset of disease. The risk was 
highest for taking fluoroquinolones (OR 2.4, 95%CI: 2.0 – 3.0). Due to the low number of Campylobacter 
isolates being tested for other antimicrobial drugs than fluoroquinolones and macrolides, it was only 
possible to calculate the interaction term (or selective effect) for these two drugs. For fluoroquinolones, 
we found an effect modification of the strain additionally being resistant to the drug taken (OR 1.6, 
95%CI: 1.1 – 2.3). The odds of being exposed to a course of fluoroquinolones was 2.4 times higher for 
cases diagnosed with a fluoroquinolone-sensitive Campylobacter than for controls whereas the odds of 
being exposed to a fluoroquinolone was 3.8 (2.4*1.6) times higher for cases with a fluoroquinolone-
resistant Campylobacter than for controls. For macrolides, the interaction term was not significant (OR 
1.0, 95%CI: 0.7 – 1.5). However, when we performed cubic spline plots of the OR of being exposed to a 
course of antimicrobials we found that being exposed to a course of macrolides provided a protective 
effect for being diagnosed with Campylobacter, up to one month before diagnosis. This effect is likely to 
be caused by the fact that the metabolites and active compound of macrolides are trapped into 
lysosomes of phagocytic cells, and get released at a very low rate and provide prolonged protection 
against invasive bacteria such as Campylobacter. 
In Manuscript III, the relation between clinical outcomes of infection with S. Typhimurium and the 
antimicrobial resistance profile of the causative strain was assessed, together with the association 
between outcome of infection and previous antimicrobial use. A prospective case-case study was 
performed, using data obtained through telephone-conducted interviews, which were merged with data 
from the NREP and the Civil Registry System. Data were analysed using logistic regression. The interviews 
were conducted between January-June 2010, and a total of 150 S. Typhimurium cases were enrolled in 
the study. Cases were divided into three different groups according to the resistance pattern of the strain 
they were infected with: pansusceptible (S), resistant (R) to 1-3 antimicrobials, or multidrug-resistant 
(MR), i.e. resistant to 4 or more antimicrobials. We found that previous antimicrobial use, unrelated to 
the current S. Typhimurium infection, was associated with a higher odds of weight loss (OR 2.4, 95%CI: 
1.1 – 5.5), hospital admission (OR 2.0, 95%CI: 1.0 – 4.1), and antimicrobial therapy for the current 
salmonellosis (OR 7.9, 95%CI: 2.8 – 16.8). The study focussed on short-term outcomes of disease 
(diarrhoea, nausea, etc.), and patients were interviewed relatively shortly after notification in the NREP. 
This may explain why this study, in contrast to other studies that focussed more on long-term outcome of 
disease (mortality, bacteraemia, etc.), did not find other more serious disease outcomes to be related to 
resistance profile. Also, it is possible that, due to our study design, we missed out on the most severely ill 
people, simply because they were too ill to participate in the interviews.  
We also found that patients with a resistant (R) susceptibility profile had a higher odds of being 
hospitalised due to their salmonellosis (OR 2.5, 95%CI: 1.0 – 6.0), experience abdominal pain (OR 2.9, 
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95%CI:1.3 – 6.5),  and feeling nauseated (OR 2.6, 95%CI: 1.1 – 6.2),  than patients with a pansusceptible 
Salmonella. We found no increasing trend with increasing antimicrobial resistance (S versus MR). These 
findings may be an extension of the competitive and selective effect of antimicrobial treatment 
(Manuscript I and Manuscript II), where past antimicrobial treatment depletes or changes the 
composition of the gut flora in a way that increases severity of infection. Alternatively, a past history of 
treatment could be an indicator or proxy of a vulnerable patient. 
The overall conclusion of this thesis is that human antimicrobial use interacts in many ways with the risk 
of being infected with antimicrobial-drug resistant strains of Salmonella and Campylobacter, and that 
treatment with antimicrobials may be associated with severity of infection as well. The protective role of 
macrolides as observed for Campylobacter infection adds another layer to the complexity of these 
interactions. Prudent use of antimicrobial drugs should always be advocated in human health practices. 
Future studies should point out whether the associations found in this thesis also applies to other 
pathogens. 
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Sammendrag 
De fleste fødevarebårne bakterielle infektioner i Danmark og på verdensplan forårsages af 
Salmonella enterica, Campylobacter jejuni og Campylobacter coli. Disse bakterier spredes fra husdyr 
til mennesker via mange forskellige smitteveje inklusive fødevarer. Den udbredte brug af antibiotika i 
husdyrproduktionen og den deraf følgende risiko for udvikling og spredning af antibiotikaresistente 
bakterier er velbeskrevet i den videnskabelige litteratur. Sammenhængen mellem humant forbrug af 
antibiotika og potentielle konsekvenser for infektioner hos mennesker er derimod kun sparsomt 
dokumenteret. 
Denne afhandling belyser sammenhængen mellem antibiotikaforbrug i mennesker og risikoen for 
infektion med antibiotikaresistente non-tyfoide Salmonella, Campylobacter coli (C. coli) og 
Campylobacter jejuni (C. jejuni). De primære formål var: 
1) At vurdere om en tidligere eksponering for antibiotika hos mennesker er en risikofaktor for at blive 
inficeret med en antibiotikaresistent stamme af Salmonella eller Campylobacter.  
2) At sammenligne symptomer og det kliniske forløb af sygdommen blandt patienter inficerede med 
Salmonella Typhimurium med forskellige antibiotikaresistensprofiler (i.e. fuldt følsomme, resistente eller 
multiresistente). 
3) At undersøge om tidligere eksponering for antibiotika giver anledning til et alvorligere kliniske forløb af 
infektionen.  
Kapitel 2 giver et generelt overblik over opdagelsen af antibiotika og mekanismer for udvikling af 
antibiotikaresistens i Salmonella, C. jejuni and C. coli. Den humane epidemiologi, kilder til infektion, 
antibiotikaresistensforhold, samt overvågning af Salmonella og Campylobacter i mennesker, dyr og 
fødevarer er beskrevet i hhv. kapitel 3 og 4. 
Sammenhængen mellem et tidligere forbrug af antibiotika (dvs. antibiotika udskrevet pga. en anden 
diagnose) og risikoen for at blive inficeret med en Salmonella eller Campylobacter stamme, der er 
resistent overfor det samme antibiotika, beskrives i Manuskript I og Manuskript II. Begge studier var 
designet som registerbaserede case-kontrol undersøgelser. Data blev udtrukket fra flere forskellige 
nationale registre og sammenkørt via cpr. nummer. Omkring 10 kontrolpersoner pr. case blev matchet på 
køn, alder og bopæl. Tidligere forbrug af antibiotika blev trukket ud af Lægemiddelstatistikregistret; cases 
der indgik i studierne blev identificeret via Den danske mikrobiologidatabase (MiBa); sociale og 
demografiske forhold for cases og kontrolpersoner blev indhentet fra IDA-databasen (Integrated 
Database on Labour Market Research); og CPR-registret blev anvendt til at få oplysninger om alder og 
bopæl.  
I alt blev der diagnosticeret 22.609 Salmonella tilfælde i Danmark mellem 1997 – 2005. Samtlige tilfælde 
blev inkluderet i studiet beskrevet i Manuskript I. Der blev fortaget separate statistiske analyser for hhv. 
S. Typhimurium (4.534 tilfælde), S. Enteritidis (4.195 tilfælde), og andre Salmonella serotyper (5.776 
tilfælde). Vi fandt, at behandling med trimethoprim, sulfonamider, bredspektrede penicilliner, 
tetracykliner and fluorokinoloner, i op til et år før diagnose, kunne associeres med en forøget risiko for 
infektion med Salmonella. Den højeste risiko var forbundet med et tidligere forbrug af fluorokinoloner, og 
risikoen steg når tidsvinduet nærmede sig det estimerede infektionstidspunkt. Odds Ratioer (OR) for 
tidligere forbrug af fluorokinoloner var OR 4,6 (95% konfidensinterval (CI): 3,8 – 5,5) for andre Salmonella 
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serotyper, OR 2,2 (95%CI: 1,7 – 2,9) for S. Typhimurium, og OR 2,1 (95%CI: 1,8 – 2,4) for S. Enteritidis. 
Derudover fandt vi et interaktionsled mellem et tidligere forbrug af fluorokinoloner og det, at bakterien 
var resistent overfor fluorokinoloner; OR 3,6 (95%CI: 1,2 – 10,3) for S. Typhimurium og OR 2,7 (95%CI: 1,2 
– 5,9). Det betyder, at risikoen for at blive diagnosticeret med en fluorokinolonresistent S. Typhimurium 
efter behandling med samme stof i op til et år før infektionen er 7,2 (2,0*3,6) gange højere for cases end 
for kontrolpersoner. For S. Enteritidis var den tilsvarende risiko 4,5 (1,7*2,7) gange højere. Disse fund 
tilskrives hhv. den kompetetive og den selektive effekt af antibiotikaresistensudvikling. Den kompetetive 
effekt opstår, når en antibiotikakur ødelægger den beskyttende effekt af den normale tarmflora. Den 
selektive effekt forekommer når en person eksponeres for et patogen, som er resistent overfor det 
antibiotika, som personen tidligere har indtaget. Sidstnævnte øger risikoen for infektion yderligere pga. 
det selektive pres som opstår på andre tilstedeværende bakterier, der er følsomme overfor stoffet og 
derved inaktiveres. 
I perioden 1999 – 2005 blev der diagnosticeret i alt 31.699 tilfælde af Campylobacter i Danmark. Alle 
tilfælde blev inkluderet i studiet beskrevet i Manuskript II. Vi fandt, at det at blive diagnosticeret med 
campylobacteriose var forbundet med en forhøjet risiko for at have været eksponeret for 
fluorokinoloner, makrolider, bredspektrede penicilliner, tetracykliner, og sulfonamider og trimethoprim, i 
op til et år før infektionen. Risikoen var højest for fluorokinoloner (OR 2,4, 95%CI: 2,0 – 3,0). Da kun få 
Campylobacter isolater undersøges for resistens overfor andre antibiotika end fluorokinoloner og 
makrolider, var det kun muligt at beregne interaktionsleddet (i.e. kvantificere den selektive effekt) for 
disse to stoffer. I denne analyse fandt vi en yderligere effekt såfremt bakteriestammen tillige var resistent 
overfor fluorokinoloner (OR 1,6, 95%CI: 1,1 – 2,3). Odds for at blive eksponeret for fluorokinoloner var 2,4 
gange højere for cases diagnosticeret med en fluorokinolon-følsom Campylobacter end for 
kontrolpersoner, mens odds for at blive eksponeret for fluorokinolon var 3,8 (2,4*1,6) gange højere for 
cases med en fluorokinolon-resistent Campylobacter infektion end for kontrolpersoner. For makrolider, 
var interaktionsleddet ikke signifikant (OR 1,0, 95%CI: 0,7 – 1,5). Cubic spline plots af OR for at blive 
eksponeret for makrolider, viste derimod en tilsyneladende beskyttende effekt af makrolidbehandling i 
op til en måned før tidspunktet for Campylobacter infektionen. Denne effekt kan forklares ved at såvel 
metabolitter som det aktive stof fanges i lysosomer på fagocytotiske celler, og derfra frigives langsomt, 
hvorved der opstår en forlænget virkning mod invasive bakterier som Campylobacter. 
I Manuscript III undersøges sammenhængen mellem det kliniske forløb efter infektion med S. 
Typhimurium og resistensprofilen på den sygdomsfremkaldende Typhimuirum stamme, samt 
sammenhængen mellem klinisk forløb og tidligere antibiotikaforbrug. Det blev foretaget som en 
prospektiv case-case undersøgelse baseret på data fra telefoninterviews, som blev sammenkørt med data 
fra MiBa og CPR-registret. Data blev analyseret vha. logistisk regression. Interviewene blev foretaget i 
perioden januar-juni 2010, og i alt 150 S. Typhimurium cases blev inkluderet i undersøgelsen. Cases blev 
inddelt i tre grupper alt efter resistensmønstret på den Typhimurium stamme, som de var inficeret med: 
fuldt følsomme (S), resistente (R) overfor 1-3 antibiotika, eller multiresistente (MR), dvs. resistente 
overfor 4 eller flere antibiotika. Vi fandt, at et tidligere antibiotikaforbrug dvs. forbrug som ikke var 
relateret til Salmonella infektionen, gav en højere odds for vægttab (OR 2,4, 95%CI: 1,1 – 5,5), 
hospitalsindlæggelse (OR 2,0, 95%CI: 1,0 – 4,1), samt antibiotikabehandling for den pågældende 
Salmonella infektion (OR 7,9, 95%CI: 2,8 – 16,8). Undersøgelsen havde primært fokus på de kortsigtede 
kliniske konsekvenser (fx diarré og kvalme), da patienterne blev interviewet relativ kort tid efter deres 
diagnose blev registreret i MiBa. Dette forhold kan måske forklare, hvorfor vi, i modsætning til andre 
studier der typisk har haft fokus på langsigtede konsekvenser (fx dødelighed og sepsis), ikke kunne påvise 
flere alvorlige konsekvenser som følge af resistens. Det er også muligt at vi pga. studiedesignet ikke fik fat 
i de alvorligste tilfælde, simpelthen fordi de var for syge til at deltage. 
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Vi fandt også, at patienter inficeret med en resistent (R) Salmonella havde en højere odds for at blive 
hospitaliserede som følge af deres infektion (OR 2,5, 95%CI: 1,0 – 6.0), hyppigere havde mavesmerter (OR 
2,9, 95%CI:1,3 – 6,5),  og kvalme (OR 2,6, 95%CI: 1,1 – 6,2), end patienter inficerede med fuldt følsomme 
Salmonella. Vi observerede ingen stigning med stigende resistensniveau (S versus MR). Disse fund er 
måske også en afspejling af den kompetitive og selektive effekt af antibiotikabehandling (Manuskript I og 
Manuskript II), hvor tidligere behandling nedbryder eller ændrer sammensætningen af tarmfloraen i en 
grad der gør at infektionen får et alvorlige forløb. En alternativ forklaring kan være, at tidligere 
behandling er en indikator for en patient som er mere modtagelig for infektioner fx på grund af et nedsat 
immunforsvar. 
Samlet konkluderes det på basis af resultaterne i denne afhandling, at humant forbrug af antibiotika 
påvirker risikoen for at blive inficeret med antibiotikaresistente stammer af Salmonella og Campylobacter 
på flere måder, og at behandling med antibiotika også kan være associeret med et alvorligere forløb af en 
infektion. Den tilsyneladende beskyttende effekt af makrolider, som observeret for Campylobacter 
infektion, tilføjer et yderligere lag til de komplekse sammenhænge. Mådeholdent forbrug af antibiotika 
bør altid anbefales – også til mennesker. Det anbefales at fremtidige studier fokuserer på at undersøge 
om sammenhængene fundet i denne afhandling kan genfindes for andre patogener. 
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1 General Introduction 1 
1.1 Introduction 2 
Salmonella enterica,  Campylobacter jejuni and Campylobacter coli are the most common causes of 3 
foodborne infections worldwide.[1] These pathogens are zoonotic, i.e., they can be transmitted from 4 
animals to humans, and a wide variety of animals have the potential of hosting these bacteria e.g. 5 
birds, cats, dogs, cows, etc. [2] Both bacterial species have many modes for transmission in the food 6 
chain through which humans can be infected. It is well acknowledged that the use of antimicrobial 7 
drugs in food animals leads to antimicrobial resistance in foodborne bacteria such as Campylobacter 8 
and Salmonella.[3, 4] However, the role of human antimicrobial use as a determinant for infections 9 
with zoonotic antimicrobial drug resistant bacteria is much less investigated. 10 
This thesis focuses on two hypotheses relating to antimicrobial resistance and infection non-11 
typhoidal Salmonella, Campylobacter coli (C. coli), and Campylobacter jejuni (C. jejuni): 12 
1) Is previous antimicrobial drug use in humans associated with a higher risk of infection with 13 
non-typhoidal Salmonella, C. coli or C. jejuni? 14 
2) Is infection with antimicrobial drug resistant Salmonella associated with more severe clinical 15 
outcome of disease? 16 
1.2 Research Objectives 17 
The main research objectives of this thesis were:  18 
1) To assess if the history of human use of antimicrobial drugs is a risk factor for acquiring infection with 19 
an antimicrobial Salmonella or Campylobacter strain.  20 
2) To compare clinical outcome of disease for patients infected with Salmonella Typhimurium with 21 
different antimicrobial susceptibility profile  (i.e. pansusceptible, resistant or multiresistant). 22 
3) To examine how clinical outcome of an infection is affected by previous antimicrobial exposure.  23 
 24 
This thesis is divided into eight chapters. The introductory section, Chapter 1, is presenting the 25 
hypothesis and research objectives. Chapter 2 describes mechanisms of antimicrobial resistance 26 
focusing on mechanisms found in Salmonella and Campylobacter. Chapters 3 and 4 give a detailed 27 
description of the zoonotic pathogens Salmonella and Campylobacter, respectively. Each of these 28 
chapters describes characteristics of the pathogens, the disease that they cause, and surveillance 29 
systems in place in Denmark. The methodologies of the studies performed, and the data used are 30 
described in Chapter 5. The results, and an overall discussion are given in Chapter 6. Finally, Chapter 31 
7 provides a general conclusion and future perspectives.  32 
 33 
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2 Antimicrobial Drug Resistance 1 
Antimicrobial treatment is the therapy of an infectious disease with an antimicrobial drug that either 2 
kills the pathogen or interferes with the growth of the pathogen. According to WHO antimicrobial 3 
resistance is: “Resistance of a microorganism (pathogen) to an antimicrobial medicine to which it was 4 
originally sensitive. Resistant organisms (including bacteria, fungi, viruses and some parasites) are 5 
able to withstand attack by antimicrobial medicines, such as antibiotics, so that standard treatment 6 
are ineffective and the infection persists and increasing the risk of spread to others. Resistance is a 7 
natural phenomenon, and certain resistant traits can be exchanged between certain types of 8 
bacteria. The misuse of antimicrobial medicines accelerates this natural phenomenon.” 9 
2.1 Discovery of antimicrobials and consequences of antimicrobial 10 
resistance. 11 
History of penicillin, the first antibiotic and penicillin resistance 12 
The first antibiotic drug that was marketed was penicillin, which was discovered by Alexander 13 
Fleming in 1928. In his article he concluded “that it had been demonstrated that a species of 14 
penicillium produces a very powerful antibacterial substance which affects different bacteria in 15 
different ways. Penicillin is the most effective against pyogenic cocci.”[5]However, it took until 1939 16 
before E. Chain managed to create a stable form of penicillin in the laboratory. In the US, in 1944, H. 17 
Florey designed a method to produce penicillin on a large scale. Only then, penicillin became widely 18 
used to treat wounded Allied soldiers during World War 2.[6] Not long after this discovery, for which 19 
Fleming, Chain and Florey received a Nobel prize in 1945, resistance against penicillin was discovered 20 
in 1945. However, resistance against this drug was discovered even before large scale production 21 
and use of the drug took place. In 1940, Chain and his colleague discovered an enzyme, penicillinase 22 
(β-lactamase), that could cleave the drug and inactivate it.[7] Once penicillin use became common,  23 
β-lactamase-producing bacteria became widely spread [6], due to selection pressure, which will be 24 
further discussed at the end of this chapter. 25 
Antibiotic resistance has been on the rise since it was discovered in the first half of the 20th century, 26 
and it is a major concern for modern medicine since resistance rates in pathogenic organisms keeps 27 
rising.[8] Resistance to the first line of treatment is a problem since first line of treatment drugs are 28 
selected on the following grounds: safety, small spectrum and the lowest cost. Which makes second 29 
line of treatment drugs less desirable because they score worse on the abovementioned grounds.[9, 30 
10] Multidrug resistance forms an even bigger problem because sometimes the second or third 31 
choice of treatment will not even be available. In the worst case scenario, doctors need to treat their 32 
patients with antibiotics that are toxic like colistin and fosfomycin.[11] Another problem with 33 
resistance against first line of treatment drugs is that these drugs are used for empirical, therapy, 34 
before  antibiotic susceptibility results are available. Resistance against empirical treatment confers a 35 
worse outcome of disease because of a delay in effective treatment. Patients can be ill for a longer 36 
periods, have a higher mortality,[12, 13] and have higher odds to develop bloodstream 37 
infections.[14, 15] 38 
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Another side-effect of antimicrobial resistance is the economic effect, patients will be ill for a longer 39 
period of time, losing working days, spend longer time in hospital and use more and more expensive 40 
drugs, and other health care utilities.[16, 17]  41 
2.2 Antibiotic resistance development 42 
Besides development of antimicrobial resistance by bacteria, other factors play a role in the 43 
occurrence and the pace of this development. These factors are all influenced by human behaviour, 44 
and affect the selective pressure.  Any use of antibiotics can increase selective pressure in a 45 
population of bacteria to allow the resistant bacteria to thrive and the susceptible bacteria to die 46 
off.[18-20]  Human behavioural factors that play a role in the dissemination and spread of resistance 47 
are numerous and can be studied at a micro-level (the effect of antimicrobial therapy  on the 48 
dissemination of resistance in the gut flora of a patient), or on a macro-level ( for example; the effect 49 
of the amount of antimicrobials consumed in the veterinary sector on the occurrence of 50 
antimicrobial resistance in foodborne pathogens).  Many books and articles describe these 51 
phenomena[21-24] , this chapter will only focus on a few mechanisms/theories that were crucial for 52 
the articles in this thesis. 53 
Gastrointestinal flora (gut flora) 54 
The gastrointestinal flora in the human gastrointestinal tract contains approximately 1012 CFU 55 
(colony forming units) per ml of colon-content, containing approximately 400 species of bacteria.[25] 56 
These bacteria help with the fermentation of non-digestible dietary residues, production of vitamin K 57 
, absorption of ions (Mg2+, Ca2+, Fe2+, etc)[25], most importantly, these bacteria form a protection 58 
against pathogens (i.e. colonisation resistance).[26] Humans (and other mammals) live in symbiosis 59 
with their gut-flora: the host provides nutrients for the bacteria and the bacteria form a colonisation 60 
barrier in the gut. A problem arises as soon as the host consumes antimicrobials, these drugs are not 61 
only beneficial for the host to fight infection, but are detrimental for the gut flora, and thus for the 62 
host as well. Most antimicrobials taken will at some point pass the gastrointestinal tract, and cause 63 
part of the gut-flora to die off, this leaves the host vulnerable for opportunistic infections. Barza and 64 
Travers[27] described the competitive and the selective effect which was the foundation  for the 65 
articles in this thesis. 66 
Competitive effect 67 
When exposing the intestinal gut flora to an antimicrobial, the intestinal flora will partly die off, due 68 
to this exposure. This will leave the patient with a low colonisation resistance and make him or her 69 
more vulnerable for weeks after the treatment, in which the patient has a higher likelihood to be 70 
colonised with any passing pathogen, until the natural gut flora is restored, which can take up to half 71 
a year after treatment with the antimicrobial. The competitive effect should apply equally to drug-72 
susceptible and drug-resistant infections. 73 
 Selective effect 74 
The selective effect occurs during the period that a course of antimicrobial treatment is taken. If, 75 
during this period, the person is infected with a drug-susceptible pathogen, the susceptible pathogen 76 
will be eliminated due to the antimicrobial. In case the infective pathogen is resistant to the 77 
antimicrobial taken, or the patient is asymptomatically infected with a pathogen resistant to this 78 
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antimicrobial, the pathogen will colonise the patient because the colonization resistance (i.e. the gut 79 
flora) is disrupted and will have space to proliferate.  80 
The risk of developing antimicrobial resistance can be reduced by choosing antimicrobials with a 81 
minimal effect at the gut flora, i.e. narrow spectrum antimicrobials[28]. 82 
Use of antimicrobials in the veterinary sector 83 
One of the main objects of this thesis is to address how much human antimicrobial use contributes to 84 
the occurrence of antimicrobial resistance in Salmonella and C. coli and C. jejuni.  In 1969, the Swann 85 
committee advocated the prudent use of antimicrobials in the veterinary sector since the use of 86 
antimicrobials as growth promoters might lead to the dissemination of resistant organisms and their 87 
transmission to humans.[29] Ever since, it has been debated whether the main reason for 88 
antimicrobial resistance is use of antimicrobials in the veterinary sector or not.  In 2005, the EU 89 
decided to put a ban on the use of antimicrobials as a growth promoter[30] as many studies 90 
demonstrated the association between the use of antimicrobials in the veterinary sector and 91 
occurrence of antimicrobial resistance in healthy animals.[31, 32] Other studies showed the bacteria 92 
isolated from human infections were the same as bacteria found in the animals, with the same 93 
antimicrobial resistance patterns.[33-36] Denmark was one of the first countries to put a ban on the 94 
use of antimicrobials as growth promoters in 1996 and studies have shown that this ban not only led 95 
to a lower prevalence of antimicrobial resistance in bacteria found in animals and animal products, 96 
but also led to a lower prevalence of resistance found in bacteria from human origin.[37] On the 97 
other hand, a clear one-on-one link cannot always be found, as in Australia fluoroquinolones have 98 
never been approved for use in the veterinary sector and resistance to fluoroquinolones is still found 99 
in Campylobacter isolates.[38] Since 2005, a list of antimicrobials that are considered critically 100 
important for human medicine exists, these antimicrobials are not supposed to be prescribed in 101 
veterinary medicine to preserve them for human use only.[39] Still antimicrobial resistance rates 102 
found in humans are increasing.[40] Suggesting that other factors, such as human antimicrobial use 103 
and misuse, and travel play a role in the dissemination of antimicrobial resistance.  104 
2.3 Acquisition of antimicrobial resistance  105 
Bacteria can be intrinsically resistant to antimicrobials (vertical transfer of resistance), acquire 106 
antimicrobial resistance through spontaneous mutations , or via the acquisition of resistance genes 107 
from other organisms (horizontal transfer). For horizontal transfer a three main mechanisms exist: 108 
transduction, conjugation, transformation.[41]  109 
2.4 Management of bacterial diarrhoea and bacterial resistance 110 
mechanisms in Salmonella and Campylobacter 111 
The most widespread mechanisms of resistance are enzymatic drug inactivation, active drug efflux, 112 
and reduced drug uptake. Other mechanisms are protection - and overproduction of the drug target, 113 
but these mechanisms are rare.[42] In this paragraph, only antimicrobial resistance mechanisms 114 
against clinically important antimicrobials against Salmonella and Campylobacter will be discussed. 115 
The cornerstone in the management of gastroenteritis remains rehydration, maintenance of 116 
hydration status and possible other supportive treatment. Antimicrobial drugs are usually not 117 
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recommended, but if the clinician decides to treat, the first line of drugs against Campylobacter will 118 
usually be a macrolide. Practically, patients are usually empirically treated with a fluoroquinolone. 119 
Since this is the first drug of choice to treat diarrhoeal disease when the causative pathogen is 120 
unknown. In case of bacteraemia due to Campylobacter,  a course of aminoglycosides is administered 121 
intravenously.  The first choice of treatment (if indicated) for Salmonella are fluoroquinolones, 122 
second- and third choice for treatment are trimethoprim-sulfamethoxazole (i.e. co-trimoxazole) and 123 
ampicillin. Children are usually not prescribed fluoroquinolones. 124 
Fluoroquinolone resistance 125 
The most common fluoroquinolone used to treat bacterial diarrhoea in humans is ciprofloxacin. 126 
Fluoroquinolones inhibit DNA replication by binding to either DNA gyrase (encoded by gyrA and gyrB) 127 
or  topoisomerase IV(encoded by (parC and parE), and thereby disrupting DNA transcription and 128 
replication.[43, 44]  129 
In both Campylobacter and Salmonella, fluoroquinolone resistance can be obtained through a 130 
mutation in a specific topoisomerase subdomaine named the quinolone resistance determining 131 
region (QRDR). Some mutations in this region lead to a decreased affinity of the drug to this region in 132 
the bacterium and thus increased resistance to fluoroquinolones. The rate in which  these 133 
spontaneous point mutation in the DNA occurs is 10-6 to 10-9 cells in a large population.[45] Most 134 
amino acid changes occur in gyrA or in parC. One single mutation in gyrA can confer low level 135 
resistance, high levels of quinolone resistance are usually associated with a double mutation in the 136 
QRDR. Plasmid-mediated quinolone resistance, encoded by qnr -genes  in both Salmonella  and 137 
Campylobacter is another commonly found mechanism.[46, 47] 138 
There has been ongoing debate on the MIC-values for quinolone resistance in Gram-negative 139 
bacteria for years[48-53]. Currently, the Clinical and Laboratory Standards Institute sets the 140 
susceptible MIC value at 0.06g/L for ciprofloxacin [54] and EUCAST set the same standard at 5*10-4 141 
g/L for Enterobacteriaceae with a note that the MIC for Salmonella typhi  is 6*10-6g/L and “The 142 
available data relate mainly to S. typhi but there are also case reports of poor response with other 143 
Salmonellas”.[55] 144 
Macrolide resistance 145 
Macrolides (e.g. erythromycin, azithromycin, roxithromycin) bind to the ribosomes of the bacterium 146 
and hence interfere with protein synthesis.[56, 57] Macrolide resistance can be acquired through 147 
several mechanisms: 1) Modification of the ribosomal target by methylation of the 23S rRNA, in such 148 
a way that the macrolide cannot bind to it. 2) Efflux of the drug by the CmeABC pump, which is also 149 
used to pump fluoroquinolones out of the cell. 3) Modification of the antimicrobial by the activity of 150 
esterases and /or phosphotransferases.[44, 58, 59] Development of macrolide resistance has been 151 
observed in vivo, and can be acquired through point mutation.[60] 152 
Trimethoprim-sulfamethoxazole resistance 153 
This is a combination of two antimicrobials which are frequently given as a combination.[61] Both 154 
drugs work on the folic-acid synthesis pathway of the bacterium and have different mechanisms of 155 
resistance. Resistance to sulfamethoxazole (i.e. sulphonamide) is usually chromosomal. The mutation 156 
either leads to either an overproduction of a precursor of folic-acid (PABA), or to production of an 157 
altered enzyme (dihydropreroatesyntethase) on which the sulphonamide binds to block the folic-acid 158 
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pathway. Resistance to trimethoprim is acquired through either a mutation or by a plasmid which 159 
codes for an altered enzyme (dihydrofolatereductase) to which trimethoprim cannot bind.[62]  160 
Ampicillin resistance 161 
Ampicillin is a beta-lactam drug and resistance to this drug is often caused by production of beta-162 
lactamases, of these TEM-1, SHV-1, PSE-1 and OXA-1 are the most frequently described 163 
mechanisms.[63] These beta-lactamases break down beta-lactam antibiotics, and can be transferred 164 
on plasmids. 165 
 166 
Aminoglycoside resistance  167 
Aminoglycoside resistance in Campylobacter is chromosomal, and the antibiotic is broken down by 168 
an enzyme. Except for kanamycin resistance, which is usually plasmid-borne. Resistance in this case is 169 
acquired by enzymatic alteration of the drug.[64] Kanamycin resistance is more common in C. coli 170 
than in C. jejuni, and is often found in combination with tetracycline resistance for which the 171 
resistance determinants are often found on the same plasmid. 172 
 173 
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3 Salmonella 1 
3.1 Salmonella  2 
Salmonella belong to the family Enterobacteriaceae together with other genera such as Escherichia, 3 
Proteus and Enterobacter. All these bacteria are characterised as Gram-negative, non-sporulating 4 
rods, facultative anaerobic, oxidase-negative (does not contain cytochrome c oxidase and can 5 
therefore not utilise oxygen for energy production), fermenting sugars to produce a variety of end 6 
products, e.g. lactic acid and acetic acid.[65] Salmonella spp. use flagella for their movement. 7 
Nomenclature  8 
Salmonella nomenclature is complex; there are more than 2600 known serotypes.[66] For a long 9 
time, two nomenclature systems based on a) Le Minor and Popoff[67] and b) the Bacteriological 10 
Code[68], were in use, which inconsistently divided the genus into species, subspecies, subgenera, 11 
groups, subgroups, and serotypes (serovars).[69]  12 
Kauffmann and White proposed the first classification system in the 1920’s and was based on 13 
serological classification of the O (somatic) and H (flagellar) antigens.[70] According to this system, 14 
each serotype originally was a separate species. In 1973, Crosa et al.[71] performed a polynucleotide 15 
sequence relatedness study. All serotypes and subgenera I, II and IV of Salmonella and all serotypes 16 
of Arizona were shown to be related at the species level and thus formed a single species Salmonella 17 
cholerasuis.[72] In 1986, the name S. enterica was proposed for the species Salmonella[73], as was 18 
previously proposed by Kauffmann and Edwards. This request for change in the nomenclature was, 19 
once more, proposed by LeMinor and Popoff of the WHO Collaborating Centre formally made a 20 
proposal as “request for an opinion” to the Judicial Commission of the International Committee of 21 
Systematic Bacteriology in 1987.[67] This request was denied by the Bacteriological Code which 22 
governs the taxonomy. Several researchers (Euzéby, Yabuuchi & Ezaki) have pleaded for an official 23 
statement to deal with the discrepancies between the nomenclature as proposed by Le Minor & 24 
Popoff and that which is officially recognised by the Bacteriological Code.[74, 75] In 2005 the Judicial 25 
Commission proposed a solution to the problem of nomenclature, even though they had no 26 
authority to make nomenclature changes that affect the taxonomy of the species.[76] Up to today 27 
the Bacteriological Code has not approved of any changes.   28 
The nomenclature used in this PhD thesis is based on recommendations from the WHO collaborating 29 
labs, and was adopted by the National Reference Centre for Enteric Pathogens at the Statens Serum 30 
Institut (SSI) in Denmark and many other official institutions such as Institut Pasteur in Paris, France, 31 
which is the international WHO reference laboratory for Salmonella, and the US Centers for Disease 32 
Control and Prevention (CDC) in Atlanta, USA, is as follows: The genus Salmonella is split into two 33 
species: S. bongori, which has only one subspecies, and S. enterica, which is divided into six 34 
subspecies. Both species can be divided into the 2600 serovars mentioned earlier. In this thesis,  S. 35 
enterica subspecies enterica serovar Typhimurium will be referred to as S. Typhimurium, and S. 36 
enterica subspecies enterica serovar Dublin as S. Dublin. Using phage typing, some serovars can be 37 
divided into phage types; S. Typhimurium DT104, S. Typhimurium U292, etc. Then, there is one more 38 
distinction to make, the difference between Salmonella enterica enterica serovar typhi,which causes 39 
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typhoid fever or enteric fever, and the non-typhoid serotypes. This thesis focuses only on infection 40 
with non-typhoid Salmonella species i.e. S Typhimurium.    41 
3.2 Disease, Reservoir, Transmission and Epidemiology 42 
Disease 43 
Infection with Salmonella usually results in a self-limiting acute diarrhoea, lasting four to seven days. 44 
In some patients, episodes end in arthritis or other autoimmune complications, or the bacteria may 45 
spread and result in bacteraemia, meningitis or other invasive illness. In these cases antimicrobial 46 
treatment is necessary.[77] Most common and acute symptoms include, nausea, vomiting, stomach-47 
cramps, diarrhoea, fever and headache. Several studies report on diseases that are directly linked to 48 
salmonellosis, especially post-infectious Irritable Bowel Syndrome (IBS).[78-80]  49 
Reservoir 50 
Salmonella can be found worldwide and has been isolated from virtually all vertebrate and 51 
invertebrate, and in the environment. It has always been thought that the main reservoir for human 52 
infection for non-typhoid salmonella is production animals.[81] A recent study of Mather et al.[82], 53 
may shed new light on this hypothesis though. By means of genome sequencing these researchers 54 
created a phylogenetic tree of 262 Scottish isolates of S. Typhimurium DT104, showing that 55 
circulation of DT104 occurred mainly separately in humans and in animals, with only a low frequency 56 
of spill-over in either direction.[82] Future research will have to proof whether this is valid for other 57 
phage types as well. 58 
Transmission  59 
Salmonella is transmitted through faecal-oral transmission, and usually has an incubation time 60 
between six and 48 hours. The infectious dose is relatively low; dose-response modelling of outbreak 61 
data suggests that an infective dose for 50% of the subjects (ID50) for infection is as low as 7 colony 62 
forming units (CFU) and the ID50 to cause illness was estimated at 36CFU’s.[83] The ID50 is 63 
depending on the health status of the host and the vehicle in which the bacteria are suspended.  64 
Four different ways of transmission for human infection can be distinguished; foodborne, contact 65 
with animals, environmental (including water) and person to person contact.[84-86] 66 
Epidemiology 67 
The most common source for human infections with non-typhoid Salmonella are foods of animal 68 
origin, typically meat and chicken eggs.[87]. These routes of food-borne transmission can 69 
theoretically be prevented by using proper kitchen hygiene and thoroughly cooking of the food 70 
products. Salmonellosis is more problematic when the bacteria are found in ready-to-eat products 71 
like instant milk for infants[88, 89], cheese[90, 91], chocolate[92], fresh herbs[93, 94], potato 72 
crisps[95], smoked salmon[96] and in ice-cream[97] to name a few. Over the past few years, fresh 73 
produce has become a more important source of contamination, which is on the increase, although 74 
imported pork still remains the most common source of infection, In Denmark.[98] 75 
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 76 
Figure 3.1: Estimated sources of 1,166 cases of human salmonellosis, Denmark 77 
Source: Annual report of zoonosis in Denmark 2011 78 
 79 
Person-specific factors also play a role in the epidemiology of Salmonella. The incidence of non-80 
typhoid Salmonella is usually the highest in young children and elderly people.[2] It should be noted 81 
that elderly patients often have a higher co-morbidity and higher 1-year mortality than younger 82 
Salmonella patients.[99] Behavioural factors such as less travelling, more institutional meals, or 83 
better kitchen hygiene amongst the elderly may counteract this surveillance bias.[100] Elderly 84 
patients are also more likely to develop serious consequences and would therefore require 85 
hospitalisation with a Salmonella infection. This is due to an impaired immune function, expressed in 86 
an elevated cytokine release by monocytes and neutrophils caused by an interaction of 87 
lipopolysaccherides with a serum factor in the blood of elderly.[101]  88 
An elaborate study conducted in Denmark on risk factors for acquiring gastrointestinal disease 89 
identified a number of modest but noticeable associations: 90 
Unlike what’s noticed in third world countries, in Denmark the risk of several bacterial infections 91 
increased with increasing income level – this might be explained by  differences in travel activity and 92 
dietary habits (eating out and eating more ‘exotic’ food).[84] Exotic food can be considered to be 93 
food that is not native to Denmark or Europe; ingredients that are used for Asian or African food for 94 
instance. Marked risk differences were seen for immigrants or persons whose parents were born 95 
outside Denmark. Specifically the risk of infection with bacteria associated with consumption of pork 96 
(S. Typhimurium) was markedly reduced.[102, 103]  97 
 98 
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Asymptomatic carriage of Salmonella 99 
Asymptomatic carriage of Salmonella has been described[104-106], and carriers may harbour the 100 
bacterium in their liver and bile ducts, which is then excreted into the bowels . The most famous 101 
healthy carrier was “typhoid Mary”.[107] 102 
As mentioned in a previous chapter on antimicrobial resistance, the human gut flora has several roles 103 
as a modifier in the risk of acquiring clinical salmonellosis upon exposure; first the gut flora provides 104 
a natural barrier for pathogens to cause damage (along with the gastric acid). On the other hand, the 105 
microbial intestinal flora can also form a niche for pathogens to hide and cause an opportunistic 106 
infection when this barrier of the commensal flora is washed out by a course of antimicrobials or 107 
other drugs. Healthy carrier status of people is well described feature of non-typhoid 108 
salmonellosis[108, 109], but there is one famous case found in history; typhoid Mary, figure 1. Mary 109 
Mallon was an Irish immigrant in the United States from 1863. This lady was an asymptomatic carrier 110 
of typhoid, at a certain moment she was known to have suffered a mild form of typhoid fever 111 
(Salmonella Typhi), and had recovered from it. Mary was working as a cook, and had to change 112 
households every time the family she had been cooking for, got ill with food-poisoning. By moving 113 
from family to family she infected 43 people of which three people died. After she was told by states 114 
health officers that she wasn’t allowed to cook anymore and was found cooking again, she was 115 
captured and held in a hospital where she eventually died 20 years later. 116 
  117 
Figure 3.2: Typhoid Mary 118 
Source: www.everseradio.com 119 
Travers and Barza described the competitive and selective effect of antimicrobial resistance[110], see 120 
description in Chapter 2. The selective effect occurs during a period when an antimicrobial is taken, 121 
according to Travers and Barza, it is possible that a patient is colonised with an antimicrobial-drug 122 
resistant Salmonella in the past, but that the dose was too low to cause disease. In this case, it is 123 
likely that Salmonella can cause disease when the patient begins  a course of antimicrobials, to which 124 
the bacterium is resistant too, causes selection and proliferation of the strain which can  trigger an 125 
infection. This hypothesis is supported by the results from two studies described in this thesis; 126 
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Manuscript I and Manuscript II.[111, 112] This selective effect has also been described in cancer 127 
patients treated with chemotherapy and acquire  Salmonella infection after, even though their stools 128 
were clean on hospital admittance.[113] 129 
3.3 Burden 130 
Incidence  131 
Salmonellosis is an important public health issue worldwide. The global incidence of salmonellosis is 132 
estimated to be 93.8 million cases (95% CI: 61.8 – 131.6 million), with 155,000 deaths (95% CI: 39,000 133 
– 303,000 deaths).[114] The reported incidence greatly differs between countries, and is dependent 134 
on the quality of the surveillance system, actual disease-load, health-care seeking behaviour of 135 
people, and laboratory practices. The European Food Safety Authority (EFSA) reports on 136 
salmonellosis in humans and food animals.[115] Human salmonellosis was reported 97,897 times in 137 
the member states of the European Union to The European Surveillance System (TESSy) in 2011[116]. 138 
Whilst Havelaar et. al. estimated the real incidence of Salmonella to be 6.2 million cases (95%CI 1.0-139 
19 million),[117], this estimation was based on disease risk of a Swedish travellers study.[118] In this 140 
study, the risk of returning home after a holiday with campylobacteriosis and salmonellosis were 141 
calculated. They calculated that only one in every 58 cases of salmonellosis were actually notified in 142 
the EU.  143 
The EU notification rate was 20.7 cases per 100.000 population, and showed a 5.4% decrease in 144 
cases compared to the previous year. Within the in EU Member States, great differences in 145 
notification rates exist, and ranges from 1.6 confirmed cases in Portugal to 80.7 confirmed cases per 146 
100,000 population in the Czech Republic.[119] However, surveillance systems in the 27 EU member 147 
countries differ greatly, making the numbers hard to compare directly. In some countries, only 148 
hospitalised cases are reported, whereas in other countries, the surveillance system is set up to 149 
capture all cases that are tested in the medical microbiological laboratories such as in Denmark.[120] 150 
The highest notification rate for these cases was for age groups 0-14 years.  151 
In Denmark the number of laboratory confirmed cases for 2011 was 1,166 (21 per 100,000 152 
inhabitants),[121, 122] and in  2010, 1598 cases were reported, corresponding to 29 cases per 153 
100,000 inhabitants.[123] 154 
Economic costs and disease burden 155 
The burden of illness due to diseases like Salmonella can not only be measured by morbidity and 156 
mortality, other major factors such as of hospitalisation, disability, long-term sequelae, and the 157 
economic costs can also be measured. These costs are hard to estimate, and differ between 158 
countries. The annual economic costs of Salmonella was estimated to be around $25.5 million (€18.2 159 
million) annually for Denmark in a study performed by Wegener et. al.[124] An estimation of the 160 
costs was also made in the UK in 2003, where modellers calculated the impact of the illness and the 161 
cost of the resources used.[125] This was an extensive study, not only taking the costs of the National 162 
Health Service (NHS) into account i.e. hospital costs, GP costs, laboratory testing cost, etc, but also 163 
the estimated time off work were adjusted for gender and occupational grouping. On top of that, the 164 
cost of people who did get infected but did not present to themselves at the GP or hospital were 165 
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included. According to this study, the average costs per case of salmonellosis was £606 (€702).[126] 166 
In 2010, a similar study was performed in the UK, and in that study the costs increased to £1282 167 
(€1484) and £993(€1150) per case of S. Typhimurium and S. Enteritidis, respectively.[127] The costs 168 
for each sequel of salmonellosis were estimated from a questionnaire filled out by patients. The 169 
substantial difference in amount of money per case can probably be attributed to the difference in 170 
the data used to calculate the cost; the last study did not include the costs of laboratory tests, 171 
sample collection and analysis. It is likely that the study of Roberts et al. is an underestimation of the 172 
real costs. In developed countries ,mortality due to salmonellosis is low, but the associated morbidity 173 
remains high.[128, 129]  174 
Underreporting and under-ascertainment 175 
Due to the way surveillance systems are set up, national registration databases only contain a 176 
fraction of the number of infections that occur in the general population. Not all exposure to infected 177 
food leads to an infection, and furthermore only a fraction of infections results in disease, of which  178 
only some of the symptomatic cases will seek medical care, see Figure 3.3. Health care seeking 179 
behaviour of individuals is influenced by several factors. Most important are a) occurrence of bloody 180 
diarrhoea, b) fear that the symptoms might be indicative of a serious disease, c) long duration of 181 
diarrhoea.  Other factors have also been associated with healthcare seeking behaviour, such as being 182 
under 5 years or over 65 years of age, low household income and male gender.[130, 131] It is 183 
estimated that between 10-20% of people with acute gastrointestinal symptoms seek medical 184 
care,[130, 132]and of those people seeking medical care between 3-19% submit a stool sample for 185 
culture.[130, 132]  186 
Reporting of national data is usually based on the numbers that are reported to the national 187 
surveillance labs, as can be seen in the surveillance pyramid below. This demonstrates the 188 
underestimation of real cases seen in the population. 189 
 190 
Figure 3.3; Pyramid of surveillance and underreporting of gastro-intestinal infections  191 
*NSS: National Surveillance System 192 
# NSS* 
#laboratory 
confirmed cases 
# cases submitting stool 
sample 
# cases seeking medical care 
# infected (symptomatic and 
asymptomatic) 
# people exposed in the general population 
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Another approach to estimate the true incidence of Salmonella in various countries is sero-incidence 193 
estimation. This method has been developed for Salmonella by Simonsen[133]. This method uses the 194 
measurement of Salmonella serum antibodies in randomly collected blood sera to make an 195 
estimation of the sero-incidence in human populations from several European countries. This 196 
method led to an estimation of 325 infections per culture-confirmed case captured in the Danish 197 
National Surveillance Programme. The same approach has also been used on collections of blood-198 
sera in other countries. Countries that were included in the study were; Finland, Sweden, Denmark, 199 
the Netherlands, Italy, Romania, France and Poland. Sero-incidences differed by ten-fold between 200 
the various countries, from 56 – 547 per 1000 person years. These estimates represented a ~100-201 
2000-fold increase compared to  the reported incidences by the National Surveillance Systems[134]. 202 
In conclusion, “serosurveillance” is a useful method to estimate the infection pressure within a 203 
country. This method is also useful for comparisons between countries, since the national 204 
surveillance systems in each country has a different set-up, and therefore a different sensitivity to 205 
pick up the true number of cases. On the other hand, serosurveillance is not a measure of the burden 206 
of illness, as an antibody response does not necessarily mean that the person got ill. It is merely an 207 
observation of the fact that a person came into contact with Salmonella, which elicited an immune 208 
response.   209 
3.4 Typing 210 
There are many different typing methods used to identify and characterise Salmonella for 211 
epidemiological investigations, surveillance and research purposes. The choice of method depends 212 
on the circumstances and the objectives, and often also the country in which the typing is performed. 213 
Typically, more than one method is used to improve the quality of the typing. In Denmark, all 214 
Salmonella isolates from human cases are serotyped.   215 
Serotyping 216 
Serotyping is the most basic and common form of Salmonella typing. Serotypes of Salmonella are 217 
based on the difference in the type of surface antigens(O) and the flagellar antigens (H). These 218 
antigens are detected using a slide agglutination test with commercially produced antisera. The O 219 
antigens uses a bacterial suspension from an agar plate, while H antigens uses a bacterial suspension 220 
from broth culture. The serotype is deduced from the specific pattern of agglutination reactions 221 
using the Kauffmann-White classification scheme. For instance Salmonella enterica serotype 222 
Typhimurium would have O antigens 4,5,12 , and H antigens i:1,2, the monophasic variant of 223 
Salmonella Typhimurium has O antigens 4,5,12 and H antigens i- (missing). 224 
 225 
Fig 3.4: Salmonella serotyping with slide agglutination (Source: Food & Drug Admisnistration (FDA)) 226 
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Phage typing 227 
(Bacterio)Phage typing is a classical technique that is commonly used to subtype the more frequently 228 
occurring Salmonella serotypes like S. Typhimurium and S. Enteritidis. Phage typing is based on a set 229 
of specific bacteriophages that lyse the bacteria. Phages are viruses that can infect and destroy 230 
bacterial cells only, and are strain specific. The method is performed by spreading the bacterium on 231 
an agar plate, and  drops containing the different phages are spotted. After overnight incubation, the 232 
plates are checked for plaques, which are clear zones that indicate a phage has inhibited the growth 233 
of the bacteria. The susceptibility of the strain to the different phages can be compared with  known 234 
phage types.[135] It is likely that molecular typing methods will replace this phenotypically based 235 
method because it is difficult to maintain phage stocks and because of problems with standardization 236 
between labs.  237 
 238 
Figure 3.5: Example of Salmonella phage typing (Source: alexmedicalteam2014.blogspot.nl) 239 
Pulsed Field Gel Electrophoresis (PFGE) 240 
PFGE is a highly discriminatory method for differentiation of bacterial isolates on the basis of DNA 241 
content. This method uses specific restriction enzymes to cut the DNA producing fragments of 242 
different sizes. These fragments can range between 20-500Kbwhich are resolved using a specialized 243 
electrophoresis setup.  The resultant banding patterns can be compared with one another strain 244 
patterns to determine genetic relatedness, see Figure 3.6 below. Because of the high discriminatory 245 
power of PFGE, it is frequently used in outbreak investigations. It should be noted that random 246 
genetic events, like point mutations or insertions or deletions as well horizontal transfer of mobile 247 
genetic elements e.g. plasmids can alter the banding patterns. Therefore it is recommended that at 248 
least ten distinct fragments of DNA are resolved for a comparison.[136] PFGE is currently a golden 249 
standard for subtyping. [137, 138]  250 
 251 
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 252 
Fig 3.6: Example of Salmonella PFGE-patterns 253 
Source: foodscience.cornell.edu 254 
Multiple locus variable number tandem repeat analysis (MLVA)  255 
MLVA has been used for typing Salmonella. It uses the naturally occurring variation in the number of 256 
tandem repeated DNA sequences found at specific loci within the genome. These loci are PCR 257 
amplified and depending on the band sizes, the number of repeats are estimated at each loci 258 
producing a combined string of integer numbers. At SSI (Denmark), MLVA-typing is commonly used 259 
for S. Typhimurium because it is more discriminatory then PFGE.[139] 260 
3.5 Surveillance in Denmark 261 
In Denmark the surveillance for Salmonella is performed in three different areas: humans, food 262 
producing animals, and food products.  263 
Surveillance of Salmonella in humans 264 
Diagnosis of human salmonellosis is performed by Enteric Reference laboratory at SSI and in 14 265 
microbiology laboratories within the country. All laboratories must notify all Salmonella cases to SSI. 266 
All strains received at SSI are serotyped, antimicrobial testing is performed, and MLVA and/or PFGE 267 
are performed on selected isolates. MLVA is used for all cases of S. Typhimurium and has been 268 
shown to be useful for outbreak detection. Antimicrobial testing is performed using the diffusion 269 
method (Neo-Sensitabs, A/S Rosco, Roskilde, Denmark, using EUCAST clinical breakpoints). Phage 270 
typing was performed at the National Food Institute at the Technical University of Denmark, which is 271 
now outsourced to a private laboratory.  272 
Since 2007, SSI also collects travel information on all Salmonella cases through a short interview 273 
performed by a special interview team at the Epidemiology Department. Information is gathered on 274 
whether patients had travelled abroad up to two weeks before onset of disease, and to which 275 
country they travelled to. This data is published in the DANMAP reports and in the Annual Report on 276 
Zoonoses.[98, 140]  277 
Trends in human infections including clusters of cases are discussed at a weekly meeting at the 278 
Danish Zoonosis Centre, which is a network that includes the National Food Institute, SSI and the 279 
Danish Veterinary and Food Administration, see Figure 3.7 for a surveillance overview. 280 
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 281 
FIG 3.7: OVERVIEW OF THE MONITORING AND OUTBREAK INVESTIGATION NETWORK FOR REPORTING INFECTIOUS PATHOGENS IN HUMANS, 282 
ANIMALS, FOODSTUFFS AND FEEDSTUFFS IN DENMARK, 2011 283 
 284 
Surveillance of Salmonella in food producing animals  285 
Poultry 286 
Laying hens and broiler chickens in Denmark have a very low prevalence of Salmonella due to a top-287 
down eradication programme.[141] The Danish National Surveillance programme for Salmonella has 288 
been in place since 1988 for broiler hens, and since 1998 for layer hens,  and was reviewed in 289 
2003.[142, 143] Infected flocks of breeding animals were removed from the breeding chain and 290 
slaughtered for consumption. As a result of this strategy, the number of Salmonella infected chickens 291 
and contaminated eggs in the Danish market was reduced drastically.[144] The incentive for farmers 292 
to co-operate with this programme was that they would receive a better price for meat that had a 293 
“Salmonella free-flock” label. Denmark also issued a ban on selling eggs from Salmonella- infected 294 
layer hens flocks, and now has now obtained a special guarantee for consumer eggs in the EU, 295 
meaning that Denmark can require that imported eggs to be Salmonella-free.  296 
Pigs 297 
Pig herds as well as pork from the slaughterhouses are routinely tested for Salmonella. Herds are 298 
categorised into three levels according to their sero-positivity. Owners of a Salmonella positive-herd 299 
are encouraged to seek advice on how to reduce Salmonella-infections on their farms using hygienic 300 
protocols, feeding schemes, etc. Furthermore, owners of sero-positive herds will receive less money 301 
from the slaughterhouse for their animals.[145] Due to introduction of the Salmonella control 302 
programme, the prevalence of Salmonella in pig herds has declined, but has not reached the same 303 
low levels observed in laying hens and broilers. [146] 304 
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Cattle 305 
Since 2002, a Salmonella surveillance programme for cattle has been in place. This programme 306 
focuses on the eradication of specifically S. Dublin, since S. Dublin causes infection in cattle and is a 307 
major economical loss. S. Dublin can also cause severe disease in humans, sometimes leading to 308 
death[147]. However, due to the testing method (ELISA) used in the programme, cross reactions with 309 
other serotypes does occur. So the outcome of the surveillance, indicates  the presence of most 310 
Salmonella species. Bulk tank milk samples are serologically tested, and the average of the last four 311 
test outcomes determines the category of contamination of the farm (three levels).[148] In an 312 
evaluation of the programme, performed by Ersbøll and Nielsen, using data between from 2003-313 
2005, the incidence of positive herds declined from 22.1% to 17.0%.[149]  314 
Surveillance of Salmonella in food products 315 
From the late 1990s, imported meat was included in the Salmonella control programme, and from 316 
2006, it was decided that all meat products on the Danish market should also be included. The 317 
Regional Veterinary and Food Competent Authorities samples imported batches of meat and meat of 318 
Danish origin for the presence of Salmonella and Campylobacter. This approach is called “case-by 319 
case-control”.  In this approach, meat is sampled from broiler, turkey, cattle and pork at the moment 320 
it is imported into Denmark.. For each batch, 12 pooled samples are taken and tested for Salmonella. 321 
If a sample is found positive, it is serotyped and tested for antimicrobial resistance[150].  322 
3.6 Salmonella success clones 323 
What is a “successful-Salmonella clone”? 324 
Some Salmonella phage types seem to be more successful than other types in establishing an 325 
infection in a human host. To identify such subtypes that may emerge to be important in the future 326 
and to determine how these subtypes interact with host factors, we need to increase our knowledge 327 
on what makes a certain subtype “successful from the bacteria’s point of view”.  328 
Success can be associated with several characteristics e.g. the ability to adapt to hostile 329 
environments, including acquisition of antimicrobial resistance (increased survivability), the ability to 330 
cause severe disease (degree of virulence) in humans and animals, and the ability to persist in the 331 
human or animal reservoir, or the environment for a long period. Table 3.1 includes examples of host 332 
factors and bacterial traits that may determine the success of a Salmonella subtypes.  333 
The focus of this study was on the type of food source that might have led to the infection, the 334 
outcome of disease, some less conventional questions such as; food handling, and cleaning habits at 335 
home, and some general health questions on smoking, sports and drinking habits of the patients.  336 
 337 
 338 
 339 
 340 
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Table 3.1: Success clones: factors or bacteria-related traits that may make a Salmonella phage type 
more successful 
Host factors Underlying disease 
 
Medication 
  Other factors compromising health 
Virulence factor of the infective strain Ability to acquire antimicrobial resistance 
 
Ability to cause severe disease 
 
Infection rate 
  Ability to infect healthy hosts 
Survivability in hostile environments Freeze tolerance 
 
Resistance to toxic products 
  Resistance to drying out 
  
  
Successful clones 341 
The following Salmonella Typhimurium phage types (or definitive types) were included in the study 342 
because they had one or more traits as described in Table 1.  343 
DT104 344 
The most well-known success clone is DT104. This phage type emerged worldwide during the 345 
1990s[151-156]. This phage type is known to be multiresistant, usually being resistant to ampicillin, 346 
chloramphenicol, streptomycin, sulphonamides and tetracyclines (i.e. resistant profile ACSSuT)[157]. 347 
In this phage type these antibiotic resistance genes have accumulated in chromosomally encoded 348 
gene cassettes. This process is mediated by the presence of class 1 integrons. Additionally, some 349 
isolates also possess plasmid-mediated resistance to trimethoprim and low-level resistance to 350 
ciprofloxacin, because of point mutations in the gyrA gene. This gene cassette has also been found in 351 
phage types DT12 and DT120, although DT12 is usually an antimicrobial susceptible phage type. 352 
U292 353 
In 2008 and 2009, a large outbreak (1466 cases) of S. Typhimurium U292 occurred in Denmark. 354 
Coinciding with this large outbreak, a smaller outbreak of DT135 (197 cases) and DT3 (89 cases) also 355 
occurred. These outbreaks were condined to Denmark and seemed to be epidemiologically linked, 356 
although a common source was never found. Outbreak investigation found that these outbreaks 357 
appeared to be linked to the consumption of traditional Danish food (e.g. pork).[158] Prior to the 358 
outbreak, all three phage types were uncommon in Denmark, but since the outbreak, a high 359 
proportion of the Salmonella Typhimurium cases in Denmark are due to U292 (36% in 2009[159], 360 
11% in 2010[160], 8% in 2011[98] (since 2012 S. Typhimurium is not routinely phage typed 361 
anymore[161]). Both phage types DT3 and DT135, are rarely found in the past few years. In 2009, 5 362 
and 16 domestically acquired cases respectively  were notified, and in 2011, 3 cases of DT135 with a 363 
history of travel abroad were notified. All cases were domestically acquired. From this data it would 364 
appear that U292 has now successfully established itself in the Danish population. However, opposite 365 
other common Salmonella Typhimurium phage types, this type is rarely found in samples taken from 366 
livestock or food, and is fully susceptible to antimicrobials.  367 
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Monophasic 368 
Since 2006, the monophasic S. Typhimurium 4,[5],12:i:− (hereafter monophasic Salmonella), 369 
emerged worldwide and has become one of the most frequently isolated Salmonella subtypes in 370 
many countries.[162-164] Monophasic Salmonella, are Salmonella strains that lack a second phase 371 
flagellar antigen. Strains missing the first phase flagellar antigen or both flagellar antigens are also 372 
found, but are less common. Monophasic variants are not separate serotypes or phage types, these 373 
types are mostly found in Typhimurium strains and are found to belong to several phage types. The 374 
most common type in Denmark is the monophasic DT193 variant[165].  375 
The reason for the success of this type is still unknown. It could be that the gene msgA (which is 376 
macrophage survival protein), which is present in 4,[5],12:i-, makes the bacteria more likely to 377 
survive an attack on the immune system[166].  378 
DT12 and DT120 379 
Salmonella Typhimurium phage type DT12  was one of the most common Salmonella Typhimurium 380 
subtypes found in humans and animals, particularly slaughter pigs, during the 1990s.  Here after, the 381 
occurrence of DT12 in both humans and slaughter pigs gradually declined [167], which may be 382 
associated with the fact that this subtype hasn’t been very successful in acquiring antimicrobial 383 
resistance.[168] In contrast to DT12, DT120 has been increasingly found since 1994, and has also 384 
become more resistant to several antimicrobials over the past years, mainly due to the acquisition of 385 
a 43-kb genomic island called Salmonella genomic island I (SGI1). This pathogenic island makes it 386 
resistant to ampicillin, chloramphenicol, florfenicol, spectinomycin, streptomycin, sulphonamides, 387 
and tetracyclines. DT12 and DT120 are now the most common Salmonella types found in pigs and 388 
pork, and DT120 is the second most common type found in humans.[98] 389 
3.7 Antimicrobial drug resistance in Salmonella 390 
Global 391 
Since the publication of the Swann report in 1969, it has been recognised that antimicrobial use will 392 
lead to an increasing amount of antimicrobial resistance through selection pressure.[169]  393 
Antimicrobial resistance in Salmonella has been increasing worldwide over the past decades.[170-394 
173] Of special concern is the rising resistance to first line treatment i.e. fluoroquinolones and third 395 
generation cephalosporins. This trend is  especially high in South-East Asia and some African 396 
countries, where the highest morbidity for salmonellosis has been found.[174-180]  In Vietnam, 397 
multidrug resistance is found in 50% of strains, and resistance to nalidixic acid (fluoroquinolone) was 398 
found in 97% of all 1,193 collected strains.[181] 399 
In the EU 400 
Salmonella resistance trends are gathered by EFSA. Overall, the most common Salmonella resistance 401 
profile belong to the ASSuT-profile (resistant to ampicillin, streptomycin, sulphonamides and 402 
tetracycline), which is associated with the most common phage types: S. Typhimurium DT193, 403 
DT120, and to a lesser extend DT7.[182] 404 
37 
 
In DK 405 
Within Denmark, trends on antimicrobial resistance in Salmonella are gathered in the yearly 406 
DANMAP report. This report makes a distinction between travel-related cases and cases that are 407 
domestically acquired. The same difference is made for imported meat and Danish meat. This is done 408 
because of large differences in resistance found between the two sources for Salmonella. As can be 409 
seen in Figure 3.8, resistance against ciprofloxacin is alarmingly high(15-20%) in human cases that are 410 
acquired abroad. Guidelines for empiric treatment cut-off values for resistance of 5% are usually 411 
considered, meaning that empiric treatment with ciprofloxacin is not an option for this group of 412 
patients.[183] In 2011, ciprofloxacin resistance in S. Typhimurium were 2% and 16% in domestically 413 
acquired and travel-related cases, respectively. For S. Enteritidis, these 18% and 24%, respectively. 414 
Ciprofloxacin resistance in 2011  has increased 10% compared with previous years.[98] Resistance to 415 
cephalosporins was found in 1% of domestically acquired cases and in 12% of the travel-acquired 416 
cases.[98] 417 
 418 
Figure 3.8 Resistance in Salmonella Typhimurium from different sources, Denmark, 2011. 419 
Source: DANMAP 2011. 420 
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4 Campylobacter  1 
4.1 Campylobacter general 2 
The genus Campylobacter belong to the class  of epsilon-proteobacteria. Campylobacter are Gram-3 
negative, oxidase positive, curved rods, and belong to the same order as Helicobacter. 4 
Campylobacter are adapted to colonise the mucosal surface of the gastrointestinal tract. 5 
Campylobacter have long flagella, which in combination with their spiral shape, enables them to 6 
move rapidly in a “corkscrew”-motion through the mucous.[184, 185] For optimal growth, 7 
thermophilic Campylobacter such as C. jejuni, require a microaerobic environment and incubation 8 
temperatures of 37–42°C.[186]  9 
 10 
Figure 4.1: Campylobacter spp. 11 
SOURCE: CAMPYLOBACTER.ORG 12 
Nomenclature 13 
Overall, there are 16 species and six subspecies of the genus Campylobacter. The two main species 14 
associated with human infections are C. coli and C. jejuni. Both C. jejuni and C. coli are thermophylic 15 
and are closely related, with the difference that C. jejuni, is capable of hydrolyzing sodium hippurate 16 
and C. coli cannot.[187] This thesis will only cover C. jejuni and C. coli infections, therefore, only these 17 
two species are meant with the term Campylobacter in the rest of this thesis 18 
Clinical manifestation of C. jejuni and C. coli infection 19 
After 2-5 days incubation, a Campylobacter-infection usually commences with sudden cramps and 20 
diarrhoea.[188] Other symptoms can include myalgia, nausea, bloody stools, headache, and 21 
vomiting.[189, 190] Campylobacter usually causes a self-limiting diarrhoeal disease but in some 22 
cases, campylobacteriosis can lead to an autoimmune disease called Guillan Barré Syndrome (GBS), 23 
which is a form of neuromuscular paralysis, and later onset of reactive arthritis.[191-194] Sepsis, and 24 
death due to campylobacteriosis are rare  but can occur occasionally.[195, 196] 25 
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Reservoir  and transmission 26 
C. coli and C. jejuni are ubiquitous, and can be isolated from most mammalian species and birds.[187] 27 
C. jejuni is particularly suited to infect birds, since the body temperature of these animals is higher 28 
(41-42°C), which is an optimal temperature for C. jejuni to grow and proliferate.[197] The main 29 
reservoir for C. coli and C. jejuni is production animals and wildlife.[198-200] Transmission to humans 30 
has been described from contaminated water sources,[201, 202] consumption of contaminated 31 
meat, in particular fresh poultry[203, 204], raw poultry food products, and other raw animal 32 
products e.g. raw milk. Direct contact with pet animals has also been shown to be a mode of 33 
transmission.[204-207] Person-to-person spread is rare.[208] 34 
Epidemiology 35 
Between 85-95% of all Campylobacter cases in Europe are caused by C. jejuni, which may be the most 36 
common cause of bacterial food-borne diarrhoeal disease throughout the world.[209] In Denmark, 37 
more than 95% of the cases are caused by C. jejuni.[121] C. jejuni is most often isolated from broiler 38 
chickens, cattle and turkeys, whereas C. coli is predominately found in pigs. 39 
Most cases of C. coli and C. jejuni infections occur sporadically, but they are known to cause large 40 
outbreaks, with a variety of sources implicated; poultry, raw milk, natural water pools, and drinking 41 
water.[210-217]  42 
Campylobacter notifications within the EU show a seasonality with the highest incidences in the 43 
summer. It is hypothesised that is due to people eating raw poultry meat from BBQs [218], but high 44 
Campylobacter notifications are also correlated with environmental factors such as temperature, 45 
rainfall and agricultural density.[219-221] A number of Campylobacter-infections are acquired during 46 
foreign travel, and returning travellers during the summer may also contribute to the 47 
seasonality.[222] 48 
Fig x seasonality of Campylobacter cases in Denmark 2009-2011 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
Figure 4.2: Seasonality of Campylobacter cases 2009-2011 58 
Source: van Alphen, ESCAIDE 2012 59 
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The infective dose for campylobacteriosis is estimated to be low as 500-800 CFU, depending on host 60 
factors and the nature of which the Campylobacter was acquired.[223]Gastric acid generally is a good 61 
natural barrier for campylobacteriosis as Campylobacter are sensitive to the acidic-environment. 62 
Bouwknegt et al. (2013) found that consumption of proton-pump inhibitors which reduces the 63 
production of stomach acid, and is linked to a higher incidence of campylobacteriosis.[224]   64 
Gut flora 65 
In several animals, Campylobacter is commonly found without causing disease to the animal, 66 
especially in cattle, which are known to be asymptomatic carriers.[225] Humans have also been 67 
observed to be asymptomatic carriers.[226-228] 68 
4.2 Burden 69 
Incidence and economic costs 70 
In 2010, the estimated global number of deaths due to campylobacteriosis was 109,700 deaths 71 
(95%CI 81,800–137,200)[229]. The amount of disability adjusted life years (DALYs: an absolute 72 
measure for health loss) in that same year due to Campylobacter infections was 7,541/100,000 73 
DALYs (95% CI 5,687–9,374).[230] The highest burden of disease for campylobacteriosis is in children 74 
under 5 years in both developing and developed countries.[231] The high disease burden in this age 75 
group is probably due to the fact that host immunity plays a large role in acquisition of a 76 
symptomatic Campylobacter infection.[231] According to Coker et al., the incidence of 77 
campylobacteriosis in children <5years of age differs in developing countries between 40,000 – 78 
60,000/100,000 to 800/100,000 in the developed world.[232, 233]  79 
In 2011, human campylobacteriosis was the most often reported zoonosis in the European Union 80 
with more than 220,000 cases.[234] The EU-notification rate was 50.3/100,000 population, and 81 
showed a 2.2% increase in comparison with data from the previous year. There is great differences in 82 
notification rates exist within EU Member States, ranging from 178 /100,000 inhabitants in the Czech 83 
Republic to 0.31/100,000 inhabitants in Latvia. As mentioned in the previous chapter 3, the 84 
surveillance systems in EU Member States differ. In some countries only hospitalisations are 85 
reported, while in other countries  there are  enhanced surveillance systems. Havelaar et. al. (2009) 86 
estimated the incidence of campylobacteriosis by using Swedish traveller data and found incidences 87 
between 30-13,500/100,000 population, with the highest incidence in Bulgaria, and the lowest 88 
incidences in Sweden and Finland. In Denmark it is estimated  that there are 251/100,000 89 
population[231], and in 2011 it was 73.1/100,000 population, which was similar to the incidence 90 
reported in 2010.[121] 91 
The actual cost of gastrointestinal disease does not only encompass direct costs made by the patient 92 
visiting the GP, and the hospital, but also include indirect costs due to days of work lost because of 93 
illness. Direct costs may also include the health care costs due to reactive arthritis and GBS after a 94 
Campylobacter infection. In Denmark, no actual costs-of-illness studies have been performed, but 95 
Mangen et. al. (2005) performed a study in the Netherlands, which is a country similar to Denmark in 96 
terms of the health care system. The researchers calculated that the annual costs as a result of 97 
campylobacteriosis  are approximately 21 million Euros per year. The Dutch population is 98 
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approximately three times the size of the Danish population, and the estimated incidence[117] in the 99 
Netherlands is approximately 6 times higher in Denmark; meaning the Danish annual cost would be 100 
approximately 1.2 million Euros per year, based on the costs calculated in 2005. However, this is a 101 
very rough calculation, and other cost-of-illness studies estimated 77[235]- 780 Euro[236] per case of 102 
gastroenteritis, depending on the variables are included in the calculation, both studies conclude that 103 
indirect costs (productivity loss) due to illness make up the largest sum. 104 
Underreporting and underascertainment 105 
Like salmonellosis and other gastrointestinal diseases, campylobacteriosis is underreported[237]. Not 106 
everyone who suffers from acute gastroenteritis will visit a GP, and not all of the cases that are 107 
reported to the GP will provide a stool-sample for analysis, see Figure 3.3 on page 20 in Chapter 3. 108 
Seroprevalence studies may be applied to estimate the exposure to Campylobacter. This is a method 109 
which uses serum antibodies as a biomarker to estimate seroconversion rates as a proxy for infection 110 
pressure.  This method, performed by Teunis et. al. estimated a rate of 0.80 infections per person per 111 
year.[238]  112 
4.3 Typing 113 
 For general diagnostic purposes, Campylobacter are usually not identified to the species level, e.g. 114 
no difference is made between C. jejuni and C. coli.  However, for surveillance purposes, 115 
identification of to the species level is usually performed in a subset of strains. Further strain typing is 116 
usually not carried out as a routine activity using phenotypic methods like serotyping and phage 117 
typing.[239] Various genetic methods that can be used for typing include a species specific PCR assay 118 
on restriction fragment length polymorphisms (RFLP), fla-typing, PFGE and ribotyping.[240-242] 119 
4.4 Surveillance in Denmark 120 
Surveillance of Campylobacter in humans 121 
Since 1980, culture based national surveillance for Campylobacter has been carried out in 122 
Denmark.[243] Campylobacter is a notifiable disease and all laboratory confirmed human cases are 123 
reported through the National laboratory surveillance system to the National Gastrointestinal Unit at 124 
SSI and entered into the National Register of Enteric Pathogens. 125 
Surveillance of Campylobacter in food producing animals  126 
All broiler flocks are under surveillance for Campylobacter since 1998. Before 1998, a subset of all 127 
flocks was monitored for DANMAP. Since 1995, pigs and in cattle (caecal content of one animal per 128 
herd) were also included in the monitoring scheme. Only on suspicion, are wildlife, zoo-animals and 129 
pets screened for Campylobacter. These numbers are low and not representative for surveillance 130 
purposes but do get published in the Annual Report on Food Zoonosis every year.  131 
Surveillance of Campylobacter in food products 132 
The Danish Veterinary and Food Administration (DVFA) collects samples from meat sold at wholesale 133 
and retail outlets. The Campylobacter species are identified and antimicrobial testing is performed at 134 
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the National Food Institute. For Campylobacter, the case-by-case-control is also applied, see chapter 135 
3.  136 
4.5 Antimicrobial drug resistance in Campylobacter 137 
Global 138 
Antimicrobial resistance levels in Campylobacter, in particular to macrolides and fluoroquinolones 139 
are of concern since these two drugs are the first line treatments for severe infections with this 140 
bacterium. Resistance against both drugs have been emerging globally in the past decades.[244-246] 141 
An example is erythromycin (macrolides) resistance, which is mainly found in strains of animal origin 142 
especially C. coli originating from pigs and chickens.[247] 143 
EU 144 
Antimicrobial resistance in EU Member States is monitored by both EFSA and ECDC, and the yearly 145 
results are published in The European Union Summary Report on antimicrobial resistance in zoonotic 146 
and indicator bacteria from humans, animals and food. In the latest report on the data from 2010, it 147 
was reported that resistance levels of Campylobacter from human isolates against fluoroquinolones 148 
(~45%), ampicillin (~35%) and tetracylines (~30%) were high, whilst resistance levels to macrolides 149 
(~15%), remain at a comparable low level in the EU.[234] In Campylobacter from animal origin i.e. 150 
fowl, pigs, cattle and broiler meat, levels of resistance against fluoroquinolones and tetracycline were 151 
high, whilst resistance levels against macrolides and aminoglycosides were low.[234] A variety of 152 
testing methods are used in the different countries, both disk diffusion and dilution methods, and a 153 
different guidelines to interprete resistance. Laboratories  use either CLSI, EUCAST, British Society for 154 
Antimicrobial Chemotherapy or the French Society for Microbiology guidelines. Interpretation 155 
differences of one or even two dilution steps exist between the guidelines. Although, according to 156 
EFSA and ECDC, laboratories and societies like CLSI and EUCAST, are working to diminish the 157 
differences that exist between these guidelines.[234]  158 
DK 159 
Denmark collects data on resistance for Campylobacter isolates of human origins in two categories: 160 
“domestically acquired” and “travel-related”. The levels of antimicrobial resistance  differs greatly 161 
between the two categories. Since 2007, SSI collects data on travel history of patients in the National 162 
Registry for Enteric Patients. Patients are asked about the date of onset of disease and whether they 163 
had travelled abroad in seven days prior to onset of disease. If the patient had not travelled abroad 164 
then the infection is categorised as “domestically acquired”.  Resistance to fluoroquinolones in 165 
domestically acquired cases are 33% and in travel-related cases it is 84%, Resistance to macrolides 166 
are 0% and 3% respectively.[121] 167 
 168 
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5 Materials & Methods 1 
This chapter describes the materials and methods used in the studies included in this thesis. The 2 
chapter consists of three sections: 1) a description of the databases used extracting data for all three 3 
studies, 2) a description of the original and final set up of the telephone-interview study (Manuscript 4 
III), including data collection and analyses, and 3) the data and methods applied in Manuscript I and 5 
Manuscript II. 6 
5.1 Databases in Denmark 7 
CPR registry (Civil Registration System) 8 
Since 1968, upon birth or immigration, every Danish citizen and resident receives a CPR number, 9 
which is a unique personal identifier. All CPR-numbers are kept in the Danish Civil Registration 10 
System; within this system CPR-numbers are associated with the name, gender, civil status, 11 
citizenship, date of birth, and vital status of each individual.[248-250] 12 
For the studies included in this thesis, encrypted CPR-numbers were used to link data from different 13 
national registries. All patient data was held and linked by Denmark Statistics on whose servers the 14 
analyses of the first two manuscripts were  performed.  15 
National Registry of Enteric Pathogens 16 
This registry contains data on all  infections with gastrointestinal bacterial pathogens, confirmed by 17 
faecal culture or by culture from a normally sterile site are diagnosed at either SSI or one of ten local 18 
clinical microbiological laboratories. In cases where a patient tests positive for the same bacterium 19 
(e.g., Salmonella serotype or Campylobacter spp.) multiple times within six months of the first 20 
diagnosis: these cases are considered to be recurrent or persistent and consequently, the laboratory 21 
enters only the first episode into the database. Each entry is coupled to the patient’s CPR number, 22 
date of onset, pathogen and antimicrobial susceptibility profile of the pathogen.[121, 251] 23 
This database was used in all three manuscripts to identify patients with either Salmonella or 24 
Campylobacter (C. coli and C. jejuni) infections. 25 
Danish National Prescription Registry 26 
Antimicrobial drugs are available by prescription only in Denmark, consequently their use can be 27 
monitored through the Danish National Prescription Registry (DNPR); a database available to 28 
researchers from Statistics Denmark, the data encompasses all prescriptions of drugs sold at 29 
pharmacies in Denmark since 1994. In 2012, the Danish Medicines Agency became the owner of the 30 
data, which is currently maintained at SSI. This registry contains information on dispensed 31 
prescriptions and includes data on the drug user (i.e. CPR number, gender, municipality and region of 32 
residence), the pharmacy (i.e. name and address), and details on the drug dispensed (i.e. ATC-code, 33 
dose, dispensing date, etc.). The DNPR does not contain data on over-the-counter drugs (drugs sold 34 
without a prescription like paracetamol), drugs administered to patients in the hospital, and the 35 
indication for prescribing the drugs. 36 
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Data from the DNPR was used to derive data on history of antimicrobial use in Manuscript I and 37 
Manuscript II. 38 
Integrated Database on Labour Market Research 39 
The Danish Integrated Database for Labour Market Research (IDA) has been developed and managed 40 
by Statistics Denmark  since 1988 and is primarily used for research purposes. The registry contains 41 
information on socio-demographics (i.e. income, employment, gender, age, educational level, family 42 
and household).[252, 253] 43 
Data from this database was used in Manuscript I and Manuscript II to control for the potential 44 
confounding effect of educational level and socioeconomic status.  45 
5.2 The registry-based studies (Manuscript I and II) 46 
Antimicrobial susceptibility testing on Salmonella and Campylobacter 47 
Susceptibility testing of Salmonella and Campylobacter was performed on a sample of submitted 48 
strains received by the Unit of Gastrointestinal Infection of SSI. Susceptibility testing of 49 
Campylobacter against macrolides and fluoroquinolones was performed on a large percentage of 50 
strains, as these antimicrobials are first line of treatment drugs,  testing  against a more extensive 51 
panel of antimicrobial drugs was performed in a random sample of.   52 
Antimicrobial drug susceptibility was tested by determining the minimum inhibitory concentration 53 
(MIC) with micro broth dilution method using a commercially available MIC technique (Sensititre, 54 
Trek Diagnostic System, UK), according to CLSI guidelines (Clinical and Laboratory Standards Institute) 55 
for samples before 2007. From 2007 on, EUCAST epidemiologic cut-off values (ECOFFs) were used. 56 
The cut-off values differed over the years included in the study (see DANMAP 1997-DANMAP 2005, 57 
and DANMAP 2010; www.danmap.org), for the analyses we included the cut-off points that were 58 
valid for the year each sample was entered in the NREP. The MICs were interpreted and denoted as S 59 
(susceptible), I (intermediately resistant), and R (resistant). All intermediate resistant samples were 60 
considered to be susceptible in all three manuscripts included in this thesis. Antimicrobial drug 61 
resistance tested for, and included in Manuscript I and II, are described in Table 5.1 below. 62 
Table 5.1: Definition of the groups of antimicrobials included in Manuscript I and II 
Groups of  
antimicrobials 
ATC 
code 
Antimicrobials tested for in  
susceptibility test 
Aminoglycosides J01GB 
streptomycin, gentamicin, apramycin 
kanamycin, spectinomycin 
Amphenicols J01B Chloramphenicol 
Extended spectrum penicillins J01CA ampicillin, mecillinam 
Fluoroquinolones J01M ciprofloxacin, nalidixic acid 
Other antibacterials J01X 
collistin, nitrofurantoin, polymixin,  
fosfomycin,  
Sulphonamids and trimethoprim J01E sulfamethoxazole, trimethoprim 
Tetracyclines J01A Tetracycline 
Third generation cephalosporins J01DD Ceftriaxone 
47 
 
Data 63 
Salmonella 64 
Data for Manuscript I, included samples from 1997 to 2005. In total, 97%  (4,534/ 4,675) of S. 65 
Typhimurium, 35% (4,195/12,195) of S. Enteritidis, and 29% (1679/5776) of other Salmonella  were 66 
susceptibility tested. Susceptibility testing for the following groups of antimicrobials were included in 67 
the study: aminoglycosides, amphenicols, extended-spectrum penicillins, fluoroquinolones, other 68 
antibacterials (ATC code J01X), sulphonamides and trimethoprim, tetracyclines and third generation 69 
cephalosporins. See Table 5.1 for the ATC-codes,  and antimicrobials included in each group. 70 
Campylobacter 71 
Manuscript II included samples taken between 1999 and 2005. Susceptibility testing for macrolides 72 
and fluoroquinolones was performed on 10,275 (32%) of 31,669 patients included in the study. 73 
Resistance to other antimicrobials was performed on a much smaller percentage of the sample and 74 
was therefore not included in our analysis. 75 
Methods 76 
For Manuscript I and Manuscript II, similar methods were applied to calculate the odds that previous 77 
antimicrobial use has a long term effect on acquiring an antimicrobial resistant infection with 78 
Salmonella or Campylobacter (C. coli and C. jejuni). Descriptive analysis were given on the prevalence 79 
of resistance and the use of different classes of antimicrobial drugs, and conditional logistic 80 
regression was performed to investigate the odds of exposure to a course of antimicrobial drugs 81 
before diagnosis with either Salmonella or Campylobacter, and to calculate the odds of a strain being 82 
resistant to the antimicrobial previous taken.  83 
Study design 84 
Both  Manuscript I and Manuscript II  are registry based, matched case-control studies, conditional 85 
logistic regression was used to analyse the data.[254] 86 
In these analyses, the odds that a person was exposed to an antimicrobial drug at six different time-87 
windows before being infected with Salmonella or Campylobacter, and the odds that the infective 88 
strain was resistant against the antimicrobial taken were estimated. The time-line in Figure 5.1 shows 89 
how the data was divided into different time-frames prior to infection for the analysis of the data.   90 
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 91 
Figure 5.1 Time line for events and measurements in Manuscript I and  II 92 
The date of infection was derived from the NREP, and we deducted 21 days to estimate the real date 93 
of infection. Firstly, seven days are deducted, as we estimated that this would be the delay between 94 
the date that the stool-sample was handed in and the date that the infection was notified in the 95 
NREP. Secondly, we deducted another 14 days, which we called the acute phase of infection. We 96 
estimated that this would be the duration between infection-date and the date that a patient would 97 
hand in a stool-sample. We excluded this time frame from our analyses as we expected that any 98 
course of antimicrobials taken during this period might have been given as early empirical treatment 99 
of the infection. Including these data would introduce protopathic bias.[255, 256] 100 
All Salmonella patients (Manuscript I) between 1997-2005 and Campylobacter patients between 101 
1999-2005 (Manuscript II), entered in the NREP were included in each study. For each case, ten 102 
controls were selected that were alive on the date that the patient was entered in the NREP, and 103 
matched on age, sex, and county of residence. We adjusted for education level (primary school only 104 
or higher level than primary school), rural/urban differences by population density (separated into 105 
five categories; >2000, 1001-2000, 351-1000, 26-350, and 1-15 persons/km2), and income (income 106 
per household / number of adults, and matched within a range of 100.000 Danish Kroner 107 
intervals.[257] Effect modification by age was determined by fitting an interaction term by three age 108 
groups (0-15 years, 15-64 years and ≥65 years).  109 
The analysis consisted of two separate parts; firstly, overall odds ratios for exposure to antimicrobial 110 
drugs prior to the estimated onset of infection (index date) were calculated, and secondly, a time-111 
dependent OR for exposure to antimicrobials was calculated, for each of the six time-frames, see 112 
Figure 5.1. The outcomes of these time-dependent calculations were plotted  and cubic splines were 113 
applied to obtain a smooth curve.[258] The coefficients for the cubic spline function were estimated 114 
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in a conditional logistic regression model. In the cubic spline model three knot points were used; at 115 
60 days, half a year and one year before the index-date. A knot point is a point where the coefficients 116 
for the third-degree polynomial were allowed to change, although only under the restriction that the 117 
curve has to be continuous and smooth at the knot points.  118 
All analyses were performed using conditional logistic regression with the PHREG procedure in SAS 119 
9.1.3 for UNIX (SAS Institute, Cary, NC, USA). 120 
5.3 Prospective case-control study (Manuscript III) 121 
Introduction 122 
Part of this PhD-study was funded by the Danish Ministry of Food Agriculture and Fishery, through a 123 
large project entitled “Targeted approaches to the control of virulent and antibiotic-resistant 124 
Salmonella clones” (project-number 3304-FVFP-07-721-01). The telephone interview study was 125 
performed to meet one of the goals of this project: to describe outcomes of infection with specific 126 
“successful-clones”, and find risk factors for acquiring an infection with a specific “successful-clone”. 127 
Successful-clones 128 
As described in chapter 3 in the paragraph on successful clones, not every Salmonella subtype is as 129 
successful in establishing infection in humans, causing severe disease or in acquiring antimicrobial 130 
resistance. For the purpose of this study we focussed on these “successful” Salmonella Typhimurium 131 
subtypes only. 132 
Original set up of the “telephone-interview study’’  133 
The original research objectives of this study were to identify specific risk factors (other than those 134 
that are food-related), for each of the above-mentioned phage types. Data were gathered by means 135 
of a telephone interview conducted by professional interviewers trained at SSI. Cases were 136 
interviewed about  symptoms of infection, previous drug prescriptions, antimicrobial resistance 137 
pattern, general health status, food exposure, cleaning habits, smoking-status, etc.. In order to 138 
reduce recollection bias, the interviews were conducted as soon as possible after notification in the 139 
National Registry of Enteric Pathogens (NREP). The preferred study type was to perform a case-case 140 
study for the following reasons: Firstly, by comparing the phage types of interest with other S. 141 
Typhimurium cases, we would be able to identify the risk factors that are specifically associated only 142 
with the phage type under investigation. As both case-case patient and case-control would have the 143 
same aetiology, this would avoid introducing the general effect of being infected with a S. 144 
Typhimurium [259]. Secondly, the risk of selection-bias would be reduced, as both case-patient and 145 
case-control would be enrolled through the same surveillance system[260] Finally, we expected the 146 
willingness to participate among patients to be higher than the willingness of healthy controls of the 147 
general population, meaning that healthy controls, that are willing to participate may not be 148 
representative of their corresponding case.  149 
Methods  150 
Patients with a culture-confirmed infection with Salmonella Typhimurium and recorded in the NREP 151 
between January-June 2010 were eligible for enrolment in the study. Cases that belonged to an 152 
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outbreak, were infected with a strain that could not be phage typed or cases that had a history of 153 
travel within two weeks of onset of disease were excluded from the study. Only the first case of a 154 
household within a time-frame of a month was included in the study. The address and, age of the 155 
patients were derived from the CPR-registry, after which the telephone numbers were looked up on 156 
the internet. After this, the interviews were performed by the trained interview-team at SSI. Data 157 
was entered in a database during the interview by means of a market research platform, Defgo.net®.   158 
Sample size calculation 159 
A sample size calculation was performed to determine the amount of case-patients and case-controls 160 
that had to be enrolled in the study. We calculated that in order to show an OR of 3 with 80% power 161 
and 95% confidence interval, we had to interview 50 case patients of each phage type and 100 162 
controls. These controls would be patients in the analyses of another phage type. In previous years, 163 
1392 (in 2008), and 559 (in 2009), domestically acquired S. Typhimurium cases were entered in the 164 
NREP.[261] Based on these numbers we expected to interview enough cases for the study sample 165 
size. 166 
Data 167 
In total, 326 S. Typhimurium patients were recorded in the NREP in the period between January-June 168 
2010, of which 228 were eligible for the study. After drop-out,  150 patients were interviewed. 169 
Reasons for drop-out are presented in the flow diagram, Figure 5.2. Isolates from these patients 170 
included monophasic S. Typhimurium (N=23) and four phage types of interest for the case-case study 171 
: DT104 (N=7), DT12 (N=8), DT120 (N=2), and U292 (N=17).  According to our sample-size calculation  172 
not any of these subgroups was large enough to perform our analysis with enough strength, and due 173 
to time-limitation we were not able to prolong the study to get more patients enrolled.  Therefore, 174 
the original aim of comparing risk factors for different subtypes  could not be met. However, the 175 
objective of the project was to investigate the association between antimicrobial resistance pattern 176 
in relation with phage type and outcome of disease. Although we did not have enough cases in each 177 
group to look at phage type in relation to resistance, analysing the resistance-pattern in relation to 178 
clinical outcome of disease was possible. This, consequently, became the main focus of the study 179 
(Manuscript III). Cases were classified into three groups according to the susceptibility profile of their 180 
infection: pansusceptible (S), resistant to three or less antimicrobials (R), or multiresistant (MR) i.e. 181 
resistant to four or more antimicrobials. The antimicrobial resistance testing panel contained data on 182 
resistance against 16 antimicrobial drugs:  ampicillin, apramycin, cefotaxime, ceftiofur, 183 
chloramphenicol, ciprofloxacin, collistin, florfenicol, gentamicin, nalidixic acid, neomycin, 184 
spectinomycin, streptomycin, sulphonamide and trimethoprim . 185 
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 186 
Figure 5.2: flow diagram for inclusion patients in the Telephone interview study 187 
 188 
Analysis  189 
The set up of this study is a prospective case-case study, this is a study set up in which a set of 190 
theory-based hypotheses, derived from literature, can be tested during a predetermined follow-up 191 
time.[262] The hypothesis tested in this prospective case-case study are described in Chapter 3, 192 
Table 3.1, in which traits that can possibly make certain phage types more successful than others are 193 
given. These hypothesis were then translated into a questionnaire, which can be found in the 194 
appendix of Manuscript III. 195 
 In Manuscript III descriptive analysis are given on the patients and their characteristics. Univariable 196 
and multivariable regression analyses were performed to describe the effect of antimicrobial use on 197 
outcome of resistance and underlying disease. Our outcome variable was resistance profile 198 
(pansuceptible, resistant, or multidrug-resistant), the independent variables included age category 199 
(<4 years, 4-17 years, 18-64 years, and 65 and older), gender, severe diarrhoea, ( >7 days, yes/no), 200 
severe weight loss (>5kg lost, yes/no), hospitalisation due to infection (yes/no), medication received 201 
to treat infection (yes/no),  vomiting more than 7 days (yes/no), feeling nauseated more than 7 days 202 
(yes/no), having stomach ache more than 7 days (yes/no), having fever more than 7 days (yes/no), 203 
having bloody faeces more than 7 days (yes/no), and having pain in joints for more than 7 days 204 
(yes/no).   205 
Statistical tests of associations between resistance profile and disease outcome were computed by 206 
use of χ2-test and Fisher’s exact tests, as well as likelihood ratio tests in a logistic regression model, 207 
where appropriate. 208 
150 patients interviewed 
154 
4 other (homeless etc) 
158 patients 
4  died before they could be interviewed 
164 patients 
6  did not want to participate 
177 patients 
13 too sick to participate 
192 possible cases 
15 infected abroad 
212 possible cases 
20 could not be reached 
228 possible cases 
16 phone number could not be found 
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Multivariate analysis was also performed; backward elimination as suggested by Hosmer and 209 
Lemeshow was used to determine the variables for the final regression model.[263] First, all 210 
univariable associations with a p-value of <0.25 were included in the multivariable model. Then, in a 211 
process of backward elimination, the least significant variables were exluded from the model one by 212 
one, until all variables in the model had a p-value of ≤0.05. During this process after each second 213 
variable was taken out of the model, each earlier eliminated variable was re-included in the model to 214 
assess whether the p-value of this variable would become significant after all.  215 
Multicollinearity, confounding and interaction were all evaluated. In order to avoid multicollinearity, 216 
scores were created in which some variables were combined into one single variable. Variables 217 
excluded in the backward elimination procedure were re-entered in the final model to assess for 218 
confounding, by checking if the p-values or the estimates of the final model would change if the 219 
variable was reintroduced. Interaction terms of all biologically plausible variables (age, level of 220 
schooling, income, smoking, and self-reported stress), and all the variables left in the final model, 221 
were introduced in the final model to asses interaction. 222 
All analyses were performed using the PROC GENMOD procedure used in SAS statistical software 223 
programme, version 9.3 (SAS Institute, Cary, NC).   224 
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6 Overview of Results  1 
This chapter includes an overview of the main results obtained in this PhD study and a discussion of 2 
their significance. The chapter is divided into two sections: The first section discusses the long-term 3 
consequences of human antimicrobial use on the development of antimicrobial resistance as 4 
explored by the register-based studies, whereas the second section describes  the short-term 5 
consequences of antimicrobial use on the health of the patient as investigated by the interview-6 
based study. 7 
6.1 Objective 1 - Assessment of the contribution of human 8 
antimicrobial use as a risk factor for acquiring an infection with an 9 
antimicrobial resistant Salmonella or Campylobacter strain 10 
 (Manuscript I and  Manuscript II). 11 
Salmonella 12 
In the study period, between 1997-2005, a total of 22,602 Salmonella cases were reported, including 13 
4,675 Salmonella Typhimurium, 12,152 Salmonella Enteritidis, and 5,776 other Salmonella serotypes. 14 
A total of 214,325 controls (1:10) were matched to these cases. Due to the low number of resistant 15 
isolates (e.g. no isolates of S. Enteritidis were resistant to third-generation cephalosporins, and no 16 
isolates belonging to the group ‘other Salmonella serotypes’ were resistant to amphenicols, see 17 
Table 6.1), the following groups of antimicrobials were excluded from the analysis: amphenicols, 18 
aminoglycosides, third generation cephalosporins, and the group named ‘other antibacterials’ with 19 
ATC-code J01X.  20 
Table 6.1 Definition of the groups of antimicrobials, total number of susceptibility tested cases and prevalence of resistance to the 
classes of antimicrobials (1997 - 2005). 
Groups of antimicrobials 
Salmonella  
Typhimurium 
(%) 
Salmonella  
Enteritidis 
(%) 
other 
Salmonella 
serotypes (%) 
Antimicrobials tested for in the  
susceptibility test 
Total number of patients 4,675 12,151 5,776 
 No. Susceptibility tested cases 4,534 (97.0) 4,195 (34.5) 1,679 (29.1) 
 No. (of all cases) resistant to: 
    
aminoglycosides 1,292 (27.6) 37  (<0.1) 242 (4.2) 
streptomycin, gentamicin, apramycin  
kanamycin, spectinomycin, neomycin 
amphenicols 302 (6.5) 1 (<0.1) 0 (0) Chloramphenicol, florfenicol 
extended-spectrum penicillins 1,354 (29.0) 87 (<0.1) 236 (4.1) ampicillin, amoxicillin-clavulanic acid 
fluoroquinolones 164 (3.5) 326 (2.7) 460 (8.0) ciprofloxacin, nalidixic acid 
other antibacterials (ATC: 
J01X) 157 (3.4) 788 (6.5) 1 (<0.1) 
collistin, nitrofurantoin, polymyxin,  
fosfomycin 
sulphonamides and 
trimethoprim 1,713 (36.3) 57 (<0.1) 295 (5.1) sulfamethoxazole, trimethoprim 
tetracyclines 1643 (35.1) 69 (<0.1) 463 (8.0) tetracycline 
3rd generation cephalosporins 7 (<0.1) 0 (0) 4 (<0.1) cefpodoxime, ceftiofur 
Breakpoints for susceptibility testing are different for each year, see DANMAP 1997 - DANMAP 2005 
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In the year prior to Salmonella diagnosis, patients more frequently had a history of antimicrobial 21 
drug use than population controls. This was observed independent of serotype and susceptibility 22 
pattern, and was found for all classes of drugs but with some variation in estimates, see Table 6.2. 23 
Table 6.2 Number of Salmonella cases and population controls exposed to antimicrobial drugs and the OR of Salmonella 
infection by history of antimicrobial drug use 2 weeks - 12 months prior to infection, Denmark 1997 - 2005; all Salmonella 
cases irrespective of susceptibility testing. 
 
No (%) exposed  OR of being exposed to  
antimicrobial drugs, OR 95%CI   cases controls 
Salmonella Typhiurium (n=4,675) 
   exposure to:  
   broad spectrum penicillins 601 (12.9) 3,998 (9.2) 1.56 (1.41 - 1.73) 
fluoroquinolones 78 (1.7) 326 (0.8) 2.21 (1.70 - 2.86) 
sulphonamides and trimethoprim 177 (3.8) 1,295 (3.0) 1.30 (1.10 - 1.54) 
tetracyclines 64 (1.4) 440 (1.0) 1.32 (1.00 - 1.74) 
Salmonella Enteritidis (n=12,151) 
   exposure to:  
   broad spectrum penicillins 1,202 (9.9) 9,169 (7.8) 1.33 (1.24 - 1.42) 
fluoroquinolones 198 (1.6) 929 (0.8) 2.07 (1.24 - 1.42) 
sulphonamides and trimethoprim 535 (4.4) 4,017 (3.4) 1.32 (1.20 - 1.45) 
tetracyclines 194 (1.6) 1,402 (1.2) 1.33 (1.14 - 1.55) 
other Salmonella serotypes (n=5,776) 
   exposure to:  
   broad spectrum penicillins 719 (12.4) 4,592 (8.5) 1.62 (1.47 - 1.77) 
fluoroquinolones 186 (3.2) 387 (0.7) 4.55 (3.78 - 5.47) 
sulphonamides and trimethoprim 317 (5.5) 1,815 (3.4) 1.72 (1.51 - 1.96) 
tetracyclines 142 (2.5) 607 (1.1) 2.24 (1.85 - 2.71) 
The ORs are adjusted for sex, age, county of residence, population density, income and schooling 
 24 
Data pertaining to susceptibility tested strains only are given in Table 6.3. For several drugs 25 
(fluoroquinolones, tetracyclines, and broad-spectrum penicillins), there was an effect modification, 26 
i.e. resistant strains conferred a higher OR for salmonellosis than susceptible strains. The effect 27 
modification was statistically significant for fluoroquinolone-resistant S. Typhimurium and S. 28 
Enteritidis. The risk of being diagnosed with a fluoroquinolone-susceptible S. Typhimurium after 29 
having taken a course of fluoroquinolones was 2.0 times higher for patients than controls, whereas 30 
the risk of having a fluoroquinolone-resistant S. Typhimurium was 7.2 (2.0*3.6) times higher for 31 
patients than for controls. The logistic model is multiplicative and the product in the bracket is the 32 
main effect (OR 2.0 for susceptible strains) multiplied by the interaction term (OR 3.6 for the tested 33 
strain being resistant to the antimicrobial taken). Following the same argument for S. Enteritidis, the 34 
OR for acquiring a fluoroquinolone-resistant strain, after being exposed to a course of 35 
fluoroquinolones, was 1.7 for a susceptible strain whereas it was 4.5 (1.7*2.7) for acquiring a 36 
resistant strain (Table 6.3).  37 
 38 
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Table 6.3 Number of Salmonella cases and controls exposed to antimicrobial drugs and the OR of infection by history of 
antimicrobial drug use 2 weeks - 12 months before infection, analysed by susceptibility pattern of the infecting strain,  
Denmark, 1997 - 2005; only susceptibility tested cases included. 
 
No. (%) of exposed 
Risk for salmonellosis 
after exposure (main 
effect), OR 95%CI 
OR for resistant straina,b 
(interaction term) 
OR 95%CI   cases controls 
Salmonella Typhimurium (n=4.628) 
    exposure to:  
    broad spectrum penicillins 595 (12.9) 3,967 (9.2) 1.50 (1.33 - 1.69) 1.17 (0.94 - 1.47) 
fluoroquinolones 75 (1.6) 329 (0.8) 2.01 (1.53 - 2.64) 3.56 (1.22 - 10.34) 
sulphonamides and trimethoprim 176 (3.8) 1,280 (3.0) 1.33 (1.07 - 1.65) 0.96 (0.67 - 1.36) 
tetracyclines 62 (1.3) 435 (1.0) 1.03 (0.70 - 1.51) 1.72 (0.97 - 3.02) 
Salmonella Enteritidis (n=4,412)) 
    exposure to:  
    broad spectrum penicillins 420 (9.5) 3,285 (7.9) 1.26 (1.12 - 1.41) 1.20 (0.54 - 2.69) 
fluoroquinolones 68 (1.5) 347 (0.8) 1.69 (1.26 - 2.26) 2.65 (1.20 - 5.85) 
sulphonamides and trimethoprim 184 (4.2) 1,401 (3.4) 1.26 (1.07 - 1.49) 2.64 (0.88 - 7.87) 
tetracyclines 83 (1.9) 495 (1.2) 1.61 (1.26 - 2.05) 0.48 (0.06 - 3.80) 
other Salmonella serotypes  
(n=1,619) 
    exposure to:  
    broad spectrum penicillins 183 (11.3) 1,224 (7.9) 1.42 (1.17 - 1.73) 1.53 (0.90 - 2.61) 
fluoroquinolones 60 (3.7) 122 (0.8) 4.36 (2.97 - 6.41) 1.22 (0.56 - 2.66) 
sulphonamides and trimethoprim 97 (6.0) 516 (3.3) 1.79 (1.38 - 2.32) 1.18 (0.60 - 2.32) 
tetracyclines 38 (2.3) 154 (1.0) 2.30 (1.46 - 3.64) 1.03 (0.47 - 2.25) 
The ORs are adjusted for sex, age, county of residence, population density, income and schooling 
a: Cases that were exposed to antimicrobials 1 year before infection (and were infected with a strain that was 
resistant to the drug previously taken) 
b: Statistically this was fitted as an interaction term, the total relative risk for infection with a drug-resistant 
Salmonella that is resistant to the drug previously taken can be estimated as the product of the two ORs 
 39 
The OR for being diagnosed with Salmonella after exposure to one of the groups of antimicrobials in 40 
different time frames before infection was determined as well. The outcomes of this analysis for 41 
fluoroquinolones and broad-spectrum penicillins are given in Figure 1. This graph shows the OR, on a 42 
log-scale, plotted against the time since latest antimicrobial exposure before infection with 43 
Salmonella, in cubic splines. In general the highest excess risk was found in a time window up to 1 44 
month before diagnosis, and levelled out and became relatively stable 24-6 months before diagnosis. 45 
Sulphonamides and trimethoprim were also associated with a time-dependent excess risk of being 46 
diagnosed, in particular for serotypes other than S. Enteritidis and S. Typhimurium. The ORs were 47 
2.14 (95%CI: 1.43 – 3.23) for 0-2 weeks, 1.17 (95%CI: 0.74 – 1.87) for 2-4 weeks, 1.23 (95%CI: 1.01 – 48 
1.50) for 1-6 months, and 1.40 (95%CI: 1.21 – 1.62) for 1-2 years before infection. The effect of age 49 
on outcome was also assessed, but no effect modification was found. 50 
 51 
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 53 
Campylobacter 54 
In the study period, between 1999-2005, a total of 31,699 Campylobacter cases were reported, no 55 
distinction was made between C. coli and C. jejuni cases. A total of 97,523 (1:10) controls were 56 
matched to these cases. 57 
During the study, 10,275 (32.4%) of these cases were susceptibility tested against fluoroquinolones 58 
and macrolides. For these strains, we calculated excess odds of campylobacteriosis after drug 59 
exposure, as well as a multiplicative interaction term (the odds that the infective strain was resistant 60 
to the antimicrobial previously taken). A total of 459 strains were tested for a broader panel of 61 
Figure 6.1: Cubic spline plots of the OR of being exposed to broad-spectrum penicillins and fluoroquinolones, 0-2 years before 
infection with S. Typhimurium, S. Enteritidis, or other Salmonella serotypes, 1997-2005, Denmark. The ORs are adjusted for sex, 
age, county of residence, population density, income and schooling. 
57 
 
antimicrobial drugs as part of the Danish Integrated Antimicrobial Resistance Monitoring and 62 
Research Programme (DANMAP) surveillance (Table 6.4). However, due to the low number of strains 63 
examined, it was not possible to calculate the interaction terms for broad spectrum penicillins, 64 
sulphonamides and trimethoprim, and tetracyclines.  65 
Overall, 21.7% of all cases were resistant to fluoroquinolones and 2.3% were resistant to macrolides, 66 
see Table 6.4. The prevalence of fluoroquinolone resistance was highest in adults 50-59 years of age 67 
and lowest in children 0-9 years.  68 
Table 6.4 Age distribution and prevalence of resistance in Campylobacter strains from 10,475 cases 
examined for susceptibility for fluoroquinolones and macrolides, Denmark, 1999-2005 
Age groups 
Total no. of  
patients N (%) 
Susceptibility 
testeda N (%) 
Fluoroquinolone 
resistanceb 
N (%) 
Macrolide 
resistancec 
N (%) 
0-9 years 4,076 (14.9) 1,556 (38.2) 224 (14.4) 25 (1.6) 
10-19 years 3.039 (11.1) 1,150 (37.8) 231 (20.1) 21 (1.8) 
20-29 years 6,841 (25.1) 2,750 (40.2) 613 (22.3) 57 (2.1) 
30-39 years 4,971 (18.2) 1958 (39.4) 428 (21.9) 40 (2.0) 
40-49 years 3,117 (11.4) 1,098 (35.2) 281 (25.6) 32 (2.9) 
50-59 years  2,505 (9.2) 992 (39.6) 256 (25.8) 32 (3.2) 
60-69 years 1,436 (5.2) 542 (37.7) 137 (25.3) 21 (3.9) 
70-79 years 835 (3.1) 293 (35.1) 72 (24.6) 8 (2.7) 
80 and older 456 (1.7) 136 (29.8) 26 (19.1) 2 (1.5) 
Total 27,276 (100) 10,475 (38.4) 2,268 (21.7) 238 (2.3) 
a: Overall χ2: 45.0, degrees of freedom: 8, P value: <0.001 
b:Overall χ2: 69.8, degrees of freedom: 8, P value: <0.001 
c: Overall χ2: 14.8, degrees of freedom: 8, P value: 0.06 
 69 
Being diagnosed with campylobacteriosis was associated with an increased odds of exposure to a 70 
course of fluoroquinolones, macrolides, sulphonamides and trimethoprim, tetracyclines and broad 71 
spectrum penicillins up to 1 year before onset of disease (Table 6.5). This risk was highest for 72 
fluoroquinolones; OR 2.4 95%CI: 1.97 – 2.97. For fluoroquinolones, we found an effect modification, 73 
where being infected with resistant strains conferred a higher risk of diagnosis with Campylobacter 74 
than susceptible strains. The odds of being exposed to a course of fluoroquinolones was 2.4 times 75 
higher for cases diagnosed with a fluoroquinolone-sensitive Campylobacter than controls, whereas 76 
the odds of being exposed to a fluoroquinolone was 3.8 (2.4*1.6) times higher for cases with a 77 
fluoroquinolone-resistant Campylobacter  infection than for controls. The logistic model is 78 
multiplicative, and the product between the brackets is the main effect (OR 2.4 for susceptible 79 
strains), multiplied by the interaction term (OR 1.6 for the tested strain being resistant to the 80 
antimicrobial taken). There was no interaction between macrolide exposure and being infected with 81 
a macrolide resistant Campylobacter (Table 6.5). 82 
  83 
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Table 6.5 Risk of Campylobacter diagnosis by exposure to a course of antimicrobial drugs 0-12 months before infection,  
Denmark, 1999-2005 
Exposed to (up to 1 year before 
infection): 
No (%) exposed  risk for campylobacteriosis 
after exposure (main  
effect) OR (95%CI) 
OR for resistant  
straina,b (inter- 
action term) OR (95%CI) cases controls 
Broad spectrum penicillins 
1,191 
(11.6) 
8.756 
(9.0) 1.35 (1.25 - 1.45) 
 Fluoroquinolones 183 (1.8) 658 (0.7) 2.42 (1.96 - 2.98) 1.61 (1.11 - 2.32) 
Sulphonamides and trimethoprim 530 (5.1) 
3535 
(1.5) 1.48 (1.34 - 1.64) 
 
Tetracyclines 202 (2.0) 
1,437 
(1.5) 1.36 (1.16 - 1.59) 
 
Macrolides 
1,158 
(11.3) 
7,642 
(7.8) 1.48 (1.38 - 1.59) 1.04 (0.70 - 1.54) 
The ORs were adjusted for sex, age, county of residence, level of schooling, and population density 
a: Cases that were exposed to antimicrobials 1 year before infection (and were infected with a strain that was  
resistant to the drug previously taken). 
b: Statistically, this was fitted as an interaction term, the total relative risk for infection with a drug-resistant  
Campylobacter that is resistant to the drug previously taken can be estimated as the product of the main effect  
and the interaction term 
 84 
In the second part of the study, a time-dependent OR for previous exposure to antimicrobials was 85 
calculated in 6 different time-frames before onset of Campylobacter infection. The results of this 86 
analysis are given in Figure 1. This graph shows the OR plotted against the time since latest 87 
antimicrobial exposure before infection with Campylobacter, in cubic splines. The results for 88 
fluoroquinolones and macrolides were different, we found a positive association for previous 89 
fluoroquinolone use and the odds of being diagnosed with Campylobacter, whereas macrolides seem 90 
to have a protective effect. 91 
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 92 
FIGURE 6.2 CUBIC spline plots of the odds ratio (OR) of being exposed to macrolides and fluoroquinolones 0–2 years before 93 
infection with Campylobacter, 1997–2005 Denmark. The ORs are adjusted for sex, age, county of residence, population 94 
density, income, and schooling. 95 
 96 
Diagnosis with Campylobacter was associated with a decreased odds of macrolide consumption in 97 
the period close to diagnosis, while it was associated with an increased fluoroquinolone consumption 98 
in the same period, see Table 6.6. The effect of macrolides was more thoroughly examined to 99 
determine the duration of this protective effect and an analysis was performed for four different 100 
macrolides separately; erythromycin, roxithromycin, clarithromycin, and azithromycin. There was an 101 
excess odds of consumption of each of these drugs up to 1 year before infection, see Table 6.6. 102 
However, if the time between last exposure and Campylobacter infection is reduced to only the 103 
acute phase of infection (the estimated time before onset of disease and appearance in our 104 
database), exposure to macrolides became a protective factor (OR 0.72, up to 1 month before 105 
infection). 106 
 107 
 108 
 109 
60 
 
Table 6.6 Risk for Campylobacter diagnosis by timing of exposure to a course of antimicrobials 0-12 months before infection,  
Denmark, 1999-2005 
Exposure to: 
 Up to 1 year 
before infectiona 
OR (95%CI) 
Up to 3 months  
before infectionb 
OR (95%CI) 
Up to 2 months  
before infectionb 
OR (95%CI) 
Up to 1 month  
before infectionb 
OR 95%CI 
Only the acute  
phase of infection 
OR (95%CI) 
Erythromycin 1.40 (1.25 - 1.57) 
Not enough statistical power to separate the analysis 
0.06 (0.01 - 0.43) 
Roxithromycin 1.63 (1.37 - 1.93) 0.39 (0.09 - 1.63) 
Clarithromycin 1.62 (1.29 - 2.02) 0.83 (0.25 - 2.71) 
Azithromycin 1.44 (1.30 - 1.60) 0.29 (0.11 - 0.79) 
Macrolides 
grouped 1.48 (1.38 - 1.59) 1.16 (1.02 - 1.31) 0.98 (0.83 - 1.16) 0.72 (0.56 - 0.92) 0.30 (0.16 - 0.56) 
Fluoroquinolones 2.42 (1.96 - 2.98) 2.54 (1.83 - 3.54) 2.65 (1.78 - 3.93) 2.94 (1.82 - 4.75) 10.32 (6.65 - 16.02) 
The odds ratios (ORs) were adjusted for sex, age, county of residence, level of schooling income and population 
density 
a: This period does not include the "acute phase" of infection 
b: This period does include the "acute phase" of infection 
 110 
6.2 Objective 2 – Comparison of clinical outcome of disease for 111 
Salmonella Typhimurium cases in relation to different susceptibility 112 
profiles (Manuscript III) 113 
 In the study period of January-June 2010, a total of 150 patients were enrolled in the study, and 114 
susceptibility testing was performed on all patient isolates.  Isolates were tested for resistance 115 
against 19 different antimicrobials: ampicillin, apramycin, augmentin (amoxicillin-clavulanic acid), 116 
chloramphenicol, ciprofloxacin, cefotaxime, collistin, florfenicol, fosfomycin, gentamicin, nalidixic 117 
acid, neomycin, sulphonamide, spectinomycin, streptomycin, tetracycline, trimethoprim, ceftiofur, 118 
and  mecillinam. The patients were grouped according to their resistance profile into three groups: 119 
pansusceptible (S), resistant (R), or multidrug-resistant (MR). 120 
The median age of the cases was 36 years, with an interquartile range of 10-57 years. Twenty-six 121 
(17%) were under 4 years of age, and 24 (16%), were 65 or older. Common symptoms included: 122 
abdominal pain (>7 days, 81%), fever (>7 days, 73%), and severe diarrhoea (>7 days, 69%). We found 123 
no major differences in clinical outcome of disease between the 3 groups of patients (Table 6.7). 124 
Patients with a drug resistant Salmonella (R), had a higher odds for being hospitalised due to their 125 
Salmonella infection (OR 2.47 95%CI: 1.02 – 5.97), vomiting > 7 days (OR 2.61 95%CI: 1.10 – 6.19), 126 
and were more like to feel nauseous >7days (OR 2.87 95%CI: 1.26 – 6.54), than patients infected with 127 
a pansusceptible strain. We also found that there appeared to be more infants in the S than in the R 128 
(OR 3.09 95%CI: 1.08 – 8.82) or MR group (OR 4.24 95%CI: 1.41 – 12.77). 129 
 130 
 131 
 132 
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Table 6.7 Odds for severity of disease per resistance profile (three levels), 150 S. Typhimurium patients, January-June 2010,  
Denmark 
 
Three resistance profiles   All patients 
 
Pansusceptible (S)* Resistant (R)* 
Multidrug-resistant 
(MR)*   
  N OR (95%CI) N OR (95%CI) N OR (95%CI) N (%) 
Total number of patients 49 
 
48 
 
53   150 100 
Median age (interquartile range) 26 (3-51) 49  (23-65) 29 (11-55) 36 
(10-
57) 
Age categorya 
 
1 (reference) 
 
3.04 (1.40-6.56) 
 
2.23 (1.06-1.68 
          Infants (<4y) 15 3.44 (1.36-8.70) 6 0.52 (0.19-1.46) 5 0.44 (0.15-1.30) 26 17.3 
        Children (4-17y) 8 1.35 (0.50-3.64) 4 0.37 (0.11-1.19) 11 1.69 (0.66-4.36) 23 15.3 
        Adults (18-64y) 21 1 (reference) 27 1 (reference) 26 1 (reference) 74 49.3 
        Seniors (=> 65y) 5 0.66 (0.22-2.01) 10 1.24 (0.49-3.18) 9 1.11 (0.43-2.88) 24 16.0 
Gender (female) 25 1 (reference) 23 1.13 (0.51-2.51) 26 1.08 (0.50-2.53) 74 49.3 
      
  
  Any underlying comorbidity 12 1 (reference) 21 2.40 (1.00-5.70) 27 3.20 (1.38-7.45) 60 40.0 
Median days of diarrhoea  
(interquartile range) 14 (7-15) 10 (7-14) 14 (8-20) 13 (7-15) 
severe diarrhoea (>7 days) 33 1 (reference) 27 0.62 (0.27 -1.43) 43 2.09 (0.84 - 5.62) 103 68.7 
Weight loss (>5kg) 8 1 (reference) 14 2.05 (0.76-5.58) 13 1.73 (0.63-4.71) 35 23.3 
hospitalised due to infection 11 1 (reference) 20 2.47 (1.02- 5.97) 18 1.68 (0.70 - 4.04) 49 32.7 
Received medication to treat 
 infection 22 1 (reference) 29 1.87 (0.84-4.20) 25 1.10 (0.50-2.39) 76 50.7 
History of antimicrobial useb 20 1 (reference) 23 1.33 (0.60-2.98) 25 1.30 (0.59-2.83) 68 35.3 
Vomiting (>7 days) 12 1 (reference) 22 2.61 (1.10-6.19) 20 1.87 (0.79-4.40) 54 36.0 
Nausea >7 days) 18 1 (reference) 30 2.87 (1.26-6.54) 27 1.79 (0.81-3.95) 75 50.0 
Abdominal pain (>7 days) 39 1 (reference) 41 1.50 (0.52-4.33) 42 0.98 (0.38-2.56) 122 81.3 
Fever (>7 days) 36 1 (reference) 35 0.97 (0.40-2.39) 39 1.01 (0.42-2.43) 110 73.3 
Bloody faeces (>7 days) 19 1 (reference) 20 1.1 (0.50-2.54) 20 0.96 (0.43-2.13) 59 39.3 
Pain in joints 13 1 (reference) 11 0.82 (0.33-2.08) 15 1.09 (0.46-2.61) 39 26.0 
* S: pansusceptible Salmonella, R: Salmonella resistant to 1-3 antimicrobials, MR: Salmonella strains resistant to =>4 
antimicrobials 
a: Age category was analysed separately within the different susceptibility profiles with adults as the reference value 
b: Antimicrobials were not prescribed for treatment of current infection, history up to 6 months. 
 134 
In Table 6.7, it can be seen that age category is associated with resistance profile. Since age is a 135 
known confounder in epidemiological research, and not a biological explanation, we assessed the link 136 
between comorbidity, age category and resistance profile a bit further. We found both age and 137 
resistance profile to be explanatory variables for comorbidity (as defined in chapter 5, see Table 6.8), 138 
explaining the effect seen in Table 6.7.  139 
 140 
 141 
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Table 6.8 Relation between comorbidity and resistance profile, crude outcomes and  
adjusted for age category 
Resistance 
profile 
Comorbidity 
 present N (%) Crude OR (95%CI) 
adjusted OR* 
(95%CI) 
S 
Yes 12 (24)  1 (Reference)  1 (Reference) 
No 37 (76)  
  
R  
Yes 21 (44) 2.40 (1.01 - 5.70) 1.73 (0.68 - 4.35) 
No 27 (56) 
  
MR 
Yes 27 (51) 3.20 (1.38 - 7.45) 2.62 (1.07 - 6.37) 
No 26 (49)   
 
< 4 years 
Yes 4 (15) 1 (Reference) 1 (Reference) 
No 22 (84) 
  
4-17 years 
Yes 6 (26) 1.94 (0.47 - 7.99) 1.52 (0.36 - 6.48) 
No 17 (74) 
  
18-64 years 
Yes 33 (43) 4.12 (1.30 - 13.12) 3.37 (1.03 - 11.01) 
No 44 (57) 
   => 65 
years 
Yes 7 (29) 13.36 (3.35 - 53.18) 10.89 (2.66 - 44.61) 
No 17 (71)   
 Total 
 
      
*Comorbidity by resistance profile and for age category 
**: Comorbidity is a yes/no variable consisting of having any of the following underlying 
diseases: asthma/bronchitis, heart and circulation disease, intestinal illness, recurrent 
diarrhoea, liver disease, diabetes, connective tissue disease, kidney problems, cancer, chronic 
infection, other disease.  
 142 
6.3 Objective 3 – Examination of the association between clinical 143 
outcome of infection and previous antimicrobial use (Manuscript III) 144 
This study used the same patient material as described above. As described in chapter 5, data on 145 
clinical outcomes were obtained through telephone-conducted interviews and logistic regression was 146 
applied to assess the association between clinical outcome of disease and previous antimicrobial use. 147 
The age- and gender distribution, as well as clinical outcomes of disease, are presented in Table 6.7. 148 
In total, 68 patients (45%) stated that they had a history of antimicrobial treatment in the six month 149 
period preceding infection. Patients with a history of treatment tended to have a higher odds of 150 
infection with a resistant or multidrug-resistant Salmonella strain, but these differences were not 151 
significant (Table 6.7). Furthermore, a simple analysis, combining resistant with multiresistant strains 152 
into one group, did also not confer statistical significance (OR 1.31 95%CI: 0.62 – 2.79).  153 
The relation between history of previous antimicrobial use (up to 6 months before infection) was 154 
examined in a multivariable analysis with the different clinical outcomes of disease. The results of 155 
this analysis are given in Table 6.9. Patients who had been exposed to a course of antimicrobials, not 156 
related to the Salmonella infection, up to half a year before they got infected with Salmonella, had a 157 
higher odds of being hospitalised (OR 2.00, 95%CI 0.97 – 4.11), lose more than 5kg of weight (OR 158 
2.01, 95%CI 0.84 – 4.82), and receive treatment for the current event of salmonellosis (OR 7.56, 159 
95%CI 3.42 – 16.70). The other outcomes of clinical illness (>7days of diarrhoea, vomiting, feeling 160 
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nauseated, abdominal pain, fever, bloody faeces and pain in joints) were not associated with 161 
previous unrelated use of antimicrobials.  162 
Table 6.9 Crude and adjusted odds ratios for people who received antimicrobials in the past 6 months prior to  
Salmonella infection 
    
History of 
antimicrobial 
 use, unrelated to 
the  current 
salmonellosis 
Odds Ratio for severe 
outcome (95%CI) 
Consequence of infection: Yes No Crude Adjusted* 
Prescribed antimicrobials yes 52 24 7.85 (3.77 - 16.78) 7.56 (3.42 - 16.70) 
 
no 16 58 1 (reference) 1 (reference) 
Hospitalised yes 28 21 2.03 (1.02 - 4.06) 2.00 (0.97 - 4.11) 
 
no 40 61 1 (reference) 1 (reference) 
Weight loss (>5kg) yes 22 39 2.43 (1.09 - 5.48) 2.01 (0.84 - 4.82) 
  no 56 13 1 (reference) 1 (reference) 
* We adjusted for age category, income, level of schooling, self-reported stress, and smoking 
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7 Discussion and Conclusions 1 
In this chapter, the pros and cons of the study designs used, and the results of the research 2 
objectives will be discussed. In the end of this chapter the general conclusions are given and some 3 
future perspectives will be outlined. 4 
7.1 Strengths and limitations of database research  5 
Since the CPR-registry came in place in 1968, many more registries have been established in 6 
Denmark, currently a total of 59 clinical databases, of which 51 are national registries, have been 7 
adopted by the National Board of Health.[264] All these databases use people’s CPR-number as an 8 
individual identifier for the data.  9 
The strength in using large national registries, like the NREP or the Danish Prescription Database, is 10 
the data amount and the time-span of the data-collection. The Danish registries are well kept and 11 
often complete, and by combining these data with microbiological susceptibility data or isolate 12 
characterisations, it provides numerous opportunities for large cohort or case-control studies. The 13 
unique identification number (CPR-number) enables linkage with other registries and allows follow-14 
up on individuals on long-term disease consequences.  15 
Using these databases also has another advantage; the data is already collected, which saves time, 16 
money, and effort for conducting studies. As mentioned before, these national registries are large, 17 
and often complete which enables very large sample-sizes, enabling high statistical power to 18 
estimate precise outcome measures of rare diseases and occurrences. Another advantage is that 19 
selection bias does not play a major role for enrolling in the study. All data entered in these 20 
databases are included on the same grounds, albeit a small part of the Danish population has 21 
refrained from being documented in these databases (“forskerundtagelse”). 22 
However, performing registry-based studies also has some disadvantages. Many registries are 23 
established for administrative purposes, and data validity can be hard to assess, which can be a 24 
source of information bias. In addition, the type of data to be collected is predetermined, with the 25 
possible consequence that discrete outcomes and possibly important confounders cannot be 26 
assessed. For example, many procedures and supplementary diagnosis may not be available from the 27 
NREP. 28 
7.2 Objective 1 29 
In objective 1 the contribution of human antimicrobial use as a risk for acquiring an infection with 30 
Salmonella or Campylobacter was assessed. The risk for acquiring an infection with either bacteria 31 
after previous use of antimicrobials was quantified, additionally, the risk for acquiring an infection 32 
resistant to the antimicrobial previous taken, was calculated.  33 
As discussed in chapter 3, a person is more vulnerable to infection with a pathogen after exposure to 34 
a course of antimicrobial drugs, because the colonisation resistance is temporarily lowered due to 35 
the effect of the antimicrobial on the gut flora in the intestines i.e. the competitive effect. When the 36 
66 
 
person in addition is exposed to an antimicrobial resistant pathogen, which is resistant to the 37 
antimicrobial taken, the selective effect applies. The patient has an increased risk of infection with 38 
this antimicrobial resistant pathogen, which is an additive to the competitive effect. This also applies 39 
if a person is an asymptomatic carrier of such an antimicrobial resistant pathogen.[265, 266] In 40 
manuscript I and manuscript II, we were able to quantify these effects. For Salmonella we visualised 41 
the selective effect in Figure 6.1, and for Campylobacter in Figure 6.2. The premise of our model is 42 
that the selective effect is a multiplication of the ORs given in Table 6.3 and Table 6.5 respectively: 43 
not only should the patient be exposed to an antimicrobial, but the infective strain also has to be 44 
resistant to the antimicrobial exposed to.  45 
For calculation of the overall or competitive effect (i.e. being exposed to a course of any 46 
antimicrobial before infection), all Salmonella and Campylobacter cases were taken into account, 47 
independent on whether they were susceptibility tested or not. The results indicate that a history of 48 
antimicrobial drugs confers an increased risk of being diagnosed with either Salmonella or 49 
Campylobacter, where the risk appears to be present up to at least 1 year post-treatment, possibly 50 
even longer. The effect may depend on several factors, including the spectrum of the antimicrobial, 51 
the antibacterial effect of its metabolites and its pharmacokinetics. Broad-spectrum penicillins, 52 
sulphonamides and trimethoprim are excreted mainly through the urine, and therefore have a lesser 53 
impact on the gut flora.[267, 268] This is also the case for most fluoroquinolones, but nevertheless, a 54 
significant part of this group of antimicrobials is excreted in the bile. Also, some of the active 55 
metabolites of fluoroquinolones are excreted through the biliary route.[269] This implies that 56 
fluoroquinolones and their metabolites have an impact on the gut flora by passing through the 57 
gastrointestinal tract, which explains why fluoroquinolones are the first drug of choice to treat 58 
gastrointestinal infections, and why the most consistent results were obtained for this drug. 59 
Tetracyclines are excreted via both the biliary and the urinary pathways. This drug also reaches fairly 60 
high concentrations in the gastrointestinal tract in its unchanged form.[270] We found that diagnosis 61 
with Campylobacter was associated with reduced odds of recent history of macrolides, compared 62 
with controls. The pharmacokinetics of macrolides are well described in the literature. The half-life of 63 
macrolides is different for each of the drugs included in the study with erythromycin having the 64 
shortest half-life (<4 hours), roxithromycin and clarithromycin an intermediate half-life (4-24 hours) 65 
and azithromycin having the longest half-life (>72 hours).[271] However, the protective effect of the 66 
drugs last at least 4 weeks, see Figure 6.2. The protective effect of macrolides, as a group, in the 67 
acute phase and 0-2 weeks before the index date (OR 0.72, 95%CI 0.56 – 0.92) was strong. The acute 68 
phase was specifically constructed so we could not confuse drugs prescribed as early empirical 69 
treatment as a risk factor for acquiring Campylobacter. It is interesting that a protective effect is seen 70 
in all the macrolides (Table 6.6), even though the kinetics of each of the macrolides is quite different. 71 
One explanation for this phenomenon is that macrolides, especially azithromycin, become trapped in 72 
the intracellular lysosomes of phagocytic cells. This intracellular uptake is easily reversible for 73 
erythromycin and clarithromycin but is extremely slow and probably not completely reversible for 74 
azithromycin.[272, 273] It is even possible that part of the azithromycin metabolites remain trapped 75 
in the lysosome until the cell dies and the drug is finally released. Whether this is an explanation for 76 
the long-term protective effect remains unknown and should be further investigated. Another 77 
possibility could be that a treatment with macrolides deplete the gut from nutrients that are 78 
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essential for the growth of Campylobacter spp.. It is obvious that it is beyond the scope of an 79 
epidemiological study to address such biological hypothesis in details.  80 
The fact that macrolides are mostly prescribed in the winter season for respiratory infections, and 81 
Campylobacter infections are most common in the late summer could create a seasonal confounding 82 
effect. Still, we adjusted for season by matching on the index date of the case and we therefore do 83 
not find this to be a likely explanation of the association observed. Furthermore, several other 84 
antimicrobial drugs are prescribed more commonly in the winter season as well, without causing a 85 
similar pattern.  86 
The effect seen in the first half year before infection, of Figure 6.1 and Figure 6.2, is a combination of 87 
the competitive effect and the selective effect. An effect of treatment (protopathic bias) can be seen 88 
if a patient had an antimicrobial prescription for diarrhoeal symptoms before the actual stool sample 89 
was taken. However, we accounted for this by introducing an index date, which excluded the ‘acute 90 
phase’ of exposure and added an extra week to allow for the sample to show up in the database, see 91 
Figure 5.1.  92 
For Salmonella, Figure 6.1, the OR for being diagnosed after a treatment with antimicrobials, up to 93 
half a year before infection, is higher for patients than for controls in all groups except for exposure 94 
to broad-spectrum penicillins in Salmonella Enteritidis. The effect seen might be explained by the low 95 
percentage of resistance to this group of antimicrobials in S. Enteritidis. Resistance levels to broad-96 
spectrum penicillins are 3-6% in S. Enteritidis and 44-56% in S. Typhimurium.  97 
In both Salmonella and Campylobacter, the effect of taking a course of antimicrobials in the period 6 98 
months – 2 years before infection remains high, but stabilises. This effect can probably be ascribed to 99 
selection bias (i.e. the effect that some people are more likely to be tested than other people, 100 
possibly due to underlying comorbidity). A history of antimicrobial drug use may also be an indicator 101 
of increased use of healthcare and thus a marker of frailty and therefore might contribute to this 102 
effect. Furthermore, a Salmonella or Campylobacter may develop diarrhoea due to the non-specific 103 
effect of the antibiotic and may get sampled on this basis. However, it cannot be ruled out that some 104 
antimicrobial drugs may have a long-term effect on the gut flora and thus render patients more 105 
susceptible to bacterial infections with either Salmonella or Campylobacter. 106 
In Manuscript II, we also investigated the effect of age on prevalence of resistance. Some statistically 107 
significant differences in the number of samples susceptibility-tested in each age-group; The 108 
prevalence of fluoroquinolone resistance was highest in adults 50-59 years of age, and lowest in 109 
children. This is effect is likely to be explained by two factors: 1) it is not common to prescribe 110 
fluoroquinolones to children, and 2) the differences in travel behaviour between the age groups. In 111 
2008, 27.4 % of Campylobacter cases were travel related cases[274], and were associated with a 112 
higher prevalence of antimicrobial resistance.[161] However, matching on age should have 113 
accounted for this problem.  114 
This study designs used in Manuscript I and Manuscript II, is subject to a number of limitations. The 115 
first one is already described above as selection bias, due to this being registry based study, and 116 
patients are only enrolled if they have handed in a stool sample, and these are likely to be the more 117 
severe cases. Another limitation is that some of the antimicrobials are mainly used in hospital setting, 118 
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and these data are not included in the Danish prescription registry. We can only speculate that the 119 
impact of antimicrobial drugs on the occurrence of antimicrobial resistance would have been higher, 120 
if we could also have included these data. Still in Denmark, 90% of the prescribed daily defined doses 121 
are administered in the primary health care sector.[161] We did not adjust for co-morbidity in this 122 
study, but in a similar study, performed by Gradel et. al.,[275] this was taken into account and it did 123 
not affect the outcomes markedly. Therefore it is not likely that adjusting for co-morbidity in this 124 
study would have had any major impact on our results.  125 
7.3 Prospective case-case interview study 126 
The major strength of using this study design is that one can include all the relevant variables and 127 
confounders.  128 
A case-case study design has several advantages over a regular case-control study. Firstly by 129 
comparing the phage types of interest with other S. Typhimurium cases, only risk factors that are 130 
specifically associated with the phage type under investigation are identified, whereas general risk 131 
factors for acquiring an infection with S. Typhimurium are filtered out. Secondly, the risk of selection-132 
bias is reduced as both case-cases and case-controls would be enrolled through the same 133 
surveillance system. Finally, the willingness to participate would be the same in either group, 134 
whereas it is usually difficult to get healthy controls from the general population to participate. 135 
The limitation of the study design in comparison to a registry-based study is that it is costly and time-136 
consuming, and, it might also be unpredictable. As was shown in the methods chapter, we needed 50 137 
case-patients of each phage type and 100 case-controls, and we only had half a year planned to do all 138 
the interviews. At the time we realised that we could not obtain the required amount of cases, we 139 
did not have the possibility to extend the interview-time. This resulted in a modification of the study 140 
set-up.  141 
7.4 Objective 2 142 
In contrast to other studies, we were not able to show convincingly that infections with antimicrobial 143 
resistant Salmonella have a worse outcome of disease than infections with pansusceptible 144 
Salmonella strains (S). Though we did find that patients with a resistant (R) susceptibility profile had 145 
higher odds of being hospitalised due to their salmonellosis, experience abdominal pain and feeling 146 
nauseated than patients with a pansusceptible Salmonella. We found no increasing trend with 147 
increasing antimicrobial resistance (S versus multiresistant; MR). It is possible that even the higher 148 
risk of vomiting and nausea are a spurious observation. But it is also possible that the observation is 149 
due to the mix of phage types in the groups. It is known that some phage types are better suited to 150 
cause disease in humans than others, it might also be possible that some of these phage types are 151 
more likely to cause disease in humans as well. Further studies could clarify this in the future. 152 
Another explanation for these findings could be that patients with a worse outcome of disease did 153 
not receive correct empirical treatment. This hypothesis is hardly tested in literature, but it is unlikely 154 
to play a large role in our study: first drug of choice for empirical treatment of diarrhoeal disease is 155 
ciprofloxacin (a fluoroquinolone), and fluoroquinolone resistance only occurred twice in our study 156 
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population. In patients with a travel-history, fluoroquinolone resistance is more common[161], but 157 
these were excluded from our study.  158 
Other investigators have shown that being infected with an antimicrobial resistant Salmonella leads 159 
to a worse outcome of disease, including higher risk of bacteraemia[276], higher mortality[277, 278], 160 
excess hospitalisation[279, 280], and more infections due to therapy failure.[281] Most likely this 161 
difference is due to our study set-up which focused on softer outcomes than the abovementioned 162 
ones. The studies of Helms (2003)[282], Lee (1994)[283], Giamarello-Bourboulis (2006)[284], and 163 
Varma (2005)[285] et. al., included hospitalised patients, or used hospitalisations as an indicator for 164 
severe disease, whereas we included disease outcomes such as days of diarrhoea, vomiting, weight 165 
loss, and other events not necessarily requiring hospitalisation. Furthermore, we included a lower 166 
number of patients compared with the higher-powered registry based. Finally, interviews were 167 
conducted relatively quickly after onset of disease, and some of the patients were still ill during the 168 
interview, and we did not follow up to look at more long-term outcome of disease including the 169 
possibility for a more severe disease development. 170 
It is possible that we missed out on the most severely ill people; however, the interviewers called 171 
patients in the evening hours (4-9 pm), thus reducing the risk of missing people due to their working-172 
hours. The interviewers managed to interview 66% (or 70% after omitting 15 patients who were 173 
infected abroad and thus not eligible to interview). This is a satisfactory participation rate compared 174 
to other similar studies[286, 287], but nonetheless, it is likely that very ill people would not, or could 175 
not, participate. The interviewers did make short notifications of the reasons that patients did not 176 
participate, and from this list we derived that 13 patients were too ill to participate when they were 177 
called.  178 
We also found that older patients seemed more likely to suffer from underlying comorbidity, and to 179 
be diagnosed with a resistant or multidrug-resistant Salmonella infection (Table 6.8). Increasing age 180 
is a classic confounder for underlying comorbidity in epidemiologic studies. Older people tend to 181 
accumulate an increasing number of health complaints and are therefore more prone to visit a GP or 182 
a hospital, and are also more likely to be tested for infections and to be subsequently treated with 183 
antimicrobials. As is shown in Manuscript I and Manuscript II, people treated with antimicrobials 184 
appear to be more likely to be diagnosed with Salmonella or Campylobacter. 185 
7.5 Objective 3 186 
A history of antimicrobial treatment, unrelated to the current salmonellosis, up to six months before 187 
infection was associated with a more severe clinical outcome of disease. Patients, who had received 188 
a course of antimicrobial treatment in the past, had higher odds for severe weight loss (>5 kgs), 189 
hospitalisation and antimicrobial treatment for their current salmonellosis. There are several possible 190 
explanations for this observation. It is possible that this is an extension of the competitive and 191 
selective effect of antimicrobial treatment (Manuscript I and Manuscript II), where past 192 
antimicrobial treatment depletes or changes the composition of the gut flora in a way that increases 193 
severity of infection. Alternatively, a past history of treatment could be an indicator or proxy of a 194 
vulnerable patient.   195 
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We found that one of every two patients (51%) was treated with antimicrobial drugs. This was a 196 
surprise, since Denmark is known for a prudent use of antibiotics. Elderly patients, over 60 years, 197 
used more antimicrobials than younger patients in our study, and this coincided with a higher 198 
percentage of these patients being admitted to a hospital for their infection. It is likely to be due to 199 
the fact that older people have a reduced functioning of the immune-system and that elderly get 200 
dehydrated more easy than younger people[288], and are therefore more likely to be seriously 201 
affected by an infection like Salmonella.[289] However, of the youngest age-group (<4 years), 35% (9 202 
out of 26) were treated with antibiotics, which is a cause for concern. Antimicrobial treatment for 203 
salmonellosis is not recommended, unless absolutely necessary. On the other hand, more mild cases 204 
presenting with mild diarrhoea and other mild symptoms are unlikely to be (stool-) sampled, and are 205 
therefore not represented in our study.  206 
Another explanation for our findings could be that asthma/bronchitis were the most common 207 
underlying disease in our study. These patients are more likely to suffer from upper-respiratory 208 
illnesses[290], which might be treated with antimicrobials adding to the antimicrobial use of our 209 
study-population. Unfortunately, the clinical indication for the earlier prescribed antimicrobial course 210 
was not investigated.   211 
7.6 General Conclusions and future perspectives 212 
In this thesis, multiple hypotheses were tested. The first conclusion is that with an increasing number 213 
of antimicrobial prescriptions, the number of clinical infection with antimicrobial-resistant 214 
Salmonella and Campylobacter are likely to rise as well. The use of broad-spectrum penicillins, 215 
sulphonamides, trimethoprim and tetracyclines, and in particular fluoroquinolones up to half a year 216 
before infection, was associated with a higher risk of infection with both Salmonella and 217 
Campylobacter. In addition, patients who were exposed to fluoroquinolones had a significantly 218 
higher risk for acquiring a Salmonella or Campylobacter infection that was resistant to the drug 219 
previously taken. In Salmonella, this tendency was also found for broad-spectrum penicillins, 220 
sulphonamides and trimethoprim, and tetracyclines.  221 
Registry-based studies are very efficient to assess hypotheses like these. The enormous amount of 222 
data provides good statistical strength to perform such analysis. We did not have enough statistical 223 
power to calculate this effect in some of the classes of antimicrobials that were initially included in 224 
the study. By now, eight more years of data have been included in the registries, and perhaps this 225 
could be re-examined.  226 
The second conclusion is that we were not able to demonstrate major negative outcomes of S. 227 
Typhimurium infection when comparing patients infected with strains classified in three levels of 228 
antimicrobial drug resistance. Nevertheless, this effect was found in many other large-scaled studies. 229 
Our negative finding is likely to be a limitation of the design of the study rather than a true absence 230 
of a detrimental effect. Therefore, it is recommended to perform a high-powered study taking 231 
advantage of electronic health records or other databases. As these databases are more appropriate 232 
to address research questions regarding the public health effect of antimicrobial drug resistance than 233 
work-intensive interview studies, such as the one presented in this thesis. 234 
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We also found that people who had received a course of antimicrobials, unrelated to their current 235 
salmonellosis, up to six months before they got ill, had higher odds for hospitalisation, severe weight 236 
loss (>5kgs lost), and treatment with antimicrobials for their current infection. To our surprise, we 237 
found that half of the patients interviewed, had received an antimicrobial treatment for the 238 
Salmonella infection. This is a concern in light of the need to advocate prudent use of antimicrobials. 239 
As mentioned in the discussion of the results, mild cases of salmonellosis (or any bacterial 240 
gastroenteritis for that matter) are not sampled, and are therefore not represented in the national 241 
registry of enteric pathogens, and thus not included in our study. To assess the actual number of 242 
prescriptions prescribed for diarrhoeal diseases, GPs could be approached. 243 
The overall, and most important conclusion of this thesis is that human antimicrobial use interacts in 244 
many ways with the risk of being infected with antimicrobial drug resistant strains of Salmonella and 245 
Campylobacter, and that it may be associated with severity of infection as well. The protective role of 246 
macrolides with regards to Campylobacter infection adds another layer of complexity to these 247 
interactions. Prudent use of antimicrobial drugs should always be advocated in human health 248 
practices. And future studies should point out whether the associations found in this thesis are also 249 
present in other pathogens. 250 
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Objectives: The use of antimicrobial drugs for food animals selects for resistant non-typhoid Salmonella strains,
but human consumption of antimicrobial drugs may also increase the risk of subsequent infection. The aim of
this study was to determine the risk of salmonellosis attributable to human consumption of antimicrobial drugs
in a case–control study of 22602 laboratory-confirmed Salmonella infections, diagnosed in Denmark between
1997 and 2005.
Methods: A population registry-based case–control study, using several Danish databases: the National Pre-
scription Database; the National Registry for Enteric Pathogens; the Civil Registry System; and the Integrated
Database on Labour Market Research.
Results: Exposure to trimethoprim, sulphonamides, broad-spectrum penicillins, tetracyclines and fluoroquino-
lones, during the year prior to diagnosis, was associated with an increased risk of non-typhoid Salmonella infec-
tion. Overall, the highest risk was associated with the prior use of fluoroquinolones. This risk increased as the
time window of exposure approached the infection date. Previous use of fluoroquinolones was associated with
an odds ratio (OR) of 4.55 [95% confidence interval (CI): 3.78–5.47] for Salmonella serotypes other than
Salmonella Typhimurium or Salmonella Enteritidis, an OR of 2.21 (95% CI: 1.70–2.86) for Salmonella Typhimur-
ium and an OR of 2.07 (95% CI: 1.76–2.42) for Salmonella Enteritidis. In particular for fluoroquinolones, there
was an interaction between the pathogen resistance pattern and a history of antibiotic drug use.
Conclusions: The increasing use of antibiotics, particularly fluoroquinolones, is likely to result in increased inci-
dence of foodborne infections with drug-resistant Salmonella.
Keywords: antimicrobial consumption, antimicrobial drug resistance, registry-based study, competitive effect, selective effect,
case–control study
Introduction
In many countries, antimicrobial drug resistance in foodborne
pathogens is recognized as an increasing problem.1 – 4 The wide-
spread use of antimicrobial drugs for food animals is the major
factor for the selection and dissemination of resistance in zoo-
notic foodborne pathogens such as non-typhoid Salmonella
enterica serotypes (hereafter named Salmonella).5 – 9 Zoonotic
bacteria are usually already resistant at the time of human
exposure from food sources. However, it has also been suggested
that human antimicrobial drug use is an additional risk factor for
antimicrobial drug resistance in foodborne pathogens. Thus,
several epidemiological studies show that pre-infection anti-
microbial therapy (for indications other than gastroenteritis) is a
risk factor for infection with antimicrobial drug-resistant bacteria
of animal origin. The use of antimicrobial drugs may cause a
transient increase in susceptibility to infection after exposure to
a foodborne pathogen. This susceptibility may be separated
into a so-called ‘competitive effect’ and a ‘selective effect’;
the selective effect offers a specific advantage for a resistant
pathogen.10,11 In other words, drug-resistant gastrointestinal
pathogens preferentially cause illness in persons receiving anti-
microbial drugs for any medical condition. This issue has been
studied in outbreak investigations and in case–control studies
of sporadic infections, but little research has been carried out
to investigate the long-term consequences of human antimicro-
bial drug use for acquiring resistant foodborne pathogens.
Recently, Gradel et al.,8 found that Salmonella patients had an
excess risk of being exposed to antimicrobials in the year
before infection compared with their controls. Whereas this
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observation could partly be ascribed to a long-term competitive
effect of broad-spectrum antimicrobial use, the study also indi-
cated that higher antimicrobial use might be a marker for
frailty and therefore an indicator of patients who are more sus-
ceptible to becoming infected with, or are more likely to be
diagnosed with, Salmonella. The study did not have sufficient
statistical power to address whether a history of consumption
of antimicrobial drugs conferred an excess risk of getting infected
with drug-resistant Salmonella.
In the present nationwide registry-based study, we analysed
the association between pre-infection exposure to antimicrobial
drugs and laboratory-confirmed Salmonella infection. Due to
the size of the study, we were able to address the role of drug
resistance, and determine the long-term consequences of a
history of antimicrobial use by different groups of antimicrobials.
We were, on this basis, able to consider three different selective
effects for acquiring resistance: the selective effect; the competi-
tive effect; and the probable effect of selection bias or frailty.
Materials and methods
Registers
During the study period, from 1997 to 2005, all cases of Salmonella infec-
tion confirmed by faecal culture or by a culture from a normally sterile
site were reported to Statens Serum Institut and data entered into the
National Registry for Enteric Pathogens.12,13 Susceptibility testing was
performed on a sample of submitted strains by the Unit of Gastrointesti-
nal Infections of Statens Serum Institut.14 For surveillance purposes, all
isolates of serotype Typhimurium were targeted for susceptibility
testing whereas we examined a random sample of other serotypes
(with Enteritidis as the most common). In total, 46% (10408 samples)
of the strains included in the present study were susceptibility tested;
ranging from 97% of the Salmonella Typhimurium strains to 29% of
other serotypes (Table 1). The data were entered into these databases
including a unique personal identification number used in the Danish
Civil Registry System. The personal identification number enables
linkage between the different surveillance and public health databases.15
Information on county and municipality can be directly deduced from the
Civil Registry System.
To obtain data on exposure to antimicrobial drugs prior to the
Salmonella infection, we used the National Prescription Database. This
database contains information on all prescriptions provided by general
practitioners, and is collected at local pharmacies. Data were entered
using the Civil Registry System number and included the generic name
of the drug, the ATC code, dosage, price and date of issue.
To control for the confounding effect of education and socio-
economic status, we obtained data on schooling and income from the
Integrated Database on Labour Market Research.16
Case patients and controls
Patients enrolled in our study were all culture-confirmed cases with
Salmonella with receipt of culture or specimen between 1 January
1997 and 31 December 2005. For each case we selected 10 control
persons who were alive at the day of receipt of the strain and matched
for sex, age and county of residence.
Data from the National Prescription Database was available from
1 January 1995 until 31 December 2005.
Data analyses
We defined the index date as the date 21 days before the date the
sample was entered in the National Registry for Enteric Pathogens.
These 21 days are composed of two time intervals; we assumed that
there is an average delay of 7 days between the visit to the doctor’s
office or admission to hospital and the date the sample is entered in
the database. The other 14 days we consider being an ‘acute phase’ of
infection. Drugs prescribed in this acute phase are likely to represent
treatment of the Salmonella infection, in particular as early empirical
treatment for diarrhoea, and therefore causes bias to the outcome:
Table 1. Definition of the groups of antimicrobials, total number of susceptibility-tested cases and prevalence of resistance to four classes of
antimicrobials, Denmark 1997–2005
Groups
Salmonella
Typhimurium
Salmonella
Enteritidis
Other
serotypes
ATC
code Antimicrobials tested for in susceptibility test
Total number of patients 4675 12151 5776
No. susceptibility tested (%) 4534 (97.0) 4195 (34.5) 1679 (29.1)
No. (of all cases) resistant to:
aminoglycosides 1292 37 242 J01GB streptomycin, gentamicin, apramycin,
kanamycin, spectinomycin
amphenicols 302 1 0 J01B chloramphenicol
extended-spectrum
penicillins
1354 87 236 J01CA ampicillin, mecillinam
fluoroquinolones 164 326 460 J01M ciprofloxacin, nalidixic acid
other antibacterials 157 788 1 J01X colistin, nitrofurantoin, polymyxin, fosfomycin
sulphonamides and
trimethoprim
1713 57 295 J01E sulfamethoxazole, trimethoprim
tetracyclines 1643 69 463 J01A tetracycline
third-generation
cephalosporins
7 0 4 J01DD ceftriaxone
Breakpoints used in this study for susceptibility testing are different for each year; see DANMAP 1997–DANMAP 2005.
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Figure 1. Cubic spline plots of the OR of being exposed to broad-spectrum penicillins and fluoroquinolones 0–2 years before infection with Salmonella Typhimurium, Salmonella
Enteritidis and other Salmonella, 1997–2005 Denmark. The ORs are adjusted for sex, age, county of residence, population density, income and schooling.
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protopathic bias.17 For this reason, drugs taken in this time frame were
excluded from our main analysis.
Odds ratios (ORs) for exposure to antimicrobial drugs before the index
date were calculated in a conditional logistic regression model; Table 1
outlines the categorization of antimicrobial drugs and the number of
susceptibility-tested cases. Further, a time-dependent OR for exposure
to antimicrobials, in six different intervals before infection, was estimated
as a function of time before onset of infection. In addition, we applied
cubic splines18 to obtain a smooth curve (Figure 1). The time frames
were the ‘acute phase’ and 0–2 weeks, 2–4 weeks, 1–6 months,
6–12 months and 1–2 years before the index date. All estimated ORs
were adjusted for rural/urban differences by population density (separ-
ated into five categories; .2000, 1001–2000, 351–1000, 26–350 and
1–25 persons/km2), schooling (primary school only or more than
primary school) and income [income per household/number of adults
in the household matched within 100 000 Danish Kroner (US $18 000)
intervals].13
Effect modification by age was determined by fitting an interaction
term by three age groups (0–15 years, 15–64 years and ≥65 years). All
analyses were performed using conditional logistic regression, with the
PHREG procedure in SAS 9.1.3 for UNIX (SAS Institute, Cary, NC, USA) or
SAS version 9.1 for Windows.
Results
In the study period, a total of 22602 Salmonella cases were
reported, including 4675 (20.7%) Salmonella Typhimurium,
12 151 (53.8%) Salmonella Enteritidis and 5776 (25.6%) other
Salmonella serotypes (Table 1). We matched a total of 214 325
controls to these patients. The median age for patients with
infections of Salmonella Typhimurium, Salmonella Enteritidis
and other Salmonella serotypes was 32, 38 and 31 years,
respectively.
There was no difference in age and gender distribution among
patients with a susceptibility-tested Salmonella strain compared
with patients with strains that were not susceptibility tested.
The numbers of resistant isolates were very low for some of the
antimicrobials (e.g. no isolates of Salmonella Enteritidis were
resistant to third-generation cephalosporins and no isolates
belonging to the group of other serotypes were resistant to
amphenicols; Table 1). Due to this limited number of observations,
we excluded the following groups of antimicrobials from our ana-
lyses: amphenicols; aminoglycosides; third-generation cephalos-
porins; and the group named ‘other antibacterials’. Either there
were not enough prescriptions or the number of resistant isolates
was inadequate for a meaningful analysis. Amphenicols have not
been prescribed in Danish general practice since 1998, aminogly-
cosides and third-generation cephalosporins are mostly prescribed
in hospitals and drugs that are prescribed in hospitals are not
included in the National Prescription Database.
Outcome data
In the year prior to Salmonella diagnosis, patients more fre-
quently had a history of antimicrobial drug use than population
controls. This was observed independent of serotype and suscep-
tibility pattern, and was found for all classes of drugs but with
some variation in estimates (Table 2).
Table 2. Number of Salmonella cases and population controls exposed to antimicrobial drugs and the OR
of Salmonella infection by history of antimicrobial drug use 2 weeks–12 months before infection, Denmark
1997–2005; all Salmonella cases, irrespective of susceptibility testing
No. (%) exposed
cases/controls
OR for being exposed to antimicrobial
drugs, OR (95% CI)cases controls
Salmonella Typhimurium (4675)
exposure to:
broad-spectrum penicillins 601 (12.9) 3998 (9.2) 1.56 (1.41–1.73)
fluoroquinolones 78 (1.7) 326 (0.8) 2.21 (1.70–2.86)
sulphonamides and trimethoprim 177 (3.8) 1295 (3.0) 1.30 (1.10–1.54)
tetracyclines 64 (1.4) 440 (1.0) 1.32 (1.00–1.74)
Salmonella Enteritidis (12151)
exposure to:
broad-spectrum penicillins 1202 (9.9) 9169 (7.8) 1.33 (1.24–1.42)
fluoroquinolones 198 (1.6) 929 (0.8) 2.07 (1.76–2.42)
sulphonamides and trimethoprim 535 (4.4) 4017 (3.4) 1.32 (1.20–1.45)
tetracyclines 194 (1.6) 1402 (1.2) 1.33 (1.14–1.55)
Other Salmonella serotypes (5776)
exposure to:
broad-spectrum penicillins 719 (12.4) 4592 (8.5) 1.62 (1.47–1.77)
fluoroquinolones 186 (3.2) 387 (0.7) 4.55 (3.78–5.47)
sulphonamides and trimethoprim 317 (5.5) 1815 (3.4) 1.72 (1.51–1.96)
tetracyclines 142 (2.5) 607 (1.1) 2.24 (1.85–2.71)
The ORs are adjusted for sex, age, county of residence, population density, income and schooling.
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Data pertaining to susceptibility-tested strains only are given in
Table 3. For several drugs (fluoroquinolones, tetracyclines and
broad-spectrum penicillins), there was an effect modification,
i.e. resistant strains conferred a higher OR for salmonellosis
than susceptible strains. The effect modification was statistically
significant for fluoroquinolone-resistant Salmonella Typhimurium
and Salmonella Enteritidis. The risk of being diagnosed with a
fluoroquinolone-susceptible Salmonella Typhimurium after having
taken a course of fluoroquinolones was 2.0 times higher for
patients than for controls, whereas the risk of having a
fluoroquinolone-resistant Salmonella Typhimurium was 7.2
(2.0×3.6) times higher for patients than for controls. The logistic
regression model is multiplicative, and the product in the bracket
is the main effect (OR 2.0 for susceptible strains) multiplied by
the interaction term (OR 3.6 for the tested strain being resistant
to the antimicrobial taken). Following the same argument, for Sal-
monella Enteritidis, the OR was 1.7 for a susceptible strain whereas
it was 4.5 (1.7×2.7) for acquiring a resistant strain.
We determined the OR for being diagnosed with Salmonella
after exposure to one of the groups of antimicrobials in different
time frames before infection. The outcomes of this analysis for
fluoroquinolones and broad-spectrum penicillins are given in
Figure 1. This graph shows the OR, on a log-scale, plotted
against the time since latest antimicrobial exposure before infec-
tion with Salmonella, in cubic splines. In general the highest
excess risk was found in a time window up to 1 month before
diagnosis, and levelled out and became relatively stable 24–
6 months before diagnosis.
Sulphonamides and trimethoprim were also associated with a
time-dependent excess risk of being diagnosed in particular for
other serotypes than Salmonella Enteritidis and Salmonella
Typhimurium. The ORs were 2.14 (95% CI: 1.43–3.23) for 0–
2 weeks, 1.17 (95% CI: 0.74–1.87) for 2–4 weeks, 1.23 (95%
CI): 1.01–1.50) for 1–6 months, 1.27 (95% CI: 1.06–1.53) for
6–12 months and 1.40 (95% CI: 1.21–1.62) for 1–2 years
before infection.
We also investigated the effect of age on the outcomes, but
we did not find any significant effect modification.
Discussion
A considerable body of research has addressed the link between
antimicrobial use for food animals and the selection of
antimicrobial-resistant pathogens, such as zoonotic Salmonella,
and the subsequent risk of humans acquiring such a
pathogen.7,19 – 23
However, it is also known that human consumption of anti-
microbial drugs is of importance. During a large outbreak of
Salmonella Typhimurium in pasteurized milk in the USA in
1984, Ryan et al.24 found that in the month before onset of
illness, use of antimicrobials to which the organism was resistant
increased the risk of a symptomatic infection by .5-fold.
Table 3. Number of Salmonella cases and population controls exposed to antimicrobial drugs and the OR of infection by history of antimicrobial
drug use 2 weeks–12 months before infection, analysed by susceptibility pattern of the infecting strain, Denmark, 1997–2005; only
susceptibility-tested cases
No. (%) exposed cases/controls Risk for salmonellosis
after exposure (main
effect), OR (95% CI)
OR for resistant straina,b
(interaction term),
OR (95% CI)cases controls
Salmonella Typhimurium (4628)
exposure to:
broad-spectrum penicillins 595 (12.9) 3967 (9.2) 1.50 (1.33–1.69) 1.17 (0.94–1.47)
fluoroquinolones 75 (1.6) 329 (0.8) 2.01 (1.53–2.64) 3.56 (1.22–10.34)
sulphonamides and trimethoprim 176 (3.8) 1280 (3.0) 1.33 (1.07–1.65) 0.96 (0.67–1.36)
tetracyclines 62 (1.3) 435 (1.0) 1.03 (0.70–1.51) 1.72 (0.97–3.02)
Salmonella Enteritidis (4412)
exposure to:
broad-spectrum penicillins 420 (9.5) 3285 (7.9) 1.26 (1.12–1.41) 1.20 (0.54–2.69)
fluoroquinolones 68 (1.5) 347 (0.8) 1.69 (1.26–2.26) 2.65 (1.20–5.85)
sulphonamides and trimethoprim 184 (4.2) 1401 (3.4) 1.26 (1.07–1.49) 2.64 (0.88–7.87)
tetracyclines 83 (1.9) 495 (1.2) 1.61 (1.26–2.05) 0.48 (0.06–3.80)
Other Salmonella (1619)
exposure to:
broad-spectrum penicillins 183 (11.3) 1224 (7.9) 1.42 (1.17–1.73) 1.53 (0.90–2.61)
fluoroquinolones 60 (3.7) 122 (0.8) 4.36 (2.97–6.41) 1.22 (0.56–2.66)
sulphonamides and trimethoprim 97 (6.0) 516 (3.3) 1.79 (1.38–2.32) 1.18 (0.60–2.32)
tetracyclines 38 (2.3) 154 (1.0) 2.30 (1.46–3.64) 1.03 (0.47–2.25)
The ORs are adjusted for sex, age, county of residence, population density, income and schooling.
aCases that were exposed to antimicrobials 1 year before infection (and were infected with a strain that was resistant to the drug previously taken).
bStatistically this was fitted as an interaction term, the total relative risk for infection with a drug-resistant Salmonella that is resistant to the drug
previously taken can be estimated as the product of the two ORs.
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At least two mechanisms may explain how antimicrobial drug
use increases the risk of infection with resistant Salmonella. First,
by depleting the normal gut flora and thus making the person
susceptible to a smaller dose of ingested Salmonella. This mech-
anism has been described as the ‘competitive effect’, which is
independent of the susceptibility pattern.10,11 Secondly, by
giving a selective advantage to resistant Salmonella strains
already colonizing the gut when the antimicrobial is taken. In
the study by Ryan et al.,24 antimicrobial use lowered the dose
of Salmonella needed to cause disease. The usual number of
cups of milk drunk was less for ill persons who had taken antimi-
crobial in the month before illness than for ill persons who had
not taken antimicrobials (2.4 versus 3.6 cups). This can be
described as a ‘selective effect’, i.e. a specific advantage for
the resistant pathogen.10,11
To our knowledge, the present study represents the first to
investigate the long-term effects of antimicrobial drug exposure
and, at the same time, distinguishes between these two mech-
anisms. The selective effect is a direct consequence of exposure
to antimicrobial-resistant bacteria, in this case Salmonella, which
has led to asymptomatic colonization. By taking a course of anti-
microbials the balance of the gut flora will be disrupted, giving
way to the antimicrobial-resistant bacteria to proliferate and
cause clinical infection. We visualized this effect by calculating
the OR that a patient was infected with a Salmonella strain
that was resistant to the antimicrobial that was taken up to
1 year prior to the index date, of which the results are shown
in Table 3. The premise of our model is that the selective effect
is a multiplication of the ORs given in this table: not only
should the patient be exposed to the antimicrobial, the infective
strain has to be resistant to the antimicrobial exposed.
For the overall effect of being exposed to a course of antimi-
crobial before infection, we have taken all Salmonella cases into
account, whether they were susceptibility tested or not. We
examined whether cases or controls were more likely to have
been exposed to a course of antimicrobials previous to the
index date of the case. Our results indicate that a history of anti-
microbial drug use may confer an increased risk of being diag-
nosed with Salmonella; this risk is present up to at least 1 year
after treatment. The effect may depend on several factors
including the spectrum of the antimicrobial, the antibacterial
effect of its metabolites and its pharmacokinetics.
Broad-spectrum penicillins, sulphonamides and trimethoprim
are excreted mainly via the urine, and therefore have a lesser
impact on the gut flora.25,26 This is also the case for most fluor-
oquinolones, but nevertheless, a significant part of this group of
drugs is excreted in the bile. Also, some of the active metabolites
of fluoroquinolones are excreted via the biliary route. This implies
that fluoroquinolones and their metabolites have an impact on
the gut flora by passing through the gastrointestinal tract,
which may explain why the most consistent results were obtained
for this drug.27 Tetracyclines are excreted via both the biliary and
the urinary pathways. This drug also reaches fairly high concen-
trations in the gastrointestinal tract in its unchanged form.28
The effect seen in the first half year before infection, in
Figure 1, is a combination of the ‘competitive effect’, the ‘selec-
tive effect’ and the effect of treatment (protopathic bias). The
effect of treatment can be seen if a patient had an antimicrobial
prescription for diarrhoeal symptoms before the actual stool
sample was taken. To account for the bias caused by the
effect of treatment we introduced an index date, which excluded
the ‘acute phase’ of exposure and an extra week that we esti-
mated it takes for a sample to show up in the database. In
Figure 1, the effect seen half a year before infection is that the
OR for being diagnosed with Salmonella increases after exposure
to a course of antimicrobials in all, except for exposure to broad-
spectrum penicillins in Salmonella Enteritidis. We are not sure of
the explanation of this effect: the half-lives of these drugs are
very short (30–80 min), so it is not caused by the physical
presence of the drug itself, and if that were the case, the
effect should have been the same for Salmonella Typhimurium
and Salmonella Enteritidis equally. The effect seen might be
explained by the low percentage of resistance to this group of
antimicrobials in Salmonella Enteritidis (3%–6%), which is
much higher in Salmonella Typhimurium (44%–56%).14
The effect of taking a course of antibiotics 6 months to 2 years
before infection can in part be ascribed to ‘selection bias’ (i.e. the
effect that some people are more likely to be tested than other
people). A history of drug use may also be an indicator of
increased use of healthcare, and thus a marker of frailty, and
therefore might contribute to this effect. Furthermore, a
Salmonella carrier may develop diarrhoea due to the non-specific
effect of the antibiotic and may get sampled on this basis.
However, it cannot be completely ruled out that some antimicro-
bial drugs may have a long-term effect on the gut flora and thus
render the patients more susceptible to salmonellosis.
Our study is subject to a number of limitations. One of the
limitations lies within the study design, because it was an obser-
vational study and selection bias may be of importance as dis-
cussed above.
Some of the antimicrobials are mainly used in hospital set-
tings, and these data are not included in the Danish prescription
database. We can only speculate that the impact of antimicro-
bials on the occurrence of antimicrobial resistance would have
been higher if we could also include these data. In Denmark,
90% of defined daily dosage of antibacterials is prescribed in
the primary healthcare sector.14
We did not adjust for co-morbidity in this study, but in a
similar study, performed by Gradel et al.,8 this was taken into
account and it did not affect the outcomes markedly. Therefore
it is not likely that co-morbidity is an interaction factor in our
study either.
To sum up, the use of fluoroquinolones, broad-spectrum peni-
cillins, sulphonamides, trimethoprim and tetracyclines, up to
1 year before infection, was associated with a higher risk of
Salmonella infection. In addition, patients who were exposed
to fluoroquinolones had a significantly higher risk of contracting
a Salmonella infection that was resistant to the antimicrobial
taken, and a similar tendency was found for other classes of
antimicrobial drugs.
Our data suggest that with an increasing number of anti-
microbial prescriptions, the number of clinical infections with
drug-resistant non-typhoid Salmonella is also likely to rise.
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Antimicrobial Use: A Risk Factor or a Protective
Factor for Acquiring Campylobacteriosis?
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Background. It is well acknowledged that the use of antimicrobial drugs in food animals leads to antimicrobial
drug resistance in foodborne bacteria such as Campylobacter; however, the role of human antimicrobial usage is
much less investigated. The aim of this study was to quantify the odds of campylobacteriosis conferred by human
consumption of fluoroquinolones and macrolides.
Methods. We conducted a registry-based retrospective case-control study on 31 669 laboratory-confirmed cases
of campylobacteriosis between 1999 and 2005 in Denmark. Data were obtained from several Danish databases: the
National Registry of Enteric Pathogens, the Danish Civil Registration System, the Danish National Prescription
Database, and the Integrated Database on Labor Market Research. Odds ratios (OR) for campylobacteriosis were
calculated by conditional logistic regression.
Results. The risk of campylobacteriosis was reduced 1 month after exposure to macrolides (OR, 0.72; 95%
confidence interval [CI], 0.56–0.92). Macrolide exposure 1 month to 2 years before infection was associated with an
increased risk of a Campylobacter diagnosis (OR, 1.5; 95% CI, 1.4–1.6). A history of fluoroquinolone use was also
associated with increased risk (OR, 2.5; 95% CI, 1.8–3.5). This risk was higher for resistant isolates than for
susceptible ones.
Conclusions. Treatment with macrolides may protect against Campylobacter infection for a limited period of
time, possibly due to the antibacterial effects of the drug or its metabolites. Fluoroquinolone treatment confers
increased risk, probably due to a combination of competitive and selective effects, similar to what has been observed
for nontyphoid Salmonella infection.
Campylobacter jejuni is recognized worldwide as the
leading cause of bacterial gastroenteritis [1]. In 2008, a
total of 190566 campylobacteriosis cases were reported
(overall incidence of 40.7 per 100 000) by 25 EU
Member States [2]. The level of antimicrobial resistance
of this bacterium has been rising for many years. Re-
sistance against fluoroquinolones and macrolides is of
particular concern for public health. A major source of
human campylobacteriosis is poultry and products
hereof, and several studies indicate that use of
antimicrobials such as fluoroquinolones and macrolides
in poultry production selects for drug-resistant Cam-
pylobacter [3–5]. Drug-resistant Campylobacter trans-
ferred to humans in the food chain may cause more
severe illness than sensitive strains [6]. Less well un-
derstood and described is the role of human con-
sumption of antimicrobial drugs. Only a few studies
highlight the role of this consumption on the de-
velopment of antimicrobial drug resistance in Cam-
pylobacter [7–9]. The vast majority of publications focus
instead on the role of other risk factors, like travel as-
sociation, consumption of chicken and other food
products, contact with animals, and other factors [10–12].
In the present registry-based study, we evaluated the
association between fluoroquinolones and macrolides
prescribed in general practice on the occurrence of
subsequent infection. We also estimated the odds of
diagnosis with a resistant strain after exposure to
a course of antimicrobials; we accomplished this by
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fitting an interaction term into the model between the odds of
being diagnosed with campylobacteriosis and the odds of being
diagnosed with a resistant strain.
METHODS
Registers
All culture-confirmed cases of Campylobacter are reported to
the Statens Serum Institut (SSI) and entered into the National
Registry for Enteric Pathogens [13]. This register only
includes each patient’s first isolate within a time frame of 6
months; if the patient has another positive sample within this
period, it is considered to be a recurrent or persistent
infection and is discarded in the database. During the study
period (1999–2005) 32.4%, of 31 669 isolates reported to SSI
were susceptibility tested against fluoroquinolones and
macrolides. For these strains, we calculated excess odds of
campylobacteriosis after drug exposure, as well as a multipli-
cative interaction term (the odds that the infective strain was
resistant to the antimicrobial previously taken). For a more
comprehensive testing of resistance, a total of 459 strains were
tested for a broader panel of antimicrobial drugs (Table 1) as
a part of the Danish Integrated Antimicrobial Resistance
Monitoring and Research Program (DANMAP) surveillance
scheme [16]. However, due to the low number of strains
examined, we did not have statistical power to calculate the in-
teraction term for these antimicrobials. The data were linked
using the unique, personal identification number used in the
Civil Registry System (CRS) [17]. Information on county of
residence can directly be deduced from this database.
To obtain data on exposure to antimicrobial drugs prior to
the Campylobacter infection, we used the National Pre-
scription Database. This database contains information on all
prescriptions provided by general practitioners, which were
filled at pharmacies in Denmark. Data were once again linked
using the Civil Registry System number and included the
generic name of the drug, the ATC-code, dosage, price, and
date of issue. To control for the confounding effect of
education and socioeconomic status, we obtained data on
schooling and income from the Integrated Database on Labor
Market Research [18].
Study Participation
We included all laboratory-confirmed patients with campylo-
bacteriosis between 1 January 1999 and 31 December 2005. For
each case, we selected 10 controls from the Civil Registry System
who were alive on the date the positive sample was received at
the SSI and matched them to the case on sex, age, and county of
residence. Data from the prescription database were available
from 1 January 1995 until 31 December 2005.
We compared the history of antimicrobial use in Campylo-
bacter patients to the history of use of their matched controls in
a period up to 2 years prior to diagnosis.
Susceptibility Testing
The antimicrobial drugs of interest for this study were fluo-
roquinolones and macrolides. To simplify the analysis, strains
that were resistant against nalidixic acid and/or ciprofloxacin
were considered resistant against fluoroquinolones; strains that
were resistant against erythromycin were considered resistant
against macrolides. All strains that were typed ‘‘intermediate’’
resistant were considered to be susceptible. All antimicrobial
susceptibility testing was performed with a commercially avail-
able MIC technique (Sensititre, Trek Diagnostic Systems Ltd).
The cells were inoculated and incubated according to the CLSI
guidelines. The breakpoints for this testing have changed over
the years and can be found in the annual DANMAP reports
(www.danmap.dk) [19].
Data Analyses
We conducted a registry-based, matched, retrospective case-
control study. For this purpose, we defined an index date as
the date 21 days before the date when the sample was entered
Table 1. Definition of the Groups of Antimicrobials Used in This Study
ATC code Antimicrobials susceptibility tested
Antimicrobials for which the excess risk of campylobacteriosis and the interaction term was calculated
Fluoroquinolones J01M Ciprofloxacin, nalidixic acid
Macrolides J01F Erythromycin
Antimicrobials for which only the excess risk of campylobacteriosis was calculated
Aminoglycosides J01GB Streptomycin, gentamicin, apramycin, kanamycin, spectinomycin
Amphenicols J01B Chloramphenicol
Other antibacterials J01X Nitrofurantoin, polymyxin
Sulfonamids and Trimethoprim J01E Sulfamethoxazole, trimethoprim
Tetracyclines J01A Tetracycline
Third generation cephalosporins J01DD Ceftriaxon
Breakpoints used in this study for susceptibility testing are different per year: see DANMAP1997 [14] and —DANMAP2005 [15].
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in the National Registry for Enteric Pathogens. These 21 days
are composed of 2 time-intervals: first, a 7-day average be-
tween the visit to the general practitioner’s office or admission
to hospital, and the date the sample was entered in the data-
base; and second, the 14 days we consider the ‘‘acute phase’’ of
infection. Antimicrobial drugs prescribed in this acute phase
are likely to be prescribed for early empirical treatment of the
Campylobacter infection, and therefore causes protopathic
bias [20]. Drugs taken in this time frame were excluded from
the main analysis but were included in an additional sub-
analysis described later.
In the main part of the analysis, we examined the odds of
exposure to a course of antimicrobials before being diagnosed
with Campylobacter, from the index date to 1 year before onset
of disease. We also calculated the odds of a strain being resistant
against the antimicrobial taken. Odds ratios (ORs) for exposure
to antimicrobial drugs before infection were calculated using
a conditional logistic regression model; Table 1 outlines the
categorization of antimicrobial drugs.
In the second part of the study, we calculated a time-de-
pendent OR for exposure to antimicrobials in 6 different time
intervals before infection. The OR was estimated as a function
of time before onset of infection. In addition, we applied cubic
splines [21] to obtain a smooth curve (Figure 1). The co-
efficients for the cubic spline function were estimated in
a conditional logistic regression model. In the cubic spline
model 3 knot points were used; these were chosen to be at
60 d, a half year, and 1 year before onset of infection. A knot
point is a point where the coefficients for the third-degree
polynomial were allowed to change, although only under the
restriction that the curve has to be continuous and smooth in
the knot points.
The time frames were the ‘‘acute phase,’’ 0–2 weeks, 2–4 weeks,
1–6months, 6–12months, and 1–2 years before index date. All of
the estimated ORs were adjusted for rural/urban differences by
population density (separated in 5 categories:.2000, 1001–2000,
351–1000, 26–350, 1–25 persons per square kilometer), schooling
(primary school or more than primary school), and income
(income per household/number of adults in the household
matched within 100 000 dkk (19000 USD) intervals) [13].
All analyses were performed using conditional logistic re-
gression with the PROC PHREG- procedure in SAS 9.1 for
Windows (SAS Institute).
RESULTS
In the study period, a total of 31 669 Campylobacter cases were
reported, of which 10 275 were susceptibility tested for both
fluoroquinolones and macrolides. These 10,275 patients were
matched (1:10) to 97 523 controls. Overall, 21.7% was resistant
against fluoroquinolones and 2.3% against macrolides (Table 2).
The prevalence of fluoroquinolone resistance was highest in
adults 50–59 years of age and lowest in children. A smaller
sample was additionally tested for susceptibility to amino-
glycosides, amphenicols, other antibacterials (ATC-code J01X),
sulfonamids and trimethoprim, tetracyclines, and third-
generation cephalosporins.
Being diagnosed with campylobacteriosis was associated with
an increased odds of exposure to a course of fluoroquinolones,
macrolides, sulfonamids and trimethoprim, tetracyclines, and
broad spectrum penicillins up to 1 year before onset of disease
(Table 3). This risk was highest for taking fluoroquinolones
(OR, 2.4; 95% CI, 1.97–2.97). For fluoroquinolones, we found
an effect modification, that is, resistant strains conferred a higher
risk of diagnosis than susceptible strains. The odds of being
exposed to a course of fluoroquinolones was 2.4 times higher for
cases diagnosed with a fluoroquinolone-sensitive Campylobacter
than for controls, whereas the odds of being exposed to fluo-
roquinolones was 3.8 (2.4 3 1.6) times higher for cases with
a fluoroquinolone-resistant Campylobacter than for controls.
The logistic regression model is multiplicative, and the product
in the brackets is the main effect (OR 2.4 for susceptible strains)
multiplied by the interaction term (OR 1.6 for the tested strain
being resistant to the antimicrobial taken). There was no in-
teraction between macrolide exposure and macrolide resistance.
In the second analysis of this study, we calculated the risk (OR)
of previous exposure to antimicrobials in different time intervals
for people who had been diagnosed with Campylobacter. The
results of this analysis are given in Figure 1. This graph shows the
OR, plotted against the time since latest antimicrobial exposure
before infection with Campylobacter, in cubic splines. The results
for fluoroquinolones and macrolides were different. Diagnosis
with Campylobacter was associated with a decreased odds of
macrolide consumption in the period close to diagnosis, while it
was associated with an increased fluoroquinolone consumption in
the same period (Table 4). We examined the effect of macrolides
more thoroughly to determine the duration of this protective
effect and performed the analyses for 4 different macrolides sep-
arately; erythromycin, roxithromycin, clarithromycin, and azi-
thromycin. There was an excess odds of consumption of each of
these drugs up to 1 year before infection (Table 4). However, if the
time between last exposure and Campylobacter infection is re-
duced to only the acute phase of infection (the estimated time
before onset of disease and appearance in our database), exposure
to macrolides became a protective factor (OR .72, up to 1 month
before infection; Table 4).
DISCUSSION
We have recently shown that a history of use of several different
classes of drugs is associated with an excess risk of being di-
agnosed with nontyphoid Salmonella [22]. Furthermore, this
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Figure 1. Cubic spline plots of the odds ratio (OR) of being exposed to macrolides and fluoroquinolones 0–2 years before infection with Campylobacter,
1997–2005 Denmark. The ORs are adjusted for sex, age, county of residence, population density, income, and schooling..
Table 2. Age Distribution and Prevalence of Resistance in 10475 Campylobacter Strains Examined for Susceptibility for Fluoroquinolones
and Macrolides, Denmark, 1999–2005
Total no. of patients No. and % susceptibility testeda Fluoroquinolone resistanceb Macrolide resistancec
Age groups N (%) N (%) N (%) N (%)
0–9 years 4076 (14.9) 1556 (38.2) 224 (14.4) 25 (1.6)
10–19 years 3039 (11.1) 1150 (37.8) 231 (20.1) 21 (1.8)
20–29 years 6841 (25.1) 2750 (40.2) 613 (22.3) 57 (2.1)
30–39 years 4971 (18.2) 1958 (39.4) 428 (21.9) 40 (2.0)
40–49 years 3117 (11.4) 1098 (35.2) 281 (25.6) 32 (2.9)
50–59 years 2505 (9.2) 992 (39.6) 256 (25.8) 32 (3.2)
60–69 years 1436 (5.2) 542 (37.7) 137 (25.3) 21 (3.9)
70–79 years 835 (3.1) 293 (35.1) 72 (24.6) 8 (2.7)
80 and older 456 (1.7) 136 (29.8) 26 (19.1) 2 (1.5)
Total 27,276 (100) 10,475 (38.4) 2268 (21.7) 238 (2.3)
a Overall v2: 45.0, degrees of freedom: 8, P value: , .001.
b Overall v2: 69.8, degrees of freedom: 8, P value: ,.001.
c Overall v2: 14.8, degrees of freedom: 8, P value: .06.
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effect was substantially modified by the resistance pattern of the
infecting strain [22]. This finding strongly supports the idea
of competitive and selective effects of antimicrobial drug use
[23, 24]. The results of the present study are in line with the
fluoroquinolone findings in our Salmonella study, as well as
our observation that a history of human antimicrobial-drug
exposure may constitute a long-term risk for being diagnosed
with Campylobacter. Surprisingly, in the current study, diagnosis
withCampylobacterwas associated with a reduced odds of recent
history of macrolides compared with controls. This raises the
hypothesis that macrolide use may protect against Campylo-
bacter infection for a limited period of time, perhaps as long as
4–8 weeks (Table 4).
To assess this hypothesis, different effects of antimicrobial
drugs should be considered, including their spectrum, the anti-
bacterial effect of their metabolites, and their pharmacokinetics.
The pharmacokinetics of macrolides are well described in the
literature; the half-life of macrolides is different for each of
the drugs included in this study; erythromycin has a short half-life
(,4 hours), roxithromycin and clarithromycin an intermediate
half life (4–24 hours) and azithromycin has a long half-life
(.72 hours) [25]. However, the protective effect of the drugs
last at least 4 weeks (Figure 1). The effect of macrolides, as
a group, in the acute phase and 0–2 weeks before the index
date (OR, .72; 95% CI, .56, .92) is strong. The acute phase
was specifically constructed so we could not confuse drugs
prescribed as early empirical treatment as a risk factor for
acquiring Campylobacter.
It is interesting that a protective effect is seen in all the
macrolides (Table 4), even though the kinetics of each of the
macrolides is quite different. One explanation for this phe-
nomenon is that macrolides, especially azithromycin, become
trapped in the intracellular lysosomes of phagocytic cells. This
intracellular uptake is easily reversible for erythromycin and
clarithromycin but is extremely slow and probably not com-
pletely reversible for azithromycin [26, 27]. It is even possible
Table 3. Risk of Campylobacter Diagnosis by Exposure to a Course of Antimicrobial Drugs 0–12 Months Before Infection, Denmark,
1999–2005
Exposed to (up to 1
year before infection):
No. (%) exposed cases/controls
Risk for campylobacteriosis after
exposure (main effect) OR (95% CI)
OR for resistant strain
a,b
(interaction term) OR (95% CI)Cases (10275) Controls (97591)
Broad-spectrum penicillins 1191 (11.6) 8756 (9.0)) 1.35 (1.25, 1.45) P # .001
Fluoroquinolones 183 (1.8) 658 (0.7) 2.42 (1.96, 2.98) P # .001 1.61 (1.11, 2.32) P 5 .01
Sulfanomids and Trimethoprim 530 (5.1) 3535 (3.6) 1.48 (1.34,1.64) P # .001
Tetracyclines 202 (2.0) 1437 (1.5) 1.36 (1.16, 1.59) P # .001
Macrolides 1158 (11.3) 7642 (7.8) 1.48 (1.38, 1.59) P # .001 1.04 (0.70, 1.54) P 5 .85
The odds ratios (ORs) were adjusted for sex, age, county of residence, level of schooling, income, and population density.
a Cases that were exposed to antimicrobials 1 year before infection (and were infected with a strain that was resistant to the drug previously taken).
b Statistically, this was fitted as an interaction term, the total relative risk for infection with a drug-resistant Campylobacter that is resistant to the drug previously
taken can be estimated as the product of the 2 ORs.
Table 4. Risk of Campylobacter Diagnosis by Timing of Exposure to a Course of Antimicrobials 0–12 Months Before Infection, Denmark,
1999–2005
Exposed to:
Upto 1 year
before infection:a
OR (95% CI)
Upto 3 months
before infectionb:
OR (95% CI)
Upto 2 months
before infectionb:
OR (95% CI)
Upto 1 month
before infectionb:
OR (95% CI)
Only the
acute phase:
OR (95% CI)
Erythromycin 1.40 (1.25–1.57)
P # .001
Not enough power for the separated analyses 0.06 (0.01–0.43)
P 5 .005
Roxithromycin 1.63 (1.37–1.93)
P # .001
0.39 (0.09–1.63)
P 5 .20
Clarithromycin 1.62 (1.29–2.02)
P # .001
0.83 (0.25–2.71)
P 5 .75
Azithromycin 1.44 (1.30–1.60)
P # .001
0.29 (0.11–0.79)
P 5 .02
Macrolides grouped 1.48 (1.38–1.59)
P # .001
1.16 (1.02–1.31)
P 5 .02
0.98 (0.83–1.16)
P 5 .81
0.72 (0.56–0.92)
P 5 .01
0.30 (0.16–0.56)
P 5 .01
Fluoroquinolones 2.42 (1.96–2.98)
P # .001
2.54 (1.83–3.54)
P # .0001
2.65 (1.78–3.93)
P # .0001
2.94 (1.82–4.75)
P # .0001
10.32 (6.65–16.02)
P 5 .002
The odds ratios (ORs) were adjusted for sex, age county of residence, level of schooling , income, and population density.
a This period does not include the ‘‘acute phase’’ of infection.
b These periods do include the ‘‘acute phase’’ of infection.
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that part of the azithromycin metabolites remain trapped in the
lysosome until the cell dies, and the drug is finally released
(N. Frimodt-Møller, personal communication, 2009).
Antimicrobial drug promotors, given to food animals in
subinhibitory concentrations, may have profound effects on the
intestinal flora and risk of infection with gastrointestinal
infections. It cannot be ruled out that macrolides or their me-
tabolites are present in intestines of humans for several weeks in
sufficiently high concentrations to produce a similar effect. This
may be the case for azithromycin, as well as other drugs. Clearly,
additional studies are needed to examine this possibility.
Other explanations for our observation should be considered.
Although macrolides are mostly prescribed in the winter season
for respiratory infections, andCampylobacter infections are most
common in the late summer [28, 29], confounding effects by
season are not a likely explanation for the association because we
adjusted for season by matching on the index date of the case.
Furthermore, several other classes of antimicrobial drugs are
prescribed more commonly in the winter season as well, without
causing a similar pattern [22].
For fluoroquinolones, we found a risk pattern similar to the risk
pattern found when examining their effects with nontyphoid
Salmonella infection [22]. The observation, as shown in Figure 1,
can be ascribed to a combination of 3 effects: the ‘‘competitive
effect,’’ the ‘‘selective effect,’’ and for fluoroquinolones, also the
effect of treatment (protopathic bias). The effect of treatment can
be seen in the ‘acute phase’ of the infection where the patient might
have received a course of fluoroquinolones as early empirical
treatment, before the stool-sample was taken. The competitive
effect is independent of the susceptibility pattern and can be ex-
plained by depletion of the normal gut-flora, thereby leaving the
person susceptible to a smaller dose of an infective agent, in this
case Campylobacter. Finally, the selective effect is the advantage to
resistant Campylobacter strains already colonizing the gut when the
antimicrobial was taken [23, 24].
We assume that the observed effect in Figure 1, from a point
where the line stabilizes (at 3 months before infection for
macrolides and a year for the fluoroquinolones) can be con-
sidered as a base-line for ‘‘selection bias’’ (the effect that some
people are more likely to be tested than other people). A history
of drug use may also be an indicator of increased use of health
care (and thus a marker of frailty) and therefore might con-
tribute to this effect [30]. Furthermore, an asymptomatic
Campylobacter carrier may develop diarrhea due to the non-
specific effect of the antibiotic and may be sampled based on
this. However, it cannot be completely ruled out that some
antimicrobial drugs may have a long-term effect on the gut
flora and thus render patients more susceptible to campylo-
bacteriosis.
We found some differences in the number of samples
susceptibility-tested in each age-group (Table 2). Even though
the differences are significant, we assume that this is due to
random error. We also found a significant difference in the
number and percentages of fluoroquinolone-resistant in-
dividuals for different age groups. This effect is likely to be
explained by 2 factors: (1) the fact that it is not common to
prescribe fluoroquinolones to children and (2) the differences in
travel behavior between the age groups. In 2008, 27.4% of
Campylobacter cases were travel related [31] and were associated
with a higher percentage of resistance [16]. However, matching
for age should have eliminated any related bias.
The study is subject to some limitations. First, some antimi-
crobial drugs are mainly used in hospital settings, and these data
are not included in the Danish prescription database. However,
in Denmark, 90% of the prescribed antimicrobials are pre-
scribed in the primary health sector [16]. We can only speculate
that the impact of these antimicrobials would have been larger if
they were included in the study.
Second, it is well known that Campylobacter shows immense
antigenic diversity, and immune-evasion strategies can differ
greatly between different strains of Campylobacter [32]. Un-
fortunately, species identification and subtyping of Campylo-
bacter is not carried out as a routine activity in Denmark;
therefore, these data were not available for use.
To conclude, human use of broad-spectrum penicillins, sul-
fonamids, trimethoprim, tetracyclines, macrolides, and in par-
ticular fluoroquinolones may form a risk factor for acquiring
campylobacteriosis. Furthermore, fluoroquinolone consump-
tion selects for infection with resistant Campylobacter. To our
surprise, Campylobacter diagnosis was associated with a reduced
odds of recent macrolide use.
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 Summary (150 words) 22 
 23 
We performed a prospective case-case telephone-interview study in Denmark, including 150 Salmonella 24 
Typhimurium patients with the aim to examine how clinical outcome of an infection is affected by previous 25 
antimicrobial exposure. In addition, we were interested in differences in outcome of disease relating to the 26 
susceptibility profile (fully susceptible, resistant and multiresistant). We found that previous antimicrobial use, 27 
unrelated to this salmonellosis was related to a higher risk of weight loss (OR 2.43 95%CI 1.09-5.48), hospital 28 
admission (OR 2.03 95%CI 1.02-4.06), or antimicrobial therapy for the current salmonellosis (OR 7.85 95%CI 29 
2.77-16.78). We were not able to demonstrate major negative outcomes of infection with antimicrobial drug 30 
resistant Salmonella Typhimurium infections in connection with the three different levels of drug-resistance.  31 
The higher risk of weight loss, hospital admission or therapy among patients with a history of antimicrobial 32 
treatment independent of the current episode adds to studies that have demonstrated competitive and 33 
selective effects of antibiotic treatment. 34 
35 
3 
 
Introduction 36 
Salmonella Typhimurium is among other non-typhoid Salmonella infections one of the most common causes of 37 
foodborne bacterial gastrointestinal infection worldwide, usually causing a self-limiting diarrhoeal disease, but 38 
occasionally causing a more severe disease outcome, such as reactive arthritis, bacteraemia or even death, 39 
particularly in very young children or the elderly.(1) Antimicrobial drugs are not recommended as a routine in 40 
the management of infections with non-typhoid Salmonella infections, however when severe illness or 41 
complications are suspected, or infections in patients with underlying illness occur, antimicrobials are often 42 
prescribed. The effect of early empirical treatment is under threat due to  increasing  antimicrobial drug 43 
resistance which has  been observed  in Salmonella, not only worldwide, but even in Denmark where 44 
antimicrobial use in the food industry has been much lower than in the rest of the world.(2-4)  A consequence 45 
of increasing antimicrobial resistance may be that  appropriate treatment for salmonellosis can be delayed, 46 
which could lead to more serious outcome of disease.(5;6)  47 
Several host-associated risk factors and high-risk food items for salmonellosis have been identified from case-48 
control studies of sporadic disease and outbreak investigations. Besides common sources including pork, eggs 49 
and chicken, Salmonella Typhimurium outbreaks have been associated with vehicles such as instant baby-50 
formula powder,  cheese consumption, dry dog- and cat-food, to mention a few of the diverse food items 51 
incriminated in outbreaks.(7-12) Infections may often be acquired during foreign travel. Host-associated risk 52 
factors include old age or being an infant(13;14) as well as presence of underlying (chronic) disease, these 53 
factors are described as  determinants for a more severe outcome for salmonellosis. Another predictor for a 54 
more severe outcome of disease is being infected with an antimicrobial resistant Salmonella (15-21), hardly any 55 
studies show the opposite(22).   56 
In a registry based study, we have showed that previous exposure to antimicrobial drugs is an important risk 57 
factor for infection with a non-typhoid Salmonella. In the present prospective case-case comparison we wanted 58 
to examine further how antimicrobial exposure before onset of Salmonella infection may affect outcome of 59 
disease.  In addition, we wanted to analyse whether Salmonella Typhimurium infections with different 60 
susceptibility profiles (fully susceptible, resistant, and multiresistant) were associated with different outcomes 61 
of disease.  62 
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Materials and Methods 63 
Study design and definitions 64 
This study was designed as a prospective case-case interview study, including patients with acute 65 
gastroenteritis or invasive infection due to Salmonella Typhimurium; for the purpose of the present study 66 
monophasic Salmonella (S.4,5,12,I-) was included as well. All patients will be referred to as Salmonella patients. 67 
The patients were split into three groups, according to the antimicrobial susceptibility profile of the Salmonella 68 
strain that they were infected with. The first group had a fully susceptible profile (S), the second group was 69 
resistant against one to three different antimicrobial classes (R), and the last group was multiresistant (MR), i.e.  70 
resistant to four or more antimicrobial drugs from different classes. MIC testing is used to determine 71 
antimicrobial resistance in the laboratory, isolates are tested susceptible (S), resistant (R), or intermediate 72 
resistant (I) for antimicrobial drugs, according to EUCAST standards (www.eucast.com).(23)  If the MIC-value of 73 
the isolate was tested I to a drug, it was coded as S. In Denmark, Salmonella are tested for 19 antimicrobials:  74 
ampicillin, apramycin, amoxicillin-clavulanic acid, cefotaxime, ceftiofur, chloramphenicol, ciprofloxacin, 75 
collistin, florfenicol, fosfomycin, gentamicin, mecillinam, nalidixic acid, neomycin, spectinomycin, streptomycin, 76 
sulfonamide, tetracycline and trimethoprim. 77 
 78 
Identification of patients 79 
Criteria for enrolment in the study were: confirmation either by means of faecal culture or by a culture from a 80 
normal sterile site, that were reported to the Statens Serum Insitut (SSI), and entered into the National Registry 81 
for Enteric Patients(24), and being reported between January and June 2010. Susceptibility testing by the Unit 82 
of Gastrointestinal Infections of SSI(25)  is generally performed on nearly all (i.e., 94% in the study period)  83 
strains submitted for subtyping.(26)  All Danish citizens can be tracked in the health care system and national 84 
registries using the unique ten digit civil registration number assigned to each person at birth or upon 85 
immigration.(27)  If several persons from the same household were reported within the same 2 weeks, only the 86 
first to be registered was interviewed.  87 
Patients belonging to outbreak clusters were excluded from the study.  Patients were also excluded if they had 88 
travelled outside of Denmark in the two-week period before onset of first symptoms.  89 
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Interview and questions 90 
All Salmonella patients were interviewed by an interview-team at SSI using a structured questionnaire, see 91 
Appendix.  92 
The interview was performed within a month of the date that the sample was submitted in the National 93 
Register for Enteric Patients. The questionnaire contained 22 questions concerning  outcome of disease, 94 
duration of symptoms,  severity of disease, and  patient characteristics.  The variables included in the study can 95 
be found in Tables 1 and 3. For children under the age of 15 years, a parent or a guardian was interviewed. For 96 
children between 15 and 17 years of age, we first asked the parents or guardian to give their consent to have 97 
their children interviewed before approaching the patient.  98 
 99 
Data analysis 100 
Data handling 101 
For the continuous variable age, we created categories in years, 0-3 ‘infants’, 4-17 ‘children’, 18-64 ‘adults’, 65 102 
and older ‘seniors’. Underlying comorbidity was added in the analysis as a 0/1 variable; consisting of having any 103 
of the following underlying illness: asthma/bronchitis, heart and circulation disease, intestinal illness, recurrent 104 
diarrhoea, liver disease, diabetes, connective tissue disease, kidney problems, cancer, chronic infection, other 105 
disease.  106 
Analyses 107 
We analysed the data in three separate groups according to resistance profile: S, R and MR. Statistical tests of 108 
associations between resistance profile and disease outcome were computed by use of χ2-test and Fisher’s 109 
exact tests, as well as likelihood ratio tests in a logistic regression model. We used a significance α−level of 5% 110 
for these analyses. We only checked for biologically reasonable confounding and interaction factors, like age, 111 
level of schooling, income, smoking, and self-reported stress. Confounding and interactions were tested for in a 112 
multivariable regression model. 113 
Data handling 114 
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Defgo.net® software was used to keep the structured interview and storage of the outcomes. All analyses were 115 
performed with SAS software version 9.3. 116 
Results 117 
Interview results 118 
In total, 228 patients were available during our study period and 150 (66%) were interviewed. The remaining 119 
78 patients could not, or did not want to be interviewed for various reasons, see Figure 1 for a flow chart. The 120 
ages of the people who died before they could be interviewed were 56, 63, 72 and 74 years of age, the cause of 121 
death was not known to the researchers. 122 
Patient characteristics 123 
Table 1 shows the age and gender distribution and variables for the severity of the disease relating to all 150 124 
patients. The median age was 36 years (interquartile range: 10-57 years). Twenty-six (17%) of these patients 125 
were under four years of age, and 24 (16%) were 65 years or older. Common symptoms included: abdominal 126 
pain (>7 days, 81%), fever (>7 days, 73%), and severe diarrhoea (>7 days, 69%). The median duration of 127 
diarrhoea was 13 days (interquartile range 7-15 days). Forty-nine patients (33%) were hospitalised for their 128 
Salmonella infection, and 76 (51%) of the patients received antimicrobial treatment for the current infection.  129 
Among 24 patients aged 65 or older, 12 (50%) had been admitted to hospital, and 18 (75.0%) had received 130 
antimicrobial treatment for the current infection. 131 
Most patients (90, i.e. 60%), had no underlying disease, among those with underlying disease, asthma was the 132 
most frequent condition, (21 patients; 14%), followed by cardiovascular disease (12 patients, 8%), connective 133 
tissue disease (nine patients, including patients with rheumatoid disease), and diabetes (eight patients).  In 134 
total, 27 (45%) of patients with underlying illness were treated with antimicrobial drugs compared with 41 135 
(46%) among those with no underlying illness.  136 
Resistance pattern and phage types 137 
Of all 150 patients, 49 (33%) had a fully susceptible resistance pattern (S), 48 (32%) had a resistant resistance 138 
pattern (R), and 53 (35%) patients had a multidrug-resistant pattern (MR). Only two cases were resistant to 139 
nalidixic acid, a marker for resistance against the quinolones.   140 
7 
 
Comorbidity was more common in patients with a resistant strain (21 of 48 patients, 44%) or multidrug-141 
resistant strain (27 of 53, 51%) compared with susceptible strains (12 of 49, 24%), Table 1. This pattern was 142 
partly related to age differences since younger patients had less comorbidity and were more likely to have a 143 
susceptible strain. There were more children under four years of age in the S group than in the R or MR  groups 144 
(OR 3.09 (95%CI 1.08 – 8.82) and OR 4.24 (95%CI1.41 – 12.77), respectively). We included both age and 145 
resistance profile to be explanatory variables for comorbidity, see Table 2. 146 
Only  few clinical outcomes were dependent on  the resistance profiles, and all of those were between the R 147 
group compared to the S group. For the R group the odds of being hospitalised, vomiting or experience nausea 148 
for more than 7 days were higher: OR 2.47 (95%CI 1.02 – 5.97), OR 2.61 (95%CI 1.10 – 6.19), and OR 2.87 149 
(95%CI 1.26 – 6.54), respectively.  150 
Different phage types were found in the different groups of patients. The most common phage types found in 151 
the MR group were DT193 and DT120 with each 11 patients (20.8%), for the R group the most pathogens were 152 
classified as  React but Did NOT Confirm (RDNC) (N=30, 62.5%) and DT120 (N=7, 14.6%), and for S group it were 153 
U292 (N=15, 30.6%) and DT135 (N=10, 20.4%).  154 
Severity of outcome in relation to antimicrobial use and age 155 
In total, 68 patients (45%) stated that they had a history of antimicrobial treatment in the six months period 156 
preceding infection. Patients with a history of treatment tended to have a higher risk of infection with resistant 157 
or multidrug-resistant Salmonella strains, but these differences were not significant (Table 1). Furthermore, a 158 
simple analysis, combining resistant with multiresistant strains into one group, did not reach statistical 159 
significance (OR 1.31; 95% CI 0.62-2.79).  However, patients who had been exposed to a course of 160 
antimicrobials, not related to the Salmonella infection, up to half a year before they got infected with 161 
Salmonella, had a higher odds of being hospitalised, losing more than 5 kg weight and receiving treatment for 162 
the current event of salmonellosis (Table 3). 163 
164 
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Discussion 165 
The main outcomes of this study were that young children have higher odds for being infected with a fully 166 
susceptible strain of Salmonella and are less likely to have underlying diseases, and older people  have higher 167 
odds for being infected with a multiresistant strain of Salmonella and also have higher odds of having an 168 
underlying comorbidity. In addition, a history of antimicrobial drug use was related to severe outcome of 169 
infection including need for treatment, hospital admission and weight loss.  This observation adds to the 170 
literature on the public health consequences of use of antimicrobials.  It is possible that human antimicrobial 171 
treatment disrupts the normal intestinal flora and can have long term negative effects for human 172 
health.(28;29)  173 
It should, however, be mentioned that because patients are treated for an infection, and that part of the 174 
association may be attributed to confounding by indication, which should be investigated in future studies. 175 
Furthermore, it can be speculated that people with underlying illnesses are more vulnerable and are therefore 176 
more likely to have been exposed to antimicrobials and consequently more likely to be infected with an 177 
antimicrobial resistant strain. These findings would be in concordance with our previous studies(39) 178 
We found that about one of two patients was treated with antimicrobial drugs. This was a surprise for us since 179 
Denmark is known for a prudent use of antibiotics. Elderly patients, over 60 years, used more antimicrobials 180 
than younger patients in our study, and this coincided with a higher percentage of these patients being 181 
admitted to a hospital for their infection. It is likely to be due to the fact that older people have a reduced 182 
functioning of their immune-system and that elderly get dehydrated easier(30), and are therefore more likely 183 
to be seriously affected by an infection like Salmonella.(31) However, of the youngest age group (<4 yrs), 35% 184 
(9 out of 26) were treated with antibiotics, which is a cause for concern. Asthma was the most common 185 
comorbidity in our study group, and these patients are more likely to suffer from upper-respiratory 186 
illnesses(32), which might be treated with antimicrobials and this might add to the antimicrobial use of patients 187 
in our study, since we did not ask specifically for which indication antimicrobials were prescribed in the six 188 
months prior to their Salmonella infection 189 
In contrast to other studies, we were not able to show convincingly that infections with antimicrobial resistant 190 
Salmonella have a worse outcome of disease than infections with a fully susceptible antimicrobial profile. In 191 
9 
 
fact, we only found a significantly worse outcome for vomiting and for feeling nauseated when comparing R 192 
versus S, and we did not find an increasing trend with increasing antimicrobial resistance (R vs. MR). It is 193 
therefore possible that even the higher risk of vomiting and nausea was a spurious observation.   194 
Other investigators have shown that  being infected with an antimicrobial resistant Salmonella  leads to a 195 
worse outcome of disease, including higher risk of  bacteraemia(33), higher mortality(34;35), excess 196 
hospitalisation(36;37) and more infections due to therapy failure.(38)  Most likely this difference is due to our 197 
study set-up which focused on softer outcomes than the abovementioned ones.  The studies of Helms, Lee, 198 
Giamarellos-Bourboulis and Varma et. al., included hospitalised patients or had hospitalisation as a major 199 
outcome of the study, whereas we included outcomes as days of diarrhoea, vomiting, weight loss, and other  200 
less serious events. Furthermore, we included a lower number of patients compared with the higher-powered 201 
registry based studies and this represents another limitation In the present study, interviews were  held 202 
relatively quick after onset of disease, some of our patients were still ill during the interview, and we did not 203 
look at long-term outcome of disease.  204 
We considered adding a group of patients that were resistant to quinolones only, similar to an earlier study 205 
performed by Hald et al.(9) Since quinolones are the standard drugs of choice for treating salmonellosis, it 206 
would be of interest to look at these patients specifically. Due to the low resistance rates to this drug found in 207 
Denmark,  (<1% for cases in Denmark(25) and only  two in the present study) we  were unable to create a 208 
quinolone-resistant group.  209 
A draw-back of the study design was the possible selection of patients that participated in this study. The 210 
interviewers called the patients in the evening-hours (4-9pm), so we ran little risk of missing people due to 211 
their working-hours. The interviewers managed to interview 66% of the 228 reported cases (or 70% after 212 
omitting 15 patients who were infected abroad and thus not eligible for the interview). This is, in our opinion, a 213 
satisfactory participation rate, but nonetheless it is likely that there is a bias towards excluding the most 214 
severely ill. It is noteworthy that 13 patients were too sick to participate and that four patients died before they 215 
could be interviewed, Figure 1. Second, our interview was reasonably long (approximately 20-30 minutes), and 216 
not everyone was willing to commit to such a long interview.  217 
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In conclusion, we were not able to demonstrate major negative outcomes of Salmonella Typhimurium infection 218 
when comparing patients infected by strains classified according to three different levels of drug-resistance. 219 
This negative finding is likely to be a limitation by design of the study rather than a true absence of a 220 
detrimental effect. We recommend that high-powered studies taking advantage of electronic health records or 221 
other databases as more appropriate to address research questions regarding the public health effect of 222 
resistance than work-intensive interview studies such as the present one. To our surprise, we found that half of 223 
the patients interviewed had received an antimicrobial treatment, which is a concern in light of the need to 224 
advocate prudent use of antimicrobials. Finally, a higher risk of weight loss, hospital admission or therapy 225 
among patients with a history of antimicrobial treatment independent of the current episode adds to studies 226 
that have demonstrated competitive and selective effects of antibiotic treatment. 227 
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Figure 1: Flow diagram of patient enrolment. 236 
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4  died before they could be interviewed 
164 patients 
6  did not want to participate 
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13 too sick to participate 
192 possible cases 
15 infected abroad 
212 possible cases 
20 could not be reached 
228 possible cases 
16 phone number could not be found 
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Table 1 Odds for severity of disease per resistance profile (three levels), 150 S. Typhimurium patients, January-June 2010,  
Denmark 
 
Three levels of resistance   All patients 
 
Pansusceptible (S)* Resistant (R)* 
Multidrug-resistant 
(MR)*   
  N OR (95%CI) N OR (95%CI) N OR (95%CI) N (%) 
Total number of patients 49 
 
48 
 
53   150 100 
Median age (interquartile 
range) 26 (3-51) 49  (23-65) 29 (11-55) 36 (10-57) 
Age categorya 
 
1 (reference) 
 
3.04 (1.40-6.56) 
 
2.23 (1.06-1.68) 
          Infants (<4y) 15 3.44 (1.36-8.70) 6 0.52 (0.19-1.46) 5 0.44 (0.15-1.30) 26 17.3 
        Children (4-17y) 8 1.35 (0.50-3.64) 4 0.37 (0.11-1.19) 11 1.69 (0.66-4.36) 23 15.3 
        Adults (18-64y) 21 1 (reference) 27 1 (reference) 26 1 (reference) 74 49.3 
        Seniors (=> 65y) 5 0.66 (0.22-2.01) 10 1.24 (0.49-3.18) 9 1.11 (0.43-2.88) 24 16.0 
Gender (female) 25 1 (reference) 23 1.13 (0.51-2.51) 26 1.08 (0.50-2.53) 74 49.3 
      
  
  Any underlying comorbidity 12 1 (reference) 21 2.40 (1.00-5.70) 27 3.20 (1.38-7.45) 60 40.0 
Median days of diarrhoea  
(interquartile range) 14 (7-15) 10 (7-14) 14 (8-20) 13 (7-15) 
Severe diarrhoea (>7 days) 33 1 (reference) 27 0.62 (0.27 -1.43) 43 2.09 (0.84 - 5.62) 103 68.7 
Weight loss (>5kg) 8 1 (reference) 14 0.49 (0.18-1.33) 13 0.58 (0.21-1.58) 35 23.3 
Hospitalised due to infection 11 1 (reference) 20 2.47 (1.02 - 5.97) 18 1.68 (0.70 - 4.04) 49 32.7 
Received medication to treat 
 infection 22 1 (reference) 29 0.53 (0.24-1.20) 25 0.91 (0.42-1.99) 76 50.7 
History of antimicrobial useb 20 1 (reference) 23 1.33 (0.60-2.98) 25 1.30 (0.59-2.83) 68 45.3 
Vomiting (>7 days) 12 1 (reference) 22 2.61 (1.10-6.19) 20 1.87 (0.79-4.40) 54 36.0 
Nausea >7 days) 18 1 (reference) 30 2.87 (1.26-6.54) 27 1.79 (0.81-3.95) 75 50.0 
Abdominal pain (>7 days) 39 1 (reference) 41 1.50 (0.52-4.33) 42 0.98 (0.38-2.56) 122 81.3 
Fever (>7 days) 36 1 (reference) 35 0.97 (0.40-2.39) 39 1.01 (0.42-2.43) 110 73.3 
Bloody faeces (>7 days) 19 1 (reference) 20 1.1 (0.50-2.54) 20 0.96 (0.43-2.13) 59 39.3 
Pain in joints 13 1 (reference) 11 0.82 (0.33-2.08) 15 1.09 (0.46-2.61) 39 26.0 
* S: pansusceptible Salmonella, R: Salmonella resistant to 1-3 antimicrobials, MR: Salmonella strains resistant to =>4 
antimicrobials 
a: Age category was analysed separately within the different susceptibility profiles with adults as the reference value 
b: Antimicrobials were not prescribed for treatment of current infection, history up to 6 months. 
  
  241 
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Table 2 Relation between comorbidity and resistance profile, crude outcomes and  
adjusted for age category 
Resistance 
profile 
Comorbidity 
 present N (%) Crude OR (95%CI) 
adjusted OR* 
(95%CI) 
S 
Yes 12 (24)  1 (Reference)  1 (Reference) 
No 37 (76)  
  
R  
Yes 21 (44) 2.40 (1.01 - 5.70) 1.73 (0.68 - 4.35) 
No 27 (56) 
  
MR 
Yes 27 (51) 3.20 (1.38 - 7.45) 2.62 (1.07 - 6.37) 
No 26 (49)   
 
< 4 years 
Yes 4 (15) 1 (Reference) 1 (Reference) 
No 22 (84) 
  
4-17 years 
Yes 6 (26) 1.94 (0.47 - 7.99) 1.52 (0.36 - 6.48) 
No 17 (74) 
  
18-64 years 
Yes 33 (43) 4.12 (1.30 - 13.12) 3.37 (1.03 - 11.01) 
No 44 (57) 
   => 65 
years 
Yes 7 (29) 13.36 (3.35 - 53.18) 10.89 (2.66 - 44.61) 
No 17 (71)   
 Total 
 
      
*Comorbidity by resistance profile adjusted for age category 
**: Comorbidity is a yes/no variable consisting of having any of the following underlying 
diseases: asthma/bronchitis, heart and circulation disease, intestinal illness, recurrent 
diarrhoea, liver disease, diabetes, connective tissue disease, kidney problems, cancer, chronic 
infection, other disease.  
 242 
 243 
  244 
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Table 3 Crude and adjusted odds ratios for people who received antimicrobials in the past 6 months prior to  
Salmonella infection 
    
History of 
antimicrobial 
 use, unrelated to 
the current 
salmonellosis 
Odds Ratio for severe 
outcome (95%CI) 
Consequence of infection: Yes No Crude Adjusted* 
Prescribed antimicrobials yes 52 24 7.85 (3.77 - 16.78) 7.56 (3.42 - 16.70) 
 
no 16 58 1 (reference) 1 (reference) 
Hospitalised yes 28 21 2.03 (1.02 - 4.06) 2.00 (0.97 - 4.11) 
 
no 40 61 1 (reference) 1 (reference) 
Weight loss (>5kg) yes 22 39 2.43 (1.09 - 5.48) 2.01 (0.84 - 4.82) 
  no 56 13 1 (reference) 1 (reference) 
* We adjusted for age category, income, level of schooling, self-reported stress, and smoking 
  245 
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Appendix: Translation of the interview 342 
Interviewer:  343 
Interview date:  344 
Patients name: 345 
Age:  346 
Region:  347 
Telephone number:  348 
 349 
1.1) Who is answering the questionnaire?  350 
__ Patient    ___mother/father   ___ other 351 
1.2) What was the date of first onset of your symptoms of disease? 352 
1.3) Have you had another microbiologically proven Salmonella infection 6 months before this current 353 
Salmonella infection? 354 
1.4) Do you have a suspicion of which food-item made you ill? 355 
If yes, what was it? 356 
And when did you eat it? 357 
Period after infection 358 
2.1) How many days passed between the first symptoms and the stool-sampling? 359 
2.2)How many days were you ill? 360 
2.3) Were you hospitalised due to your salmonellosis? 361 
2.4) Did you receive antibiotics to treat your salmonellosis??  362 
If yes, do you know the name of the antibiotic? 363 
2.5) Did you take any other drugs for your salmonellosis? 364 
2.6) Did you have any of the following symptoms? 365 
Symptoms yes no Not sure Number of days 
Diarrhoea     
Blood in stool     
Nausea/vomiting     
Pain in stomach     
Fever     
19 
 
other     
If other, which?  366 
2.7) Did you lose weight due to your salmonellosis?  367 
If yes, how much? __>5kg   __2-5kg   ___0-2kg 368 
2.8) Did you have pain in your joints due to your salmonellosis? 369 
2.9) Do you have any of the following symptoms? 370 
Disease Yes  No Not sure 
Asthma/bronchitis    
Heart- circulation disease    
Stomach disease (f. ex. gastritis, ulcer)    
Intestinal disease (IBS, Chrohn’s, collitis ulcerosa)    
Returning diarrhoea of unknown cause    
Liver disease    
Diabetes    
Connective tissue disease (f.ex. arthritis, Sjögren’s syndrome)    
Kidney disease    
Cancer    
Chronic infection (f.ex. HIV, TB, hepatitis)    
Other disease    
 371 
2.10) Did you take any of the following drugs in the past 6 months? 372 
Drugs Yes  No Not sure 
Painkillers    
Antibiotics    
Diarrhoea-stoppers    
Painkillers    
Antacids    
 373 
20 
 
Period before infection 374 
3.1) Did you undertake any foreign travel up to 14 days before onset of disease?  375 
If yes: Where did you travel to?  376 
What were the travel-dates? 377 
 378 
Socio-economic status and other 379 
4.1) Are you vegetarian? 380 
4.2) How many other people do you share your household with? 381 
How old are your housemates? 382 
4.3) What is your highest level of education?  383 
4.4) What is your households yearly income? 384 
4.5) Do you smoke? 385 
4.6) Did you experience high levels of stress in the last 6 months? 386 
If yes, did stay home because of these high stress levels? 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
